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Abstract 
CDKL5 deficiency disorder (CDD) is a severe, neurodevelopmental disorder associated with lesions in the 
X-linked cyclin-dependent kinase-like 5 (CDKL5) gene. Despite the simple genetic etiology of CDD its 
pathophysiology remains poorly understood, and the treatability of specific CDD symptoms is untested. 
Using genetically modified mouse models of CDD, we demonstrate that aberrant glutamatergic signaling 
through NMDA receptors underlies the disrupted circuit hyperexcitability connected to several CDD-
related deficits in mice. We also temporally manipulated endogenous Cdkl5 expression, and find that 
post-developmental loss of CDKL5 disrupts numerous behavioral domains, hippocampal circuit 
communication, and dendritic spine morphology, demonstrating an indispensable role for CDKL5 in the 
adult brain. Accordingly, adult restoration of Cdkl5 in knockout mice significantly ameliorates CDD-related 
behavioral impairments and aberrant NMDA receptor signaling. These results demonstrate that adult 
neural function requires CDKL5, and suggest chronic treatment may be required in CDD. Furthermore, our 
results uncover a broad therapeutic time window for numerous CDD-related deficits, and substantiate 
aberrant NMDA receptor signaling as underlying numerous CDD pathologies. These discoveries expand 
upon our current understanding of CDKL5 in regulating neurological function, and comprise a critical 
foundation for future studies aiming to develop therapeutics for CDD patients, especially beyond the early 
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CDKL5 deficiency disorder (CDD) is a severe, neurodevelopmental disorder associated 
with lesions in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene. Despite the simple 
genetic etiology of CDD its pathophysiology remains poorly understood, and the treatability of 
specific CDD symptoms is untested. Using genetically modified mouse models of CDD, we 
demonstrate that aberrant glutamatergic signaling through NMDA receptors underlies the 
disrupted circuit hyperexcitability connected to several CDD-related deficits in mice. We also 
temporally manipulated endogenous Cdkl5 expression, and find that post-developmental loss of 
CDKL5 disrupts numerous behavioral domains, hippocampal circuit communication, and dendritic 
spine morphology, demonstrating an indispensable role for CDKL5 in the adult brain. Accordingly, 
adult restoration of Cdkl5 in knockout mice significantly ameliorates CDD-related behavioral 
impairments and aberrant NMDA receptor signaling. These results demonstrate that adult neural 
function requires CDKL5, and suggest chronic treatment may be required in CDD. Furthermore, 
our results uncover a broad therapeutic time window for numerous CDD-related deficits, and 
substantiate aberrant NMDA receptor signaling as underlying numerous CDD pathologies. These 
discoveries expand upon our current understanding of CDKL5 in regulating neurological function, 
and comprise a critical foundation for future studies aiming to develop therapeutics for CDD 
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CHAPTER 1 – INTRODUCTION 
 
Overview 
CDKL5 deficiency disorder (CDD) is a severe, childhood epileptic encephalopathy 
associated with pathogenic variants in the X-linked cyclin-dependent kinase-like 5 (CDKL5) 
gene(Fehr et al., 2013; Kalscheuer et al., 2003; Tao et al., 2004; Weaving et al., 2004). Currently, 
CDD has a reported incidence of one in 40,000 to 50,000 live births, making it one of the most 
common genetic causes of epilepsy in children(López-Rivera et al., 2020; H. E. Olson et al., 
2019). The majority of cases are heterozygous females who carry a constellation of debilitating 
phenotypes including early-onset seizures, global neurodevelopmental delay, motor dysfunction, 
intellectual disability, and several autonomic dysfunctions (e.g., feeding and gastrointestinal 
problems, sleep disturbances, and breathing abnormalities)(H. E. Olson et al., 2019). Despite the 
strong genetic link, the evolution of CDD pathophysiology and neurological impairments resulting 
from disrupted CDKL5 function remain unclear. 
Several animal models of CDD have been generated and characterized to date, 
demonstrating a general overlap in phenotypic presentation and highlighting the importance of 
CDKL5 in establishing proper brain development and neurological function(Amendola et al., 
2014; Okuda et al., 2018; I. T. Wang et al., 2012). Importantly, these animal models have also 
provided an in vivo setting to discover and validate the molecular, cellular, and circuit disruptions 
associated with loss of CDKL5 function. Despite this progress, the time course of CDD 
pathogenesis, specific roles for CDKL5 in nervous system development versus maintenance, and 
reversibility of CDD-related phenotypes remain undetermined. Thus, there remains a pressing 
need to address these unknowns, and thereby support future examinations into CDKL5 function 
as well as therapeutic efforts aimed towards treating CDD. 
2 
 
The Genetics and Clinical Features of CDKL5 Deficiency Disorder 
A history of the classification of CDKL5 Deficiency Disorder 
CDKL5 Deficiency Disorder (CDD) only became recognized as an independent clinical 
entity in 2013, however, clinical reports of patients presenting with an “atypical” pattern of Rett 
syndrome date back as early as the 1980s(Fehr et al., 2013). In 1985, Dr. Folker Hanefeld 
reported on a case in which a young girl presented with atypical infantile spasms in conjunction 
with progressive Rett-like symptoms, now known to be characteristic of CDD(Hanefeld, 1985). As 
early seizures are unusual in the evolution of Rett syndrome, and infantile spasms had yet to be 
reported in these patients, this collection of phenotypes was hereafter referred to as the early-
onset-seizure, or “atypical,” variant of Rett syndrome. In 2003, Kalscheuer et al. reported an 
association between lesions in the X-linked CDKL5 gene and severe infantile spasms coupled to 
global neurodevelopmental delay(Kalscheuer et al., 2003). The two, severely affected, female 
patients in this case report carried de novo X chromosome translocations, both of which disrupted 
the (then named) serine-threonine kinase 9 gene, STK9 (since renamed CDKL5)(Montini et al., 
1998). The neurological impairments and infantile spasms presented by these two patients 
carried characteristics of X-linked West syndrome, also referred to as X-linked infantile spasms 
(ISSX), which presents with early-onset generalized seizures, hypsarrhythmia, and mental 
retardation(Bienvenu, 2002). Thus, disruptions in STK9/CDKL5 were grouped with previously-
reported ARX mutations, and postulated to serve as a second X-chromosomal locus for 
ISSX(Kalscheuer et al., 2003). 
 Independently, and shortly thereafter, Weaving et al. reported on two additional, 
unrelated families carrying mutations in CDKL5 whose children (including one male) presented 
with severe neurodevelopmental delay and infantile spasms(Weaving et al., 2004). This study, 
published in 2004, also examined the CDKL5 locus within MECP2-mutation negative Rett 
syndrome patients, and found an additional female patient reported to present with the early-
onset-seizure variant of Rett to carry a de novo CDKL5 splice-site mutation (CDKL5 IVS13-
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1GA). In this same 2004 issue of American Journal of Human Genetics, an independent clinical 
report demonstrated further evidence linking de novo mutations in the CDKL5/STK9 gene to 
early-onset infantile spasms, intellectual disability, and severe neurodevelopmental delay(Tao et 
al., 2004). Although ~80% of Rett syndrome patients carry a mutation in the X-linked MECP2, 
only ~20-40% of patients presenting with atypical Rett syndrome have reported MECP2 
mutations. This study reported previously-unidentified CDKL5 mutations in several MECP2-
mutation negative atypical Rett syndrome patients, further linking lesions in CDKL5 to the atypical 
clinical features associated with this subtype of Rett. Therefore, these early studies comprised a 
seminal foundation for connecting lesions in CDKL5 to the etiology of this distinct constellation of 
features characterized by early-onset seizures/infantile spasms, severe neurodevelopmental 
delay, and autistic features. Although it would be another ten years before CDD became 
classified as an independent clinical entity, distinct from Rett syndrome(Fehr et al., 2013). 
Clinical presentations and phenotypic variations in CDKL5 Deficiency Disorder 
 The most updated reports of the clinical features of CDKL5 Deficiency Disorder (CDD) 
currently classify it as a developmental encephalopathy(H. E. Olson et al., 2019). This class of 
diseases share a common constellation of features beyond traditional autism spectrum disorders 
or intellectual disability, most notably refractory epilepsy as well as motor and autonomic 
dysfunctions(Paciorkowski, Seltzer, & Neul, 2018). The current incidence of reported pathogenic 
variants in CDKL5 is one in 40,000 to 50,000 live births, making it only half as prevalent as 
traditional Rett syndrome, and as an X-linked disorder CDD predominately afflicts young females 
over males (~4:1)(López-Rivera et al., 2020; H. E. Olson et al., 2019). 
 One of the hallmark features of CDD, refractory epilepsy, significantly impacts patient and 
family quality of life, with 80% of CDD patients presenting with daily seizures and fewer than half 
reporting more than 2 months of sustained seizure freedom(Fehr et al., 2013; Fehr, Wong, et al., 
2016). Most families report a median age of onset at 6 weeks of age, with 90% of patients 
developing seizures by three months of age. This severe, early-onset feature of CDD can also 
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have profound impact on neurodevelopment and carries a high risk of behavioral and cognitive 
comorbidities(Fehr et al., 2015; Fehr et al., 2013; Mangatt et al., 2016). Thus, seizure treatment in 
CDD has been a central focus of recent therapeutic endeavors. The epilepsy of CDD typically 
progresses in three stages across the first several years of life: 1) early-onset infantile spasms, 2) 
epileptic encephalopathy with hypsarrhythmia, and finally 3) refractory multifocal and myoclonic 
epilepsy. The evolving epilepsy phenotype in CDD appears to be mixed focal and generalized, 
with spasms, tonic, and tonic-clonic seizures being the most common(Bahi-Buisson, Kaminska, et 
al., 2008). The autonomic dysfunctions associated with CDD, such as irregular respirations and 
apnea, can also arise during this time(H. E. Olson et al., 2019). Broad spectrum antiseizure 
medications are most commonly prescribed including clobazam, valproate, topiramate, 
levetiracetam, and vigabatrin in combination with a ketogenic diet(Fehr, Wong, et al., 2016; Muller 
et al., 2016). Cannabidiol has been more recently explored with regards to the treatment of motor 
seizure frequency, and is in phase 2 of clinical trials for use in CDD(Devinsky et al., 2018). 
However, seizure management remains an issue for the majority patients, and the efficacy of 
most therapies does not appear to extend beyond 12 months for most individuals(Muller et al., 
2016).  
Unlike Rett syndrome, CDD patients do not typically carry a developmental regression, 
and instead present with severe global developmental delays and intellectual disability(Bahi-
Buisson, Nectoux, et al., 2008; Fehr et al., 2013; Liang et al., 2011; D. Mei et al., 2010; H.E. 
Olson & Poduri, 2012). Only 22-23% of reported female patients can independently walk, and 
26% of individuals could produce spoken language with only 7.5% speaking in sentences(Fehr, 
Downs, et al., 2016; Fehr et al., 2015). However, microcephaly is only reported in fewer than 10% 
of individuals(Fehr et al., 2013; H.E. Olson & Poduri, 2012). The cortical visual impairment 
reported for CDD also limits the use of nonverbal communication and eye gaze(H. E. Olson et al., 
2019). Accordingly, although autistic features are commonly reported in CDD, a diagnosis of 
autism spectrum disorder is infrequently provided given the significance of global developmental 
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impairments(Bahi-Buisson, Nectoux, et al., 2008; Liang et al., 2011; D. Mei et al., 2010; Nemos et 
al., 2009; H.E. Olson & Poduri, 2012). 
Over 80% of CDD individuals also present with hand stereotypies such as self-
stimulatory behavior as well as repetitive leg crossing, and hypotonia is a nearly universal feature 
for most patients(Fehr et al., 2013; Fehr, Wong, et al., 2016; H. E. Olson et al., 2019),. 
Gastrointestinal symptoms such as constipation, reflux, and air swallowing are reported in up to 
86.5% of patients along with dysphagia, with only 5.3% able to eat and drink independently(Fehr 
et al., 2013; Mangatt et al., 2016). Furthermore, sleep difficulties for CDD individuals are reported 
by over 85% of parents often comorbid with breathing abnormalities and hyperventilation(Mangatt 
et al., 2016). 
Together, these clinical reports highlight a heterogeneous assortment of phenotypes, 
including treatment-resistant epilepsy, autistic traits, and severe cognitive and motor 
developmental delays, that can comprise CDD. However, significant phenotypic heterogeneity 
has been reported, and growing efforts in diagnosis and variant mapping of CDD patients will 
hopefully lead to better genotype-phenotype correlations(H. E. Olson et al., 2019). With further 
clinical and preclinical studies, there is hope that future drug and therapy development will 
ultimately provide more efficacious treatments for this devastating and debilitating disorder. 
Genetic characteristics of CDKL5 Deficiency Disorder patients 
 CDD is associated with mutations, typically de novo, in the X-linked cyclin-dependent 
kinase-like 5 (CDKL5) gene(Archer et al., 2006; Evans et al., 2005; Fehr et al., 2013; Kalscheuer 
et al., 2003; H.E. Olson & Poduri, 2012). CDKL5 resides on the distal portion of the short arm of 
the X chromosome (Xp22), and encodes a serine-threonine kinase of the same name, 
CDKL5(Montini et al., 1998). Pathogenic missense variants mapped to date occur exclusively 
within the catalytic domain of the protein, and deletion and truncating variants nearly universally 
cause CDD(R.D. Hector et al., 2017). There have also been reports of patients carrying CDKL5 
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duplications, which are typically associated with macrocephaly and learning disability without 
epilepsy(Szafranski et al., 2015). 
 As mentioned, there is at times significant phenotypic heterogeneity amongst CDD 
patients, however, genotype-phenotype correlations are limited. Individuals carrying early 
truncating variants, compared with some pathogenic missense variants, appear to have a more 
severe disorder(Bahi-Buisson et al., 2012; Fehr, Downs, et al., 2016; Fehr et al., 2015; Fehr, 
Wong, et al., 2016). Being an X-linked disorder, some of the phenotypic heterogeneity observed 
in CDD female patients may be due to variable X-chromosome inactivation (XCI), however, the 
influence of somatic CDKL5 mosaicism on the clinical phenotype of CDD remains unknown(R.D. 
Hector et al., 2017; H. E. Olson et al., 2019; Stosser et al., 2018). In the Weaving et al. clinical 
reported discussed above, one female patient demonstrated slightly skewed XCI that favored 
expression of the normal CDKL5 allele, however, the XCI pattern of blood leukocytes profiled in 
this study may not accurately reflect XCI patterns in the brain(Weaving et al., 2004). In fact, the 
same study reported twin sisters displaying similar XCI patterns in peripheral blood, yet 
completely different clinical features. Furthermore, mosaic exon deletions and mosaic de novo 
variants have been reported in both male and female CDD patients, and although their exact 
incidence remains undetermined, they may be an underappreciated phenomenon in 
CDD(Stosser et al., 2018). 
Animal Models of CDKL5 Deficiency 
In 2012, the first knockout mouse model of CDD was generated and found to recapitulate 
several of the cardinal phenotypes of the human disease including learning and memory 
impairments, motor deficits, and autistic-like behaviors but not overt seizures(I. T. Wang et al., 
2012). This line carries a deletion of Cdkl5 exon 6, mimicking a reported CDD patient splice site 
mutation resulting in exon 6 skipping and loss of protein(Archer et al., 2006). The male mice 
examined in this report exhibited normal growth, brain and body weight, and a lack of gross brain 
pathology. Several additional knockout and knock-in lines have since been generated with 
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behavioral assessments, despite a few discrepancies, highlighting a general overlap of 
phenotype presentation across different Cdkl5 knockout models. These include three 
independent Cdkl5 knockout lines (Cdkl5Δ4, Cdkl5Δ2, and Cdkl5STOP (first reported in this study; 
Chapter 4)) as well as a knock-in line, Cdkl5R59X, modeling a reported patient nonsense mutation 
resulting in early truncation and loss of CDKL5 protein(Amendola et al., 2014; Okuda et al., 2018; 
Tang et al., 2019; Yennawar, White, & Jensen, 2019). A summary of the behavioral phenotypes 
evaluated across various CDD mouse models is summarized in Table 1. 
CDKL5 is expressed throughout various cell types in the heterologous brain highlighting 
the importance of dissecting any cell type-specific and circuit-level network disruptions relevant to 
CDD(Chen et al., 2010; Johnson et al., 2017; Rusconi et al., 2008; I. T. Wang et al., 2012; Zeisel 
et al., 2015). There have accordingly been Cdkl5 conditional knockout studies wherein Cdkl5 was 
ablated selectively from either forebrain glutamatergic (Nex-cKO) or forebrain GABAergic (Dlx-
cKO; Chapter 2) neurons(Tang et al., 2019; Tang et al., 2017). These two studies, as discussed 
further in Chapter 2 below, reflect a general segregation of Cdkl5 constitutive knockout 
phenotypes with Nex-cKO mice selectively demonstrating impaired learning and memory 
(reminiscent of the intellectual disability of CDD), and Dlx-cKO mice selectively demonstrating 
autistic-like features. Prior to this work, Amendola et al. had also performed a conditional deletion 
of Cdkl5 from forebrain glutamatergic neurons and glial cells (Emx1-cKO) versus GABAergic 
(Dlx-cKO) neurons, but only evaluated general locomotion, finding a selective decrease in activity 
in Dlx-cKO males(Amendola et al., 2014). Although the results of cell-type-specific loss of CDKL5 
within different circuits and brain regions remain to be expanded upon, these data reveal that 
distinct phenotypes in Cdkl5 knockout mouse models can be mapped to diverse forebrain 
neuronal populations. 
Interestingly, although early-onset epilepsy is one of the hallmark features of CDD, no 
overt seizure phenotype or abnormal basal EEG pattern was reported in any of the hemizygous 
knockout male mice observed in the above-mentioned studies. However, a recent finding by our 
group suggests that spontaneous seizure activity in CDD mouse models is confined to aged, 
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heterozygous knockout females (Chapter 5). This highlights X-linked mosaicism as a potential 
driver for overt, spontaneous seizure activity and underscores why previous reports to date may 
not have observed this phenotype. Further details on the EEG and network phenotypes reported 
in Cdkl5-deficient animal models is discussed in the ‘Synaptic, Circuit, and Network Phenotypes 
of CDKL5-Deficient Mice’ section below. Despite these multitude of behavioral and EEG 
characterizations of various CDD mouse models, the endogenous function of CDKL5 and its role 
in nervous system development, maintenance, and CDD pathogenesis remain undetermined. 
Molecular Features and Signaling Pathways of the CDKL5 Protein 
CDKL5 protein characteristics 
The CDKL5 protein is serine-threonine kinase highly conserved among vertebrates, 
carrying 99% identity within its 960 amino acids between mouse and human orthologues of 
CDKL5(Montini et al., 1998). As mentioned, all pathogenic missense mutations appear to cluster 
within the region of CDKL5 encoding the amino(N)-terminal kinase domain, suggesting that 
disrupted kinase function likely underlies disease pathophysiology(R.D. Hector et al., 2017). The 
CDKL5 kinase domain carries significant homology to those of the cyclin-dependent kinase 
(CDK) and mitogen-activated protein (MAP) kinase families, however, it is distinct from these and 
other cyclin-dependent kinase like (CDKL) family members in that it also possess a long, proline-
rich carboxy(C)-terminal domain of about 700 amino acids(Canning et al., 2018; R. D. Hector et 
al., 2016). Previous in vitro and heterologous cell line studies have suggested this C-terminal 
domain to serve as a negative regulator of CDKL5 kinase activity as well as to affect protein sub-
cellular localization(Bertani et al., 2006; Lin, Franco, & Rosner, 2005). In addition, the CDKL5 
protein carries two predicted nuclear localization sequences (NLS) and a nuclear export 
sequence (NES), suggesting that it may shuttle between the nuclear and cytoplasmic 
compartments(Bertani et al., 2006; Rusconi et al., 2008). More recently, visualization of CDKL5 in 
neuronal cultures as well as post-synaptic density fractionation from brain tissues has suggested 
that CDKL5 is enriched at the post-synaptic density of neurons(Bayés et al., 2012; Reim et al., 
9 
 
2017; Ricciardi et al., 2012; Zhu et al., 2013). However, the in vivo relevance of these findings 
has yet to be tested, and the limited availability of tools to visualize and tag the endogenous 
CDKL5 make these results difficult to corroborate. 
CDKL5 transcript isoforms and expression pattern 
Analysis of the human and mouse CDKL5/Cdkl5 transcript sets has identified at least five 
unique isoforms(R. D. Hector et al., 2016). hCDKL5_1/mCdkl5_1 is the predominant isoform in 
the brains of humans and mice, respectively, with detectable levels in additional tissues 
(particularly testis), albeit at significantly lower levels. Alternative CDKL5 mRNA isoforms 
(hCDKL5_2-5; mCdkl5_2 & mCdkl5_6-8) arise from the inclusion of additional 3’ exons as well as 
alternative splicing of exon 17, however, in mice, their expression pattern appears to be mostly 
restricted to the testis. The human hCDKL5_2 (inclusion of exon 17) and hCDKL5_3 (alternative 
splicing of exon 11) are also detectable in brain tissues, but are only predicted to constitute ~10% 
of CDKL5 transcripts in brain(R. D. Hector et al., 2016). Therefore, the 960 amino acid protein 
product of isoform 1 is thought to be the predominant product regulating neuronal function in both 
mouse and human.  
In rodents, the CDKL5 protein is most highly expressed in the central nervous system, 
particularly within regions of the forebrain (e.g., cortex, striatum, amygdala, and 
hippocampus)(Chen et al., 2010; Rusconi et al., 2008; I. T. Wang et al., 2012; Zeisel et al., 2015). 
More recent findings have also demonstrated a role for CDKL5 within the peripheral nervous 
system in the regulation of pain perception by sensory neurons of the dorsal root ganglia(Paolo 
La Montanara et al., 2020). Our lab and others have also observed detectable, but significantly 
lower, CDKL5 protein levels in additional tissues of mice such as lung, kidney, and testis(Lin et 
al., 2005; Rusconi et al., 2008). Interestingly, a recent kinome-wide screen identified CDKL5 as a 
critical regulator of a stress-response pathway in renal tubular epithelial cell death during acute 
kidney injury, highlighting the potential importance of CDKL5 in additional tissues(Kim et al., 
2020). The role of CDKL5 and its various isoforms in additional tissues remains ripe for 
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exploration, however, the remainder of this report will focus on its role in neurological function 
with relation to CDD.  
RNA-sequencing analysis of mouse embryonic brain tissue finds Cdkl5 transcripts 
significantly detectable by embryonic day 15(Smith CM, 2019). This embryonic expression 
pattern is supported by post-mortem, human brain transcriptome data reflecting a significant 
expression of CDKL5 RNA within several brain regions by the second trimester of gestation(H. J. 
Kang et al., 2011). Several groups have previously reported on the developmental expression 
pattern of CDKL5 protein within the rodent brain, albeit with conflicting conclusions likely due to 
the lack of a specific CDKL5 antibody. These reports range from suggesting the kinase to be 
detectable in brain as early as embryonic day 7.5 to expression being restricted until the postnatal 
period, and then usually peaking in expression during the critical period of synaptogenesis for 
several brain regions in mice (i.e. postnatal day 10-14)(Lin et al., 2005; Rusconi et al., 2008; Zhu 
et al., 2013). Despite slight embryonic discrepancies, our group and others have consistently 
demonstrated that CDKL5 remains stably expressed throughout life in the forebrain of mice 
(Chapter 3). These results ultimately motivated our exploration of the post-developmental role of 
CDKL5 in neurological function (Chapter 3). 
CDKL5 interacting proteins and signaling pathways 
As mentioned above, CDKL5, unlike its family members CDKL1-4, is expressed 
predominantly in post-mitotic neurons as opposed to dividing cells, likely conferring a distinct set 
of signaling targets and pathways(Canning et al., 2018; Dubos, Pannetier, & Hanauer, 2008; He 
et al., 2020; Li et al., 2014; Qin et al., 2017; Smith CM, 2019). To date, several in vitro and cell 
culture studies have identified a variety of CDKL5 interacting proteins. Given the clinical overlap 
between Rett syndrome and CDD, it was initially postulated that CDKL5 and MECP2 might 
function within the same molecular pathway. In fact, it was shown in an in vitro kinase assay that 
CDKL5 was capable of interacting with and phosphorylating MECP2(Mari et al., 2005). However, 
this finding has yet to be replicated by other groups or in vivo, and more recent reports suggest 
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the two proteins likely function within unique molecular signaling networks(Lin et al., 2005). Thus, 
the clinical overlap between CDD and Rett syndrome may simply occur due to converging 
disruptions at the cellular or network levels. 
In line with the idea of a nuclear function for CDKL5, additional nuclear binding partners 
and targets have been postulated, mainly identified via in vitro kinase assays or through work in 
heterologous cell lines. These include the DNA methyltransferase 1 (DNMT1), as well as a role 
for CDKL5 in regulating mRNA splicing activity via its association with the nuclear speckle 
component SC35(Kameshita et al., 2008; Ricciardi et al., 2009). A more recent, 
phosphoproteomic screen for direct CDKL5 substrates also highlighted proteins involved in the 
DNA damage response, such as centrosomal protein 131 (CEP131)(Munoz et al., 2018). These 
findings align with the increase in cell death and DNA damage-associated biomarkers reported 
with CDKL5 deletion in mouse hippocampal cultures and human neuroblastoma (SH-SY5Y) cell 
lines(Barbiero et al., 2017; Fuchs et al., 2019; Loi et al., 2020). 
 Additional hypotheses have focused on a synaptic role for CDKL5 within neurons. In rat 
primary neuron cultures, knockdown of CDKL5 was found to disrupt neuronal morphogenesis and 
neurite outgrowth upon BDNF-induced actin remodeling via its association with Rac1(Chen et al., 
2010). Similarly, two independent reports highlighted a role for CDKL5 in dendritic spine 
morphology in cultured hippocampal neurons via its interaction with components of the 
postsynaptic compartment such as phosphorylating netrin-G1 ligand (NGL-1) and co-localizing 
with palmitoylated post synaptic density protein 95 (PSD-95)(Ricciardi et al., 2012; Zhu et al., 
2013). CDKL5 was also linked to the phosphorylation of amphiphysin 1 at the pre-synaptic 
terminal, again, using an in vitro system(Katayama, Sueyoshi, & Kameshita, 2015; Sekiguchi et 
al., 2013). Furthermore, a yeast two-hybrid screen identified an interaction of CDKL5 with 
shootin1, a regulator of neuronal polarization during axon development(Nawaz et al., 2016). 
Interestingly, a mind bomb 1 (Mib1) interactome screen that identified CDKL5 demonstrated that 
CDKL5 is ubiquitinated by Mib1 and targeted for degradation by the proteasome(Mertz et al., 
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2015). The direct relevance of these synaptic and axonal targets in vivo has yet to be validated, 
again likely due to the limitation of tools to visualize and tag the endogenous CDKL5.  
 More recently, a chemical-genetic approach was leveraged to identify direct CDKL5 
kinase targets by harnessing an ATP analog-specific CDKL5 mutant in mouse brain tissue 
lysates coupled with thiophosphopeptide-targeted mass spectrometry. This study reported that 
CDKL5 directly phosphorylates peptides at the RPXS* motif that mapped to proteins associated 
with the microtubule network of neurons(Lucas L. Baltussen et al., 2018). These targets included 
the microtubule associated protein RP/EB family member 2 (MAPRE2/EB2), the microtubule 
associated protein 1S (MAP1S), and Rho guanine nucleotide exchange factor 2 (ARHGEF2). 
These results were corroborated by an independent group performing a global, TMT-based 
phosphoproteomic screen for CDKL5 substrates. This second study confirm the enrichment of 
CDKL5 phosphorylated proteins as involved in the actin cytoskeleton and microtubule-associated 
proteins, including MAP1S(Munoz et al., 2018). Together, these findings highlight a novel, 
activity‐dependent molecular pathway in dendritic microtubule regulation that may underlie the 
pathology of CDD. These more recent results also align with some of the cellular and synaptic 
phenotypes reported in CDKL5-deficient models (see ‘CDKL5 Loss-of-Function Cellular 
Phenotypes’ section below). A summary of all reported CDKL5 interacting proteins and targets 
identified to date is listed in Table 2.  
 Loss of CDKL5 was shown to disrupt signaling of the AKT-mammalian target of 
rapamycin (mTOR) cascade within several brain region tissue lysates of the first Cdkl5 knockout 
mouse (Cdkl5Δ6)(I. T. Wang et al., 2012). Similar findings were reported in whole brain extracts 
of an independent knockout mouse line (Cdkl5Δ4) with reduced phosphorylation of AKT and 
ribosomal protein S6 reflecting an overall disruption of neuronal growth/plasticity and protein 
translation(Amendola et al., 2014). More specifically, altered AKT/GSK-3β signaling was also 
reported within Cdkl5 knockout mouse hippocampal tissue, concomitant with a significant 
reduction of dendritic arborization and length(Fuchs et al., 2014). However, the direct role of 
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CDKL5 within the action of these pathways, as opposed to compensatory or non-specific 
AKT/mTOR disruptions, has not been tested. 
Cellular Phenotypes Resulting from CDKL5 Loss 
At the cellular level, loss of CDKL5 has been reported to result in morphological deficits 
such as reduced dendritic arborization and complexity as well as aberrant spine 
morphology/stability in pyramidal neurons. In culture models, shRNA knockdown of CDKL5 
impairs neurite outgrowth in rat primary hippocampal neurons, and several Cdkl5 knockout mice 
have been reported to display reduced dendritic complexity in the hippocampus(Amendola et al., 
2014; Chen et al., 2010; Okuda et al., 2018; Tang et al., 2017). Our group recently demonstrated 
little effect on dendritic morphology upon post-developmental deletion of CDKL5, bringing into 
question the timing or specificity of this phenotype to CDKL5 loss. These results are discussed 
further in Chapter 3. 
The effects of CDKL5 loss on spine dynamics/stability, however, remain inconclusive. 
Ricciardi et al. demonstrated that shRNA-mediated knockdown of CDKL5 in primary mouse 
hippocampal neuron cultures leads to an increased density of filipodia-like, or immature, spine 
protrusions that is corroborated by a decreased frequency of miniature excitatory postsynaptic 
currents (mEPSCs), and this was recapitulated by Zhu et al. in 2013(Ricciardi et al., 2012; Zhu et 
al., 2013). In line with these culture studies, Okuda et al. reported a significantly increased length 
and density of spines on hippocampal pyramidal neurons of Cdkl5 knockout mice, and similarly, 
conditional knockout of CDKL5 selectively from forebrain excitatory cells resulted in an increased 
spine density and frequency of mEPSCs in this same region(Okuda et al., 2018; Tang et al., 
2017). However, additional studies have demonstrated that loss of CDKL5 in mice reduced 
dendritic spine stability and density in somatosensory cortex and reduced excitatory synaptic 
puncta markers in visual cortex(Della Sala et al., 2016; Pizzo et al., 2016). In the visual cortex, 
loss of CDKL5 was associated with a decrease in excitatory puncta markers associated with 
PSD-95 and Homer with a concomitant increase in parvalbumin-positive interneurons, suggestive 
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of a disruptive synaptic organization within this region(Pizzo et al., 2016). Conflicting results on 
these cellular phenotypes between groups is likely due to regional differences within the brain as 
well as in vitro versus in vivo variability on circuit activity and spine dynamics. Furthermore, the in 
vivo functional effects of these synaptic morphological abnormalities associated with CDKL5 loss 
remain unresolved. 
As mentioned, more recent molecular advances have begun to reveal a potential 
mechanistic role for CDKL5 within the microtubule network of neurons, supporting the above-
mentioned morphological phenotypes. However, the in vivo relevance and cellular defects that 
directly result from CDKL5-mediated disruption of microtubule dynamics remain poorly 
understood. In particular, in vivo and genetic models such as knockout mice do not allow for a 
mechanistic dissection of kinase roles in the brain that are direct versus a result of network and 
developmental compensation.  
 
Synaptic, Circuit, and Network Phenotypes of CDKL5-Deficient Mice 
Synaptic phenotypes regulated by CDKL5 
 As highlighted above, several studies to date in both knockout mouse models and 
knockdown cell culture systems have demonstrated an altered synaptic density and morphology 
with loss of CDKL5. In hippocampal primary neurons and in vivo, CDKL5 knockout appears to 
lead to an increased proportion of thin, filipodia-like, or morphologically immature, dendritic 
spines(Della Sala et al., 2016; Ricciardi et al., 2012; Zhu et al., 2013). These have been 
supported by a decreased frequency and amplitude of mEPSCs in hippocampal neuron cultures 
and onto pyramidal neurons in vivo within somatosensory cortex(Della Sala et al., 2016; Ricciardi 
et al., 2012; Zhu et al., 2013). Surprisingly, selective loss of CDKL5 from forebrain excitatory 
neurons was reported to increase both spine density and the frequency of mEPSC in the 
hippocampal CA1 region(Tang et al., 2017). In parallel, selective loss of CDKL5 from GABAergic 
forebrain neurons also leads to an increased mEPSC frequency onto hippocampal pyramidal 
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neurons coupled with circuit hyperexcitability in the form of aberrant paired-pulse facilitation(Tang 
et al., 2019). Whether these varied results are the outcome of region-specific effects of CDKL5 
loss, in vitro versus in vivo models, or the effects of conditional versus whole-network CDKL5 
deletion remains to be confirmed, but highlight a potentially context-specific role for CDKL5. 
Regardless, these previous findings have established precedence for altered synaptic signaling 
with loss of CDKL5. 
 Okuda et al. reported an increased postsynaptic localization of GluN2B-containing NMDA 
receptors in the hippocampus of Cdkl5 knockout mice. This finding was supported by an 
increased ratio of NMDAR/AMPAR -mediated EPSCs, and in particular, a significantly larger 
decay time constant of NMDA receptor-mediated EPSCs reflective of an increased contribution of 
GluN2B-containing NMDARs. Accordingly, this aberrant NMDAR signaling activity was mitigated 
by the GluN2B-selective antagonist ifenprodil, further highlighting NMDAR subunit mislocalization 
within this circuit upon CDKL5 loss(Okuda et al., 2017). 
 In an independent study of Cdkl5 knock-in mice (Cdkl5R59X), there was no reported 
alterations in the postsynaptic localization of NMDAR subunits measured by protein 
quantification. Instead, this study reported a decrease in GluA2 protein within postsynaptic 
density fractions of knockout mice, highlighting an increased contribution of GluA2-lacking AMPA 
receptors that was accompanied by an increased rectification ratio of AMPAR-mediated EPSCs 
within the CA1. Interestingly, a GluA2-lacking-specific AMPAR blocker (IEM-1460) was capable 
of rescuing several behavioral deficits in this mouse model such as context-dependent 
memory(Yennawar et al., 2019). 
These synaptic phenotypes may arise through CDKL5’s regulation of postsynaptic 
proteins such as NGL-1, SAP-102, or PSD-95, or alternatively, due to a disruption of microtubule 
network-mediated receptor trafficking and synaptic maturation. However, the direct association 
between CDKL5 loss, postsynaptic protein and receptor trafficking, and these synaptic 
phenotypes has yet to be confirmed. 
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Disrupted circuit activity with loss of CDKL5 
Despite the lack of overt, behavioral seizures in animal models of CDD reported to date, 
several groups have observed synaptic and circuit-level hyperexcitability in various brain regions 
as well as altered sensitivity to specific chemoconvulsants. Constitutive loss of CDKL5 was found 
to result in enhanced long-term potentiation in the hippocampus by a misregulation of 
postsynaptic GluN2B-containing NMDA receptor localization(Okuda et al., 2017). In line with this, 
Cdkl5 KO mice exhibit significant hyperexcitability to NMDA, and this NMDA-sensitivity phenotype 
was recapitulated in an independent Cdkl5 knock-in line (Cdkl5R59X; reported in Chapter 2)(Tang 
et al., 2019). In contrast, a different study demonstrated impaired long-term potentiation in 
somatosensory cortex of Cdkl5 knockout mice coupled to decreased dendritic spine stability and 
mEPSC frequency(Della Sala et al., 2016).  
Furthermore, conditional deletion of CDKL5 from forebrain excitatory neurons was 
reported to disrupt hippocampal microcircuitry with an increased frequency of both mEPSCs and 
mIPSCs onto CA1 pyramidal neurons but no change in their amplitude(Tang et al., 2017). 
Specifically, voltage-sensitive dye imaging (VSDI) demonstrated spatio-temporally-distinct 
increases in depolarization and inhibition within the stratum radiatum and stratum 
pyramidale/oriens highlighting a differential spatial distribution of aberrant excitation and inhibition 
within the hippocampus. This disrupted hippocampal microcircuit was associated with the 
impaired learning and memory phenotype selectively demonstrated by these conditional knockout 
mice(Tang et al., 2017). A follow-up study of this conditional knockout line demonstrated overall 
hippocampal circuit hypo-excitability in the form of aberrant paired-pulse depression(Tang et al., 
2019). In contrast, in the same study we demonstrate that conditional deletion of CDKL5 from 
forebrain inhibitory neurons (Dlx-cKO; Chapter 2) leads to aberrant circuit hyperactivity within the 
hippocampus in the form of aberrant paired-pulse facilitation(Tang et al., 2019). Intriguingly, these 
Dlx-cKO mice also exhibited significantly enhanced frequency of mEPSCs onto pyramidal 
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neurons of the hippocampus, highlighting a likely non cell-autonomous mechanisms for 
disruptions of excitatory signaling via conditional CDKL5 loss from inhibitory neurons. 
Network activity and epilepsy in models of CDKL5 deficiency 
The drug-resistant, refractory, and high burden nature of the seizures associated with 
CDD make them a particularly debilitating aspect of the disorder for both patients and their 
families(H. E. Olson et al., 2019). However, until this year, no animal models to date had been 
reported to recapitulate the spontaneous seizures that are a hallmark feature of the disorder. 
Establishing animal models with stronger face validity for this epilepsy within CDD will be 
imperative in order to dissect the nature of the seizures associated with mutations in Cdkl5 as 
well as further preclinical development/screening of more targeted therapeutics to manage 
seizure occurrence. 
Hippocampal electroencephalographic (EEG) recordings in postnatal day (P) 70-90 male 
Cdkl5Δ6 knockout mice demonstrated disruptions in event-related neuronal oscillations in 
response to auditory stimuli, however, chronic video-EEG recordings revealed no spontaneous 
seizure activity(I. T. Wang et al., 2012). Furthermore, basal EEG patterns and power distribution 
across various oscillation frequencies were unchanged in these hemizygous male Cdkl5 knockout 
mice versus littermate controls. Shortly afterwards, Amendola et al. developed and characterized 
the Cdkl5Δ4 deletion mouse that also results in early reading frame truncation and loss of CDKL5 
function(Amendola et al., 2014). Similarly to the exon 6 deletion mouse, EEG recordings in this 
novel knockout line did not reveal spontaneous epileptiform activity in hemizygous male Cdkl5 
knockout mice. More recently, an exon 2 deletion mouse of Cdkl5 (Cdkl5Δ2; also resulting in 
constitutive knockout) was created, and although it was reported that these animals carried an 
increased sensitivity to NMDA-induced seizures, no overt spontaneous seizure activity was 
reported(Okuda et al., 2017). In summary, despite the presence of multiple behavioral and 
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neurophysiological impairments, no spontaneous seizure activity has been reported across three, 
independent constitutive Cdkl5 knockout mouse lines.  
It was long purported that the lack of a robust seizure phenotype in CDD mouse models 
was due to neural network differences between human and mouse brains. Despite this, several 
groups have observed synaptic and circuit-level hyperexcitability in various brain regions 
(described above) as well as altered sensitivity to specific chemoconvulsants. Although high-dose 
kainic acid induces overt seizures in Cdkl5 hemizygous knockout males at similar latency to wild-
type littermates, the mean duration of these epileptic EEG bursts is reported to be 
longer(Amendola et al., 2014). Cdkl5 KO mice have also been reported to display decreased 
latency to seizure upon low-dose pentylenetetrazol administration(Yennawar et al., 2019). 
Although EGG recordings in loss-of-function models of CDD have not revealed spontaneous 
seizures, the majority of these studies have been limited to hemizygous males or 
young/adolescent animals. These early findings suggest that seizure susceptibility may in fact be 
altered in the absence of CDKL5, but perhaps only under certain environmental conditions or 
even specific periods of development and aging.   
In Chapter 5, we describe the first report of overt, myoclonic behavioral seizures in two 
distinct mouse models of CDD: the Cdkl5Δ6 and Cdkl5R59X. These events are specific to aged, 
female mice heterozygous for mutations in Cdkl5, with no hemizygous knockout male mice, 
homozygous knockout female mice, or wild-type mice displaying spontaneous seizure activity. 
This suggests that X-linked mosaicism of Cdkl5 deficiency may be a driving factor of the seizure 
phenotype in mouse models of CDD. A simultaneous report, in collaboration with our lab, 
characterized the ictal and interictal EEG features of epileptic spasms in these female Cdkl5 
heterozygous knockout mice, finding them to be most frequently associated with generalized 
slow-wave activity during sleep(Mulcahey et al., 2020). The precise mechanisms driving this 
mosaicism-linked seizure phenotype remain to be dissected. Nonetheless, these seminal findings 
not only contribute to our understanding of the effects of CDKL5 loss on network hyperactivity in 
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Co-immunoprecipitation of overexpressed GFP-CDKL5 
and endogenous MeCP2 in HEK293T cells; GST pull-
down assay of GST-MeCP2 with 35S-hCDKL5 & co-
immunoprecipitation of GFP-CDKL5 with myc-MeCP2 in 
293T cells
Mari et al. 2005; Lin et al. 
2005; Bertani et al. 2006; 
Williamson et al. 2012
DNMT1
Pull-down assay using GST-DNMT1(1-290) incubated with 
mouse brain extract, followed by fractionation and LC-
MS/MS
Kameshita et al. 2008
SC35
Co-immunoprecipitation of YFP-SC35 with GFP-CDKL5 in 
NIH3T3 cells
Ricciardi et al. 2009
Rac 1
Pull-down assay using GST-CDKL5(670-934) in COS-7 
cells
Chen et al. 2010
NGL-1
Co-immunoprecipitation of NGL-1 using a CDKL5 
antibody in P4 mouse brain synaptosome extract
Ricciardi et al. 2012
Amphiphysin 1
Liquid-phase isoelectric focusing, followed by an in vitro 
kinase assay using incubation with CDKL5(1-352)
Sekiguchi et al. 2013
PSD-95
Co-immunoprecipitation from rat brain 
synaptosomes using CDKL5 and PSD-95 antibodies
Zhu et al. 2013
Mind Bomb 1
Affinity purification of rat brain lysate using GST-
Mib1, followed by sequential elution and LC-MS/MS 
analysis
Mertz et al. 2015
Shootin-1
Co-immunoprecipitation from P5-7 mouse brain 
lysate using CDKL5 and Shootin-1 antibodies
Nawaz et al. 2016
HDAC4
Co-immunoprecipitation of overexpressed CDKL5-FLAG 
with endogenous HDAC4 in SH-SY5Y cells
Trazzi et al. 2016
MAP1S, EB2, and 
ARHGEF2
chemical-genetic identification of direct CDKL5 
substrates, followed by validation of reduced 
phosphorylation in Cdkl5  knockout mouse brain 
Baltussen et al. 2018
MAP1S, CEP131, 
and DLG5
TMT-based CDKL5 phosphoproteomic screening in U2OS 
osteosarcoma cells followed by validation of reduced 
phosphorylation in CDKL5 KD HEK293 cells




Decreased AKT and 
mTOR 
phosphorylation
Western blotting of whole mouse brain lysate; 
kinome profiling
Wang et al. 2012; 
Amendola et al. 2014; 
Fuchs et al. 2014
Decreased GSK3-β 
phosphorylation
Western blotting of mouse hippocampal lysate Fuchs et al. 2014
Increased levels of 
GluN2B and 
SAP102
Western blotting of PSD fraction from adult mouse 
hippocampus and quantification of GluN2B and 
SAP102 protein level
Okuda et al. 2017; Tang 
et al. 2019
Table 2. Putative protein interactions and signaling pathways involving CDKL5 (results in 
bold have been validated in vivo )
Decreased levels of 
GluA2
Western blotting of PSD fraction from adult mouse 
hippocampus and quantification of GluA2 protein 
level




CHAPTER 2 – ALTERED NMDAR SIGNALING UNDERLIES AUTISTIC-LIKE 
FEATURES IN MOUSE MODELS OF CDKL5 DEFICIENCY DISORDER 
 
Adapted from: Tang S*, Terzic B*, Wang ITJ, Sarmiento N, Sizov K, Yue C, Takano H, 
Marsh ED, Zhou Z. Altered NMDAR signaling underlies autistic-like features in mouse 
models of CDKL5 deficiency disorder. Nature Communications. 2019 Jun;10:2655 
*these two authors contributed equally to this work 
 
Abstract 
CDKL5 deficiency disorder (CDD) is characterized by epilepsy, intellectual disability, and 
autistic features, and CDKL5-deficient mice exhibit a constellation of behavioral phenotypes 
reminiscent of the human disorder. We previously found that CDKL5 dysfunction in forebrain 
glutamatergic neurons results in deficits in learning and memory. However, the pathogenic origin 
of the autistic features of CDD remains unknown. Here, we find that selective loss of CDKL5 in 
GABAergic neurons leads to autistic-like phenotypes in mice accompanied by excessive 
glutamatergic transmission, hyperexcitability, and increased levels of postsynaptic NMDA 
receptors. Acute, low-dose inhibition of NMDAR signaling ameliorates autistic-like behaviors in 
GABAergic knockout mice, as well as a novel mouse model bearing a CDD-associated nonsense 
mutation, CDKL5 R59X, implicating the translational potential of this mechanism. Together, our 
findings suggest that enhanced NMDAR signaling and circuit hyperexcitability underlie autistic-





Mutations in cyclin-dependent kinase-like 5 (CDKL5) cause a severe 
neurodevelopmental disorder characterized by early-onset seizures, intellectual disability, and 
autistic features(Kalscheuer et al., 2003; Tao et al., 2004; Weaving et al., 2004). Mouse models 
of CDD have recapitulated numerous aspects of the human disorder, and despite a subtle overall 
degree of impairment, they show behavioral deficits such as impaired learning, reduced 
sociability, motor dysfunction, and altered anxiety-related behaviors(Amendola et al., 2014; 
Jhang, Huang, Hsueh, & Liao, 2017; Okuda et al., 2018; I. T. Wang et al., 2012). The extent to 
which these behavioral deficits arise from common or distinct mechanisms, however, remains 
unclear. 
CDKL5 protein expression is enriched in the forebrain, primarily in glutamatergic and 
GABAergic neurons(Chen et al., 2010; Johnson et al., 2017; Rusconi et al., 2008; I. T. Wang et 
al., 2012; Zeisel et al., 2015). In glutamatergic neurons, CDKL5 has been found at the 
postsynaptic density, where it interacts with PSD-95 and NGL-1(Ricciardi et al., 2012; Zhu et al., 
2013). In addition, loss of CDKL5, both in vitro and in vivo, is associated with changes in dendritic 
morphology, spine density, excitatory synaptic transmission, and synaptic plasticity(Della Sala et 
al., 2016; Okuda et al., 2017; Ricciardi et al., 2012; Tang et al., 2017). Mice lacking CDKL5 
selectively in forebrain glutamatergic neurons (Nex-cKO) show impaired learning and memory, 
reminiscent of the intellectual disability found in CDD(Tang et al., 2017). Interestingly, Nex-cKO 
mice did not show other behavioral deficits found in Cdkl5 constitutive knockout mice, such as 
alterations in sociability, stereotypic behavior, locomotion, motor coordination, and anxiety-related 
behavior(Tang et al., 2017). These findings imply that distinct, cell-type specific etiologies 
underlie CDD-related behavioral phenotypes in mice. 
Mice lacking CDKL5 show numerous functional changes at the synaptic and circuit 
levels. A recent study found that Cdkl5 constitutive knockout mice demonstrated increased 
NMDA-dependent synaptic transmission and enhanced long-term potentiation at hippocampal 
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synapses(Okuda et al., 2017). In contrast, long-term potentiation is decreased in the 
somatosensory cortex of Cdkl5 knockout mice(Della Sala et al., 2016). Furthermore, selectively 
ablating CDKL5 from glutamatergic neurons leads to increased glutamatergic and GABAergic 
synaptic transmission, disrupted microcircuit dynamics, and learning and memory 
impairment(Tang et al., 2017). While some of these differences are potentially attributable to 
different genetic backgrounds of mouse models of CDD, the differences between Cdkl5 
constitutive knockout mice and Nex-cKO mice suggest the existence of additional, non-
glutamatergic mechanisms that may mediate CDD-related behavioral deficits. Notably, the 
function of CDKL5 in forebrain GABAergic neurons, where CDKL5 is also highly expressed, has 
yet to be elucidated(Johnson et al., 2017). 
Here, we selectively ablate CDKL5 expression in forebrain GABAergic neurons (Dlx-
cKO). We found that these mice exhibit an autistic-like phenotype, but, in contrast to Nex-cKO 
mice, show preserved learning and memory(Tang et al., 2017). In addition, Dlx-cKO mice show 
an enhancement of excitatory synaptic transmission and circuit-level hyperexcitability, coupled 
with elevated levels of NMDA receptors. Reducing NMDAR activity using an uncompetitive 
antagonist, memantine, significantly mitigated the behavioral deficits found in Dlx-cKO mice. To 
examine the translational potential of these findings, we generated a novel CDD model bearing a 
patient mutation and found that these mice, similarly to Dlx-cKO mice, show an elevation of 
NMDA receptors. Importantly, acute, low-dose NMDAR blockade selectively ameliorates autistic-
like features in this CDD model. Taken together, our findings support a novel mechanism by 
which CDKL5 loss in GABAergic neurons leads to excessive NMDAR signaling and contribute to 




CDKL5 GABAergic deletion results in autistic-like features 
Our previous findings showed that CDD-related learning and memory impairment has 
origins in forebrain glutamatergic neurons in mice(Tang et al., 2017). Given that CDKL5 is also 
highly expressed in forebrain GABAergic neurons, we generated conditional knockout mice 
selectively lacking CDKL5 in this cell population (Dlx-cKO) using the Dlx-5/6 Cre driver (Figure 
1A, B)(Monory et al., 2006). Dlx-cKO mice showed normal growth and body weight through 
adulthood and no obvious physical abnormalities (Figure 2A). We then performed a battery of 
behavioral assays, similar to those in previous studies of Cdkl5 constitutive KO and Nex-cKO 
mice(Tang et al., 2017; I. T. Wang et al., 2012). Compared to WT controls, Dlx-cKO showed no 
changes in locomotor activity, anxiety-related behaviors, and motor coordination (Fig. 2B–D). 
In contrast, Dlx-cKO mice demonstrated significantly reduced social interaction on the 
three-chamber social approach assay, showing diminished preference for investigating a social 
stimulus as compared to an object (Fig. 3a, b). When allowed the opportunity for direct interaction 
with a novel stimulus mouse, Dlx-cKO mice also spent significantly less time initiating contact in 
comparison to wild-type controls (Fig. 3c). To rule out the involvement of an olfactory deficit 
underlying reduced social preference, we conducted the olfactory habituation-dishabituation test. 
Dlx-cKO mice showed an intact ability to discriminate between different scents but spent reduced 
time sniffing a social scent, a feature consistent with a reduced interest in social stimuli (Fig. 3d). 
In addition to social deficits, another defining feature of human autism spectrum disorders 
(ASDs) is the presence of repetitive or stereotypic behaviors. We next assessed repetitive 
behaviors in Dlx-cKO mice. In a home-cage like environment, Dlx-cKO mice showed significantly 
increased time engaging in stereotypic behaviors such as grooming and digging (Fig. 3e), and 
also exhibited a nesting deficit (considered by some to be a home-cage social behavior) 
compared to littermate controls (Fig. 3f). 
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We next assessed learning and memory, a behavioral domain significantly impaired in 
both Cdkl5 constitutive knockout mice and Nex-cKO mice. Interestingly, Dlx-cKO showed no 
impairment in spontaneous alternation behavior on the Y-maze, suggesting intact working 
memory (Fig. 3g, h). On the Barnes maze, an assay of spatial learning and memory, Dlx-cKO did 
not show a significant difference from wild-type controls in the number of errors made on probe 
trials (Fig. 3i). However, when the target hole location was altered to the opposite side of the 
maze after acquisition (reversal probe trials), Dlx-cKO mice demonstrated a significant 
impairment in adjusting to this new target hole (Fig. 3j). In addition, Dlx-cKO mice show an 
increased number of perseverations on reversal probe trials, or visits to the previous target hole 
location (Fig. 3k). These results suggest that Dlx-cKO mice have intact learning and memory, but 
impaired cognitive flexibility, another feature reminiscent of autism spectrum disorders. 
Taken together, Dlx-cKO mice show a set of autistic-like features with relatively 
preserved learning and memory that stand in contrast to previous findings in Nex-cKO mice, 
which exclusively show impaired learning and memory(Tang et al., 2017). These results 
demonstrate a segregation of behavioral deficits in Cdkl5 conditional knockout mice, suggesting 
that impaired learning and autistic-like features have distinct cellular origins in CDD. 
Dlx-cKO mice show aberrant circuit activation 
In previously established mouse models of ASD, the finding of excitation-inhibition (E/I) 
imbalance has emerged as a prominent theme underlying patterns of circuit and network 
dysfunction(Bourgeron, 2015; Rubenstein & Merzenich, 2003). Specifically, hyperexcitability at 
the circuit and network levels has been found to be associated with many of the autistic-like 
features reported in these models. Importantly, reversal of hyperexcitability in these models is 
often sufficient to ameliorate disease phenotypes, demonstrating a causal role for E/I imbalance 




The exhibition of autistic-like features in Dlx-cKO mice, coupled to the previous findings 
of E/I imbalance in other models of ASD, prompted us to investigate any circuit irregularities in 
CDD mouse models. We first used voltage-sensitive dye imaging (VSDI), a technique that has 
been consistently used in mouse models of neurologic disease to assess circuit function with high 
spatiotemporal resolution(Ang, 2005; Ang, Carlson, & Coulter, 2006; Calfa, Hablitz, & Pozzo-
Miller, 2011; Carlson & Coulter, 2008; Tang et al., 2017). We conducted our experiments with 
WT, Dlx-cKO, and Nex-cKO mice, to facilitate a side-by-side comparison of circuit function in the 
context of the distinct behavioral profiles of Dlx-cKO and Nex-cKO mice. 
We began by interrogating the function of the perforant path-dentate gyrus pathway, a 
hippocampal microcircuit often perturbated in disease states that critically relies on both excitation 
and inhibition for proper function(Douglas A. Coulter et al., 2011; Dengler & Coulter, 2016; 
Goldberg & Coulter, 2013). Using VSDI responses as a readout, we assessed the layer-specific 
responses of the molecular layer, granule cell layer, as well as the downstream hilar region in 
response to perforant path stimulation (Fig. 4a). We used a paired-pulse paradigm, which 
assesses both the baseline excitability of the circuit and its short-term plasticity. We first focused 
our analysis on the response of the granule cell layer (Fig. 4b–e), which contains the cell bodies 
of the principal neurons of the dentate gyrus. WT mice showed comparable responses in the 
granule cell layer to the first and second stimuli without significant facilitation or depression (Fig. 
4b–d), showing a paired-pulse ratio that was not significantly different from one (Fig. 4e). Neither 
Nex-cKO or Dlx-cKO mice showed a significant difference from WT in their peak responses to the 
first stimulation, suggesting similar baseline excitability of the dentate gyrus (Fig. 4b, c). 
Interestingly, Nex-cKO mice showed a diminished peak response to the second stimulus, with a 
paired-pulse ratio significantly less than one (Fig. 4b, d, e). In contrast to Nex-cKO mice, Dlx-cKO 
mice exhibited paired-pulse facilitation, evident by an increase in depolarization upon a second 
successive stimulus and a peak ratio significantly greater than one (Fig. 4d, e). Importantly, this 
aberrant paired-pulse facilitation in Dlx-cKO was also observed in an upstream input region 
(molecular layer) and downstream output region (hilus) (Fig. 4f–k). Furthermore, we repeated this 
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experiment at a second stimulation intensity and observed similar results (Fig. 5). Taken together, 
our findings reveal that the distinct behavioral phenotypes of Cdkl5 conditional knockout mice are 
accompanied by contrasting patterns of circuit dysfunction. Specifically, Dlx-cKO mice show 
circuit hyperexcitability in the form of aberrant paired-pulse facilitation, whereas Nex-cKO mice 
show circuit hypo-excitability in the form of aberrant paired-pulse depression. 
Dlx-cKO mice show enhanced excitatory synaptic transmission 
Given the finding of circuit hyperexcitability in Dlx-cKO mice, we next investigated the 
synaptic origins of this E/I imbalance. Previous studies have found enhanced synaptic 
transmission and long-term potentiation in the hippocampal CA1 region of Cdkl5 constitutive 
knockout mice(Okuda et al., 2017). Interestingly, these changes were not fully recapitulated in the 
glutamatergic conditional knockout mice, suggesting that CDKL5 function in other neuronal 
populations, such as GABAergic neurons, may contribute to synaptic hyperexcitability(Tang et al., 
2017). Therefore, using whole-cell patch-clamp recordings, we assessed both excitatory and 
inhibitory synaptic transmission in the hippocampal CA1 region in Dlx-cKO mice. We found that 
Dlx-cKO mice exhibited significantly enhanced frequency of miniature spontaneous excitatory 
postsynaptic currents (mEPSCs), but no changes in amplitude or kinetics of these events (Fig. 
6a–e and Fig. 7A, B). In contrast, miniature spontaneous inhibitory postsynaptic currents 
(mIPSCs) were not significantly different in either amplitude, frequency, or kinetics between Dlx-
cKO and WT mice (Fig. 6f–j and Fig. 7C, D). This suggests that despite CDKL5 loss in 
GABAergic neurons, adult Dlx-cKO mice do not show a significant alteration of inhibitory signaling 
at CA1 pyramidal neurons. In turn, synaptic transmission between excitatory neurons is 
enhanced upon selective loss of CDKL5 in GABAergic neurons. Taken together, our results 




Dlx-cKO mice have an increase in postsynaptic NMDA receptors 
The finding of excess glutamatergic synaptic transmission in Dlx-cKO mice suggests a 
potential alteration in the molecular composition of postsynaptic receptors. Indeed, previous 
studies have suggested a role for CDKL5 in regulating synaptic receptor composition and 
homeostasis(P. La Montanara et al., 2015; Okuda et al., 2017). For example, excessive 
glutamatergic synaptic transmission can result from an enhancement of postsynaptic AMPA 
receptors (AMPAR), NMDA receptors (NMDAR), or both. We therefore examined the composition 
of major ionotropic glutamate receptors in postsynaptic density membrane preparations from Dlx-
cKO and WT mice, including GluA1, GluA2, GluN1, GluN2A, and GluN2B. Interestingly, we found 
a selective increase in the protein level of NMDARs, but not AMPARs in Dlx-cKO mice (Fig. 8). 
Specifically, the NMDAR subunits GluN1 and GluN2B were significantly elevated in Dlx-cKO 
mice. (Fig. 8d, f). These findings are consistent with results from Cdkl5 constitutive knockout mice 
and suggest a non-cell autonomous mechanism underlying the enhancement of glutamatergic 
synaptic transmission through CDKL5 loss from GABAergic neurons(Okuda et al., 2017). 
NMDAR blockade ameliorates autistic-like features in Dlx-cKO 
Our findings in Dlx-cKO mice raised the possibility that enhanced NMDAR signaling may 
underlie the autistic-like phenotype exhibited by these mice. We first investigated the extent to 
which NMDAR signaling is responsible for the repetitive behavior phenotype in Dlx-cKO mice. We 
used low doses of memantine, a non-competitive NMDA receptor blocker that has been 
previously found to rescue behavioral deficits in numerous mouse models of neurodevelopmental 
disorders(Chung et al., 2015; Figueiredo et al., 2013; J. Kang & Kim, 2015). We observed that 
acute memantine administration (5 mg kg−1, intraperitoneal) ameliorated excessive grooming in 
Dlx-cKO mice, significantly reducing both total time spent grooming and the duration of the 
longest grooming bout (Fig. 9a, b). Next, we employed a modified dyadic interaction assay to 
quantitatively assess social interactions in drug- and vehicle-treated Dlx-cKO mice. Whereas 
vehicle-administered Dlx-cKO mice showed significantly reduced social interaction, memantine 
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ameliorated this deficit, significantly increasing the time spent by Dlx-cKO mice in social 
interaction (Fig. 9c). This effect was specific to Dlx-cKO mice, as memantine normalized the ratio 
of time spent in social interaction in pairs of Dlx-cKO and WT control mice co-tested side-by-side 
in identical cages (Fig. 9d). Taken together, these results suggest that enhanced NMDAR 
signaling underlies, at least in part, the autistic-like features of Dlx-cKO mice, and that an acute 
reduction of NMDAR activity can ameliorate these phenotypes. 
NMDAR blockade improves autistic-like features in CDKL5 R59X 
To investigate the translational potential of our findings in Dlx-cKO mice, we generated a 
novel mouse model of CDD, Cdkl5R59X (referred to as R59X). R59X mice bear a knock-in 
mutation mimicking a human CDD nonsense mutation at arginine 59, leading to the loss of 
CDKL5 kinase function (Fig. 10a). We found that full-length CDKL5 protein expression was 
abolished in R59X mice, similar to a knockout model we previously developed (Fig. 11)(I. T. 
Wang et al., 2012). Similar to Dlx-cKO mice and other mouse models of CDD, R59X mice 
demonstrate autistic-like features, including increased repetitive behaviors and diminished social 
interaction (Fig. 12). 
We next investigated the extent to which enhanced NMDAR signaling is also present in 
R59X mice. Using a similar approach as for Dlx-cKO mice, we examined the protein levels of 
NMDAR and AMPAR subunits in postsynaptic density fractions (Fig. 10b–g). In R59X mice, we 
found an upregulation of NMDAR subunit levels, with a selective increase in GluN2B, mirroring 
previous findings in Cdkl5 constitutive knockout mice (Fig. 10g)(Okuda et al., 2017). 
Using R59X mice as a model of CDD, we next examined the extent to which enhanced 
NMDA signaling is responsible for CDD-related behavioral deficits. We first tested the possibility 
that enhanced NMDAR signaling may underlie impaired learning and memory in CDKL5-deficient 
mice. Using the Y-maze assay, we found that R59X mice demonstrated a robust working memory 
deficit, demonstrated by reduced spontaneous alternation behavior, similar to our previous 
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findings in both Cdkl5 constitutive KO and Nex-cKO mice (Fig. 12a)(Tang et al., 2017; I. T. Wang 
et al., 2012). Notably, acute memantine administration at a range of doses (1.25–10 mg kg−1, 
intraperitoneal) did not ameliorate this behavioral deficit, suggesting that excess NMDAR 
signaling is unlikely to be the major mechanism underlying learning and memory deficits in R59X 
mice (Fig. 12a). 
In contrast, we observed that acute memantine administration (5 mg kg−1, intraperitoneal) 
rescued excessive stereotypic behaviors in R59X mice, significantly reducing both total time 
spent grooming and the duration of the longest grooming bout to a level similar to that of WT mice 
(Fig. 12b, c). Similarly, whereas vehicle-treated R59X mice showed significantly reduced social 
interaction, memantine ameliorated this deficit, significantly increasing the time spent by R59X 
mice in social interaction (Fig. 12d). This effect was specific to R59X mice, as memantine 
normalized the ratio of time spent in social interaction in pairs of R59X and WT control mice co-
tested side-by-side in identical cages (Fig. 12e). Taken together, these results suggest that 
enhanced NMDAR signaling underlies the autistic-like features, but not learning and memory 
deficits, in CDKL5-deficient mice, and reveal the translational potential of this pathway in the 
treatment of CDD. 
Discussion 
Our behavioral studies in Dlx-cKO mice revealed an autistic-like phenotype characterized 
by reduced social preference and increased stereotypic behaviors, but relative preservation of 
other behaviors such as learning and memory, motor coordination, and anxiety-related behaviors. 
This behavioral profile stands in contrast to our previous findings in Nex-cKO mice, which exhibit 
selectively impaired learning and memory. Our results delineate the distinct cellular origins of 
CDD-related behavioral phenotypes: whereas impaired learning primarily originates from the loss 
of CDKL5 in forebrain glutamatergic neurons, autistic-like features primarily originate from the 
loss of CDKL5 in forebrain GABAergic neurons. Interestingly, anxiety-related behavior, 
locomotion, and motor coordination were not altered in either Nex-cKO or Dlx-cKO mice. These 
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additional phenotypes may be mediated by 1) CDKL5 function in other cell populations and brain 
regions and/or 2) the synergistic functions of CDKL5 in forebrain glutamatergic and GABAergic 
neurons. 
Our findings in Cdkl5 conditional knockout mice support a model whereby CDKL5 loss in 
glutamatergic and GABAergic neurons lead to divergent changes in E/I balance that generate 
distinct behavioral deficits. We show that in Dlx-cKO mice, hippocampal circuit hyperexcitability is 
coupled with autistic-like features, a finding corroborated in numerous other mouse models of 
autism(Chung et al., 2015; Lee, Lee, & Kim, 2017; Sacha & Valakh, 2015; Yizhar et al., 2011). In 
specific cases, autistic-like behaviors have been linked to a dysfunction of inhibitory neuronal 
transmission(Chao et al., 2010; Han et al., 2012; Rothwell et al., 2014). In contrast, we show that 
in Nex-cKO mice, hippocampal circuit hypo-excitability is linked to learning and memory deficits. 
Interestingly, reduced E/I ratio has been demonstrated in numerous mouse models of intellectual 
disability(Dierssen, 2012; Fernandez & Garner, 2007). Therefore, our studies reveal a novel 
avenue toward treating specific CDD-related symptoms, but also suggest that modulation of E/I 
balance in CDD may be a double-edged sword. To date, the majority of reported CDD patients 
have been predicted to carry loss-of-function mutations, such as nonsense, indels, or missense 
mutations abolishing CDKL5 kinase activity, suggesting that our knockout and R59X knockin 
mouse models may carry a high translational relevance. In order to develop targeted therapies for 
CDD, additional studies are needed to elucidate the specific signaling pathways and neural 
circuits responsible for each of the behavioral symptoms. 
In our VSDI studies of Nex- and Dlx-cKO mice, we employed a paired-pulse stimulation 
paradigm, which assesses the integration of excitatory and inhibitory synaptic transmission in the 
dentate gyrus. Interestingly, previous work has shown that NMDA signaling is a necessary 
component for the paired-pulse facilitation response in the dentate gyrus, suggesting a potential 
mechanism for circuit excitability in Dlx-cKO mice(Joy & Albertson, 1993). On the other hand, the 
aberrant paired-pulse depression in Nex-cKO mice may result from enhanced inhibition, given 
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that feedforward and feedback inhibition play key roles in regulating the activity of the dentate 
gyrus(Amaral, Scharfman, & Lavenex, 2007; D.A. Coulter & Carlson, 2007; Tang et al., 2017). In 
our electrophysiologic studies of Dlx-cKO mice, the most prominent change was, surprisingly, an 
enhancement in glutamatergic synaptic transmission. This change likely arises from a non-cell 
autonomous mechanism, especially in the absence of a concomitant change in GABAergic-
glutamatergic inhibitory synaptic transmission. For example, the loss of CDKL5 in GABAergic 
interneurons may lead to a modulation of presynaptic release probability at glutamatergic 
synapses. Alternatively, enhanced excitatory synaptic transmission may be a homeostatic 
response to a transient alteration of GABAergic signaling during early development. Supporting 
this notion, a previous study has found that GABAergic transmission cooperates with NMDA 
receptor activation during development for excitatory synapse formation(D. D. Wang & Kriegstein, 
2008). Furthermore, the loss of CDKL5 may lead to different disruptions in distinct populations of 
forebrain interneurons that as of yet we are unable to dissect from our Dlx5/6-Cre-driven 
dissection. Future studies looking into the role of CDKL5 at specific sub-populations of 
interneurons will provide clarity on its non-cell autonomous roles. 
Interestingly, despite the findings of synaptic and circuit-level hyperexcitability, we did not 
observe spontaneous seizure-like behaviors in Dlx-cKO mice during our routine assays, at least 
in male mice and at the ages examined. This is similar to what has been observed in constitutive 
loss-of-function models of CDD where EEG recordings have not revealed spontaneous 
seizures(Amendola et al., 2014; Okuda et al., 2017; I. T. Wang et al., 2012). However, this does 
not exclude the possibility that seizure susceptibility is altered in the absence of CDKL5 under 
certain environmental conditions and during specific periods in development and aging. Thus far, 
the lack of a robust seizure phenotype in CDD mouse models suggests that neural network 
differences between human and mouse brains may prevent the development of overt seizures in 
CDKL5-deficient mice. In addition, given the contrasting profiles of hypo- and hyperexcitability in 
Nex-cKO and Dlx-cKO mice, respectively, the state of circuit excitability in constitutive loss-of-
function models of CDD remains to be further characterized. Indeed, previous studies have 
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revealed changes in synapse density, distribution, and plasticity of both excitatory and inhibitory 
neurons(Della Sala et al., 2016; Okuda et al., 2017). Therefore, it is possible that both pro- and 
anti-epileptogenic changes occur in the CDKL5-deficient brain, each playing a distinct role in 
mediating the various behavioral deficits of CDD. 
The finding of enhanced NMDAR signaling reveals a novel synaptic mechanism that may 
potentially underlie the behavioral deficits of mouse models of CDD. Our results in Dlx-cKO mice 
suggest that GABAergic dysfunction leads to an enhancement of NMDAR signaling, which in turn 
is responsible for autistic-like features. We validate this mechanism in R59X mice, demonstrating 
that the acute reduction of NMDAR signaling ameliorates select CDD-related behavioral deficits. 
Whereas acute memantine administration specifically rescued repetitive behavior and 
significantly improved social interaction in R59X mice, it did not positively affect the learning and 
memory deficit in R59X mice. Altogether with our previous findings in Nex-cKO mice, our studies 
suggest that distinct subsets of CDD-related phenotypes are mediated by distinct synaptic and 
circuit mechanisms(Tang et al., 2017). Future studies are expected to refine these mechanisms 
by testing brain region- and circuit-specific mechanisms for specific CDD-related phenotypes. For 
example, given that we found enhanced NMDAR subunit levels in our postsynaptic density 
membrane fractions, we cannot rule out the possibility that extra-synaptic NMDAR levels are also 
altered in Dlx-cKO and R59X mice. Indeed, memantine is known to act at both synaptic and 
extra-synaptic receptors in a dose-dependent manner, and its effects on behavior may be 
mediated by both mechanisms(Beconi et al., 2011). Although it may be difficult to distinguish 
between these two populations of NMDARs in vivo, further work in this direction can elucidate the 
mechanism that underlies the enhancement of synaptic NMDAR signaling in mouse models of 
CDD. 
Taken together, our studies delineate the forebrain GABAergic origins of autistic-like 
features in CDKL5-deficient mice, showing for the first time that CDKL5 is required in this diverse 
population of neurons for proper neural development and function. At the synaptic level, we 
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reveal an enhancement of NMDAR signaling that contributes to circuit hyperexcitability. Finally, in 
a novel disease model of CDD, we show that acute reduction of NMDAR signaling can ameliorate 
behavioral deficits, highlighting a potentially important mechanism for CDD-related phenotypes in 
mice and supporting a novel therapeutic avenue for the treatment of these symptoms in CDD 
patients. 
Materials and Methods 
Mouse strains. The Cdkl5 floxed mouse line with Cre-dependent excision of exon 6 was used for 
the generation of conditional knockout mice(Tang et al., 2017). Dlx5/6-Cre, a mouse line 
expressing Cre in forebrain inhibitory neurons, was obtained from Jackson Laboratories and 
maintained in the C59BL/6J background (Stock No. 008199)(Monory et al., 2006). The CDKL5 
R59X knock-in line was generated as follows: a targeting vector was designed to insert a frt-
flanked neomycin resistance (neo) cassette downstream of exon 5, and a single-nucleotide 
change of C to T, leading to a nonsense mutation at arginine 59 (R59X) of the Cdkl5 gene. The 
construct was electroporated into C57BL/6N embryonic stem (ES) cells. Correctly targeted ES 
cells were injected into BALB/c blastocysts and resulting chimeric mice were bred with B6.Cg-
Tg(ACTFLPe)9205Dym/J (Jackson Laboratories, Stock No. 005703) to remove the neo cassette. 
Resulting offspring were bred to C57BL/6J mice (Jackson Laboratories, Stock No. 000664) for at 
least ten generations. The R59X knock-in mouse line has been deposited at Jackson 
Laboratories (Stock No. 028856). 
 
Mouse husbandry. Experiments were conducted in accordance with the ethical guidelines of the 
National Institutes of Health and with the approval of the Institutional Animal Care and Use 
Committee of the University of Pennsylvania. Cdkl5flox and R59X mice were backcrossed to 
C57BL/6 for at least ten generations before breeding for experiments. Mouse lines were 
genotyped using a PCR-based strategy, with their respective primer sequences and other details 
found on the Jackson Laboratories website under the appropriate stock numbers listed above. 
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Mice were group-housed in cages of three to five in a 12-h light/dark cycle with food and water 
provided ad libitum. 
For breeding of Dlx-cKO and wild-type control mice, each breeding cage consisted of two 
homozygous female mice (genotype: Cdkl5flox/Cdkl5flox) and one male mouse (genotype: Dlx5/6-
Cre/+). Male littermates (genotypes: Cdkl5flox/y; +/+ and Cdkl5flox/y; Dlx5/6-Cre) were weaned at 3 
weeks of age and housed together, with all experiments performed on age-matched adult mice 
between 9 and 12 weeks of age. For behavioral experiments, wild-type control mice (genotype: 
Cdkl5flox/y; +/+) from Nex-cKO breedings14 were pooled with wild-type control mice from Dlx-cKO 
breedings (genotype: Cdkl5flox/y; +/+). Nex-cKO mice were generated using a similar strategy as 
described previously. For breeding of R59X and wild-type control mice, each breeding cage 
consistent of two heterozygous female mice (genotype: R59X/+) and one male mouse (genotype: 
+/y). Male littermates (genotypes: R59X/y and +/y) were weaned at 3 weeks of age and housed 
together, with all experiments performed on age-matched adult mice between 9-12 weeks of age. 
 
Behavioral assays. All animal behavioral studies were carried out blinded to genotype. Mice 
were allowed to habituate to the testing room for at least 1 h before the test, and testing was 
performed at the same time of day. All animal behaviors were performed on adult male mice at 9–
12 weeks of age, and the analysis of behavioral data was carried out by a researcher blinded to 
genotype. 
Elevated zero maze. The elevated zero maze (Stoelting, Illinois, USA) consists of a circular-
shaped platform elevated above the floor. Two opposite quadrants of the maze are enclosed (wall 
height, 12 inches), whereas the other two are open (wall height, 0.5 inches). Mice were placed in 
one of the closed quadrants and their movement traced over the course of 5 min. Analysis, 
including the quantification of percent of time spent in open arms and the number of entries, was 
performed manually using a stopwatch. An entry was defined as a transition from a closed to 
open arm, or vice versa, that involves all four paws. 
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Three-chambered social approach assay. The social approach assay was performed as 
previously described(Fairless et al., 2013; Sankoorikal, Kaercher, Boon, Lee, & Brodkin, 2006). 
The social choice test was carried out in a three-chambered apparatus that consisted of a center 
chamber and two end chambers. Before the start of the test and in a counter-balanced sequence, 
one end chamber was designated the social chamber, into which a stimulus mouse would be 
introduced, and the other end chamber was designed the nonsocial chamber. Two identical, clear 
Plexiglas cylinders with multiple holes to allow for air exchange were placed in each end 
chamber. In the habituation phase of the test, the test mouse was placed in the center chamber 
and allowed to explore all three chambers for 10 min. During this acclimation period, baseline 
measurements of how much time the mouse spent in each of the three chambers and the 
distance traveled by the test mouse were collected. In the social choice phase of the test, a 
stimulus mouse (adult gonadectomized A/J mice; The Jackson Laboratory) was placed in the 
cylinder in the social chamber while a novel object was simultaneously placed into the other 
cylinder in the nonsocial chamber. During the 5-min social choice period, chamber times and 
numbers of transitions among chambers were again recorded. In the direct social interaction test, 
the cylinders were removed simultaneously following the social choice test, and the amount of 
time test and stimulus mice spent in direct contact (sniffing, allogrooming) was measured. If 
fighting persisted for more than several seconds, the mice were removed from the apparatus and 
excluded from the study. 
Y-maze. Spontaneous alternation behavior was measured on a Y-maze apparatus (San Diego 
Instruments, California, USA), composed of three arms (Arm A: 8in. x 5in. x 3in.; Arms B and C: 
6in. x 5in. x 3in.). For habituation, the test mouse was placed in each of the three arms, facing the 
center, and allowed to make one choice to enter another arm. For testing, the mouse was placed 
in Arm C, facing the center, and allowed to freely explore the maze for 5 min. A spontaneous 
alternation was defined an entry into the arm less recently explored. Percent spontaneous 
alternation was calculated as the number of spontaneous alternations over the total number of 
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entries. For example, the sequence C,B,A,B,C,B,A,C (starting in arm C) resulted in a percent 
spontaneous alternation of 4/6 = 67%. 
Barnes maze. Hippocampal-dependent memory was assessed on a Barnes Maze apparatus 
(San Diego Instruments, California, USA), a circular platform with 36-inch diameter and 20 
equally spaced escape holes along the perimeter, one of which leads to a “target” escape box. 
Bright lighting was used as stimulus to complete the task. The assay consisted of five phases: 
adaptation, forward acquisition training, forward probe trials, reversal training, and reversal probe 
trials. For adaptation, each mouse was placed in a dark start chamber in the middle of the maze 
for 10 s, then uncovered and guided gently to the escape box. Forward acquisition training 
consisted of two trials per day for 4 days, with each mouse starting in the dark start chamber in 
the middle of the maze and subsequently allowed to explore the maze for 3 min. The trial ends 
when the mouse enters the target escape hole or after 3 min have elapsed, after which the 
mouse is guided gently to the escape hole. After reaching the escape hole, the mouse is allowed 
to remain there for 1 min. Forward probe trials were conducted on day 5, 24 h after the last 
training day. During the probe trial, the maze is in the same position as the training days, and the 
target hole is closed. Each trial lasted 90 s, during which the number of errors (pokes into non-
target holes) made prior to reaching the target hole is quantified. Days 6–10 consisted of reversal 
training, conducted using a similar protocol as forward acquisition training, except that the target 
was a stable escape hole moved 180° from its location during forward acquisition training. 
Reversal probe trials were conducted on day 11 and identically to forward probe trials. In addition 
to quantifying the number of total errors, the number of perseverations, defined as pokes into the 
previous target hole during forward acquisition training, was counted. 
Locomotor assay. Locomotor activity was measured by beam breaks in a photobeam frame (Med 
Associates, Vermont, USA). Mice were individually placed into a clean home-cage like 
environment lined with bedding and resting within a photobeam frame. The number of beam 
breaks as a measure of locomotor activity was quantified over 30 min in 5-min bins. 
39 
 
Accelerating Rotarod assay. Mice were placed on an accelerating Rotarod apparatus (Med 
Associates) for 16 trials (four trials a day for 4 consecutive days) with at least 15 min of rest 
between the trials. Each trial lasted for a maximum of 5 min, during which the rod accelerated 
linearly from 4 to 40 rpm. The amount of time for each mouse to fall from the rod was recorded for 
each trial. 
Olfaction. Mice were tested for whether they could detect and differentiate odors in a habituation–
dishabituation protocol modified from Yang and Crawley. Mice were presented with cotton-tipped 
wooden applicators dipped in water, vanilla, or swiped across the bottom of an unfamiliar social 
cage. Each stimulus was presented for 2 min with a 1-min inter-trial interval. Time spent sniffing 
was defined as when the animal was oriented with its nose 2 cm or closer toward the cotton tip. 
Repetitive behavior. Mice were individually placed into a clean home-cage like environment lined 
with bedding. After allowing 5 min for habituation, 10 min of activity was videotaped for each 
mouse. The duration of repetitive behavior, defined as grooming or digging, was scored manually 
using a stopwatch. 
Nesting. Nesting behavior was scored in accordance with the standard protocol and rating scale 
originally described by Deacon(Deacon, 2006). Four- to five-week old mice were assessed for 
amount of cotton material used after 20 h and for the height and shape of the nest. Rating scale 
as follows: (1) nestlet not noticeably touched (>90% intact); (2) nestlet partially torn (50–90% 
remaining intact); (3) nestlet mostly shredded but often no identifiable nest site: <50% of the 
Nestlet remains intact, but <90% is within a quarter of the cage floor area; (4) an identifiable but 
flat nest: >90% of the Nestlet is torn and the material is gathered into a nest within a quarter of 
the cage floor area, but the nest is flat, with walls higher than mouse body height (of a mouse 
curled up on its side) for <50% of its circumference; (5) a (near) perfect nest: >90% of the Nestlet 
is torn and the nest is a crater, with walls higher than mouse body height for >50% of its 
circumference. 
Dyadic interaction. The dyadic interaction test is an abbreviated version of the three-chambered 
assay to quantitatively assess the duration of direct social interaction in two freely behaving mice. 
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One week prior to the assay, male R59X and wild-type control mice were singly housed to 
increase the motivation for social interaction and reduce aggression. Age-matched, novel, wild-
type male stimulus mice were group-housed. On the day of the test, test and stimulus mice were 
acclimated to the room for 1 h prior to the start of the assay. Following this period, each test 
mouse is placed individually in a clear, round Plexiglass cage (Pinnacle Technology, Lawrence, 
Kansas, USA) measuring 8 inches tall and 9.5 inches in diameter, with a thin layer of bedding. 
Following 30 min of habituation in the cage, a novel, age-matched stimulus mouse was placed 
into the cage, and the mice were allowed to freely interact under video monitoring for 10 min. The 
total duration of social interaction initiated by the test mouse in the first 2 min was scored, and this 
included oro-genital sniffing, oro-facial sniffing, close following, placing one or both paws on the 
stimulus mouse, or allogrooming of the stimulus mouse. “Co-tested pairs” refer to side-by-side 
tests involving two littermate R59X and wild-type control mice, each interacting with a novel 
stimulus mouse in a separate cage. 
 
Drug administration. Mice were acclimated to daily intraperitoneal (i.p.) injections of vehicle 
(saline) for 3 days prior to each set of behavioral assays. For each behavioral cohort, the entire 
cohort was administered either vehicle or drug, with the experimenter blinded to the genotypes of 
mice throughout. All animal behaviors were performed on adult male mice at 9–12 weeks of age, 
and the analysis of behavioral data was carried out by a researcher blinded to genotype. Vehicle 
and drug (memantine hydrochloride, Tocris Biosciences, United Kingdom) were diluted in saline 
at 10 μL per gram mouse body weight for administration. Vehicle or drug was administered 1 h 
prior to the start of each behavioral assay, and during this period, mice were allowed to habituate 
in the room where the assay would be carried out. Notably, we used doses of memantine similar 
to those from studies in other mouse models of neurodevelopmental disorders, which are 
expected to result in reversible blockade of a relatively small fraction of synaptic NMDA 




Ex vivo slice preparation. All steps of electrophysiological experiments, including data collection 
and analysis, were performed by a researcher blinded to genotype. Acute hippocampal slices 
were prepared from mice 9 to 12 weeks of age. Animals were anesthetized with isoflurane and 
transcardially perfused with ice-cold oxygenated (95% O2, 5% CO2) cutting artificial 
cerebrospinal fluid (aCSF) solution (comprised of (mM): 2.5 KCl, 1.25 NaH2PO4, 5 MgSO4, 0.5 
CaCl2, 200 sucrose, 25 NaHCO3, 25 glucose, ~300 mOsm, 7.2–7.4 pH). After decapitation, 
brains were removed for sectioning in the same ice-cold cutting aCSF using a Vibratome (Leica 
Microsystems 1200 s). For whole-cell patch-clamp recordings of mE/IPSCs and the measurement 
of intrinsic membrane properties, 350-μm transverse hippocampal sections were prepared. For all 
voltage-sensitive dye experiments, 400-μm transverse hippocampal sections were prepared. 
Slices were recovered in the same cutting aCSF solution at 32 °C for 30 min and transferred to an 
oxygenated room-temperature solution composed of 50% cutting aCSF and 50% regular aCSF 
(comprised of (mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 10 glucose, 26 NaHCO3, 2 CaCl2, 1 
MgCl2, ~300 mOsm, 7.2–7.4 pH) for 30 min. Subsequently, slices were transferred to 100% 
regular aCSF at room temperature for an additional 30 min before recording. All recordings were 
performed at 34 °C. 
 
Miniature spontaneous excitatory postsynaptic currents (mEPSCs). A pipette internal 
solution comprised of (mM): 140 KCH3OSO3, 5 KCl, 0.5 EGTA, 1 MgCl2, 10 HEPES, 5 MgATP, 
0.25 NaGTP, ~292 mOsm, ECl = −78.8 mV was used. Pipettes 4–6 MΩ in resistance were pulled 
from borosilicate glass capillaries (World Precision Instruments, 1B150F-4) on a Sutter 
Instruments P-1000 pipette puller. Voltage-clamp traces 5 min in duration were recorded at a 
holding potential of −70 mV in the presence of 1 μM tetrodotoxin (Tocris). All recordings were 
conducted with access resistance of <20 MΩ, leak current of <100 pA, and an applied series 
resistance compensation of 80%. Cells that did not maintain these parameters for the duration of 
the recording were eliminated. Analysis of mEPSCs was performed using pCLAMP10 (Axon 
Instruments, Molecular Devices) using a variable-amplitude template method, generated from a 
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stable recording of at least 50 mEPSC events. Each trace was first low-pass filtered at 1 kHz, and 
negative-going mEPSCs were detected using a template match threshold of 4, without fitting. 
 
Miniature spontaneous inhibitory postsynaptic currents (mIPSCs). In order to record 
mIPSCs while maintaining a hyperpolarized membrane voltage, a high-chloride pipette internal 
solution (comprised of (mM): 100 CsCH3O3S, 50 CsCl, 10 HEPES, 0.2 BAPTA, 3 KCl, 1 MgCl2, 
0.25 GTP-Tris, 2.5 creatine phosphate disodium, 2 MgATP, ~296 mOsm, ECl = −23.7 mV) was 
used. Pipettes 4–6 MΩ in resistance were pulled from borosilicate glass capillaries (World 
Precision Instruments, 1B150F-4) on a Sutter Instruments P-1000 pipette puller. Voltage-clamp 
traces 3 min in duration were recorded at a holding potential of −70 mV in the presence of 1 μM 
tetrodotoxin (Tocris) and 2 mM kynurenic acid (Sigma Aldrich). All recordings were conducted 
with access resistance of <20 MΩ, leak current of <100 pA, and an applied series resistance 
compensation of 80%. Cells that did not maintain these parameters for the duration of the 
recording were eliminated. Analysis of mIPSCs was performed using pCLAMP10 (Axon 
Instruments, Molecular Devices) using a variable-amplitude template method, generated from a 
stable recording of at least 50 mIPSC events. Each trace was first low-pass filtered at 1 kHz, and 
negative-going mIPSCs were detected using a template match threshold of 4, without fitting. 
 
Voltage-sensitive dye imaging. Following recovery, each slice was bulk-loaded with 100 μL of a 
solution containing the voltage-sensitive dye di-2-ANEPEQ49,50 (JPW1114, Molecular Probes) 
diluted at 0.05 mg/mL in aCSF(Antic & Zecevic, 1995; Habib-E-Rasul Mullah et al., 2013). Each 
slice was stained for 14 min, washed with aCSF, and imaged in an interface chamber using an 
80 x 80 CCD camera recording with a 1 kHz frame rate (NeuroCCD; RedShirt Imaging). 
Illumination was provided by a 530 nm Green LED (Thor Labs, M530L3-C2). A filter set (Chroma 
Technologies 11007v2 wide Green) was used to allow excitation at 510–560 nm and collection of 
emitted fluorescence at a wavelength > 592 nm. 
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A concentric bipolar tungsten microelectrode was used for stimulation of the perforant path. Two 
successive stimuli were applied with an inter-stimulus interval of 200 ms. Two stimulation 
intensities (200 μA and 400 μA) were used. Imaging trials lasted a total of 1000 ms each, with a 
20 s inter-trial interval. Interleaved trials without stimulation allowed for background subtraction. 
All data analysis was performed in IGOR (Wavemetrics) on the average of 12 trials. Data 
were displayed as the change in fluorescence divided by the resting fluorescence (ΔF/F). 
Regions of interest (ROIs) were drawn for the molecular layer of the dentate gyrus, the dentate 
granule cell layer, and the hilus. Like other dyes of the ANEPP family, di-2-ANEPEQ decreases in 
fluorescence upon membrane depolarization. To be consistent with electrophysiological 
conventions, depolarizing ΔF/F signals were displayed as upward signals (warmer colors) and 
hyperpolarization ΔF/F signals were displayed as downward signals (colder colors). Snapshots of 
VSDI represent an 80 × 80 pixel window, corresponding to an ~1.7 × 1.7 mm field of view. 
 
Postsynaptic density protein purification. We adapted a widely used protocol for the 
preparation of PSD fractions(Bermejo, Milenkovic, Salahpour, & Ramsey, 2014). Mice were 
sacrificed via cervical dislocation, and their brains quickly extracted. Forebrain cortical tissues 
were microdissected and Dounce-homogenized in 10 mL of homogenization buffer (0.32 M 
sucrose, 4 mM HEPES, pH 7.4 with protease inhibitors). The homogenate was centrifuged at 
1000 × g for 10 min at 4 °C to pellet cellular debris and nuclei (P1), and the subsequent 
supernatant (S1) was centrifuged for another 15 min at 10,000 × g at 4 °C. The resulting pellet 
(P2, “crude” synaptosomes) was resuspended in another 10 mL of homogenization buffer and 
centrifuged at 10,000 × g for 15 min at 4 °C. The supernatant was discarded, and the resulting 
pellet (P2’) was resuspended in 10 mL of 4 mM HEPES (pH 7.4) then homogenized on ice. The 
lysate was incubated at 4 °C for 30 min while shaking to hypo-osmotically lyse the synaptosomes, 
and then centrifuged for 20 min at 25,000 × g at 4 °C. The pellet (LP1) was resuspended in 1 mL 
of homogenization buffer and layered on top of a discontinuous sucrose gradient (bottom to top: 
1.5 mL of 1.2 M sucrose, 1 mL of 1.0 M sucrose, and 1 mL of 0.8 M sucrose). The gradient was 
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ultracentrifuged at 150,000 × g for 1.5 h at 4 °C. The turbid layer between the 1.0/1.2 M sucrose 
interphase containing the synaptic plasma membranes (~1 mL) was collected and resuspended in 
5 mL of 4 mM HEPES to dilute out the sucrose. This fraction was ultracentrifuged again at 
200,000 × g for 30 min at 4 °C. The resulting pellet was resuspended in 1 mL of 50 mM HEPES 
with 2 mM EDTA (pH 7.4), and the membrane proteins extracted by adding Triton X-100 at a final 
concentration of 0.5% and incubating at 4 °C while rotating for 15 min. The proteins were 
centrifuged at 32,000 × g for 20 min at 4 °C, and the resulting pellet resuspended in 75 µL of 
50 mM HEPES with 2 mM EDTA. 
 
Brain microdissection. To assess CDKL5 protein expression in various brain regions, adult 
male mice were sacrificed by cervical dislocation. After decapitation, brains were removed and 
sectioned into 1 mm coronal slices using a mouse brain matrix. Tissue was dissected from the 
somatosensory cortex, striatum, hippocampus, and cerebellum and homogenized in lysis buffer 
containing 1% NP-40, pH 8.0. 
 
Western blot. Protein concentration was measured using a Bradford assay. Purified synaptic 
density membrane proteins or protein lysates were prepared for gel electrophoresis by adding 4X 
LDS Sample Buffer (NuPAGE, NP0008) to a final concentration of 1x and β-mercaptoethanol to a 
final concentration of 5%. Samples were heat-denatured at 75 °C for 20 min, and 7.5 µg of protein 
was loaded into each well of a 4–12% Bis-Tris gradient gel (Invitrogen 10-well, 1.5 mm; NP0335). 
Protein gels were run for 2 h at 125 V at room temperature on a ThermoFisher XCell SureLock 
mini-cell electrophoresis box (EI001) using BioRad PowerPac HC High-Current Power Supply 
(1645052), then transferred onto a nitrocellulose membrane (0.45 µm pore-size; Biorad 162–
0115) for 1 h and 10 min at 27 V at room temperature. The resulting membrane was blocked with 




Primary antibodies used for CDKL5 detection are anti-N-terminal CDKL54 (in house; 
diluted 1:500), anti-GAPDH (MA5–15738, Invitrogen; RRID: AB_10977387; diluted 1:1000), anti-
EB2 (AB45767, Abcam, diluted 1:1000). Secondary antibodies (Licor) are goat anti-rabbit IRDye 
800CW and donkey anti-rabbit IRDye 680RD at dilutions of 1:10,000. Standard protocols were 
used for the Odyssey Infrared Imaging System for visualization and quantification. 
For postsynaptic density studies, the primary antibodies used were anti-N-terminal CDKL5, anti-
GluN1 (ThermoFisher, OMA1–04010; diluted 1:1000), anti-GluN2A (Frontier Institute, 
AB_2571605; diluted 1:200), anti-GluN2B (Frontier Institute AB_2571761; diluted 1:200), anti-
GluA1 (Abcam, ab31232; diluted 1:1000), anti-GluA2 (Abcam, ab133477; diluted 1:2000), and 
anti-ß-Actin (Abcam, ab8226; diluted 1:10,000). Secondary antibodies (LI-COR) were goat anti-
rabbit IgG IRDye800CW and goat anti-mouse IgG IRDye680LT at dilutions of 1:10,000, and 
incubated for 1 h at room temperature. Standard protocols were used for the Odyssey Infrared 
Imaging System (LI-COR) for visualization and quantification. 
 
Statistical analyses. For behavioral assays involving Dlx-cKO mice, we chose similar sample 
sizes for all behavioral experiments based on previous published studies of Cdkl5 constitutive 
knockout mice and Cdkl5 glutamatergic conditional knockout mice(Tang et al., 2017; I. T. Wang 
et al., 2012). For behavioral assays involving drug administration, we used pilot behavioral 
cohorts to estimate effect sizes required for detecting significant wild-type-mutant differences and 
used similar samples sizes for saline- and drug-administered cohorts. Importantly, the number of 
mice used were pre-determined prior to the start of each experiment. 
For behavioral assays, statistical analyses were performed using Prism (GraphPad). All 
data sets were analyzed using the Shapiro-Wilk test for normality. For one-sample comparisons, 
data sets with normal distributions were analyzed for significance using the one-sample t-test, 
whereas data sets with non-normal distributions were analyzed using the Wilcoxon signed-rank 
test. For two-sample comparisons, data sets with normal distributions were analyzed for 
significance using the unpaired Student’s t-test, whereas data sets with non-normal distributions 
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were analyzed using the Mann–Whitney test. Two-way repeated measures ANOVA or the 
Kruskal–Wallis test was conducted for the appropriate data sets with Holm-Sidak’s multiple-
comparison test. All one-sample, two-sample, and multiple-comparison tests were two-tailed. 
All other assays that involved sub-sampling of animals were analyzed using R (The R 
Project for Statistical Computing). Each data set was analyzed using a linear mixed effect model, 
where Genotype was modeled as a fixed effect term and Animal was modeled as a random effect 
term. This model accounts for both between-animal and between-cell variation. For each assay, 
null and alternative models were constructed using the lmer function in the lme4 package52 in the 




For data sets involving a third term (e.g., cumulative frequency bin), the following null and 
alternative models were constructed, in order to test the significance of an interaction between 




To make statistical comparisons, the KRmodcomp function from the pbkrtest package 
(Halekoh and Højsgaard, 2014) was used: 
KRmodcomp (m0,m1) 
 
The KRmodcomp function reports a modified F-test statistic based on the Kenward and 
Roger approximation, which accounts for the small sample sizes in our study, modified numerator 
and denominator degrees of freedom, and a p-value. The estimated effect of Genotype is 
obtained from the alternative model constructed using the lmer function from lme4. 
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Post-hoc testing for linear mixed effect models (e.g., at cumulative frequency bins) was 
performed using the least-squares means method for multiple comparisons. The lsmeans 
package was used53 on the alternative model generated by lmer(Lenth, 2016): 
lsmeans(m1, pairwise ~ Genotype | Bin, mode = ‘kenward-roger’) 
For the analysis of cumulative distributions (mEPSC and mIPSC inter-event intervals and 
amplitudes), all samples from each individual cell was sorted, binned, and averaged at percent 
intervals, effectively generating a binned cumulative distribution curve for each cell. Data from all 
cells of a given genotype were plotted at these distinct binned percent intervals with the mean 
and error bars indicating s.e.m. The results were analyzed using linear mixed effect models, 
incorporating a third term, cumulative frequency bin. 
All graphs are plotted using Prism (GraphPad). Boxplot limits indicate the minimum and 
maximum, and boxplot center line indicates the median. In our figures, p-values between 0.05 
and 0.1 are shown explicitly, * is used to denote all 0.01 < p < 0.05, ** for 0.001 < p < 0.01, *** for 































Figure 1. Generation and validation of mice lacking CDKL5 selectively in forebrain 
GABAergic neurons (Dlx-cKO). 
 
(A) Schematic representing the generation of Dlx-cKO mice using a conditional Cdkl5 exon 6-
floxed Cdkl5 mouse line (Tang et al., 2017) and the Dlx5/6-Cre driver (Monory et al., 2006). (B) 
Validation of the cell type-specificity of CDKL5 protein knockout using microdissected brain 
tissue. Two pairs of WT and Dlx-cKO littermates were used. In the cortex, a region enriched for 
glutamatergic neurons, Dlx-cKO mice show comparable amounts of CDKL5 protein to WT. In the 
striatum, a region enriched for GABAergic neurons, Dlx-cKO mice show reduced CDKL5 protein 
in comparison to WT. The residual CDKL5 protein likely originates from non-GABAergic cells in 








Figure 2. Dlx-cKO mice show unaltered growth, locomotion, anxiety-related behavior, and 
motor coordination. 
 
(A) Unaltered body weight of Dlx-cKO mice at various ages (WT, n = 4-36 mice / time point; Dlx-
cKO, 14-29 mice / time point; unpaired t-tests with Holm-Sidak’s correction for multiple 
comparisons). (B) Dlx-cKO mice show unaltered home-cage locomotion on the beam break 
assay (WT, n = 43, Dlx-cKO, n = 32; one-way repeated-measures ANOVA). (C) Dlx-cKO mice, 
show unaltered anxiety-related behavior, as assessed by the percent time spent in open arms, on 
the elevated zero maze assay (WT, n = 28, Dlx-cKO, n = 24; unpaired t-test). (D) Dlx-cKO mice 
show unaltered motor coordination and learning on the Rotarod assay (WT, n = 39, Dlx-cKO, n = 























Figure 3. Dlx-cKO mice exhibit an autistic-like phenotype. 
 
(A) Dlx-cKO mice showed similar times spent interacting with empty cylinders during the 
habituation phase of the three-chambered social assay. Cyl1/Cyl2: empty cylinders 1 and 2. Soc: 
social cylinder containing a stimulus mouse. Non-soc: non-social cylinder containing an object. 
(WT, n = 28; Dlx-cKO, n = 26; paired t-test). (B) Wild-type mice showed a significant preference 
for interacting with the cylinder containing a social stimulus, but Dlx-cKO mice did not show a 
significant difference in time spent sniffing the social and non-social cylinders (paired t-test). (C) 
Dlx-cKO mice also spent significantly reduced time initiating social contact during the direct 
interaction phase (unpaired t-test). (D) Dlx-cKO mice showed unaltered ability to discriminate 
between odors and habituation to the same odor upon repeated presentation. However, Dlx-cKO 
mice show a reduced time sniffing a social scent compared to WT (WT, n = 20; Dlx-cKO, n = 14; 
two-way ANOVA with Holm-Sidak’s multiple comparisons test; error bars demonstrate s.e.m.). (E) 
Dlx-cKO mice spent significantly more time engaging in repetitive behaviors, including grooming 
and digging, within a 10-minute period in a home cage-like environment (WT, n = 18; Dlx-cKO, n 
= 16; unpaired t-test). (F) Dlx-cKO mice show significantly reduced nesting scores on the nesting 
assay (WT, n = 9; Dlx-cKO, n = 8; Mann-Whitney test). (G) Dlx-cKO mice show unaltered 
spontaneous alternation percentage in comparison to WT mice (WT, n = 20; Dlx-cKO: n = 12; 
unpaired t-test). (H) The total number of entries made were not significantly different between 
Dlx-cKO and WT mice (unpaired t-test). (I) Dlx-cKO mice did not show a significant difference in 
the total number of errors made on forward probe trials of the Barnes maze (WT, n = 18; Dlx-
cKO: n = 14; unpaired t-test). (J) Dlx-cKO mice made significantly more errors on the reversal 
probe trials of the Barnes maze (unpaired t-test). (K) On the reversal probe trials, Dlx-cKO mice 
also made significantly more perseverations, or visits to the original target hole location (Mann-






























Figure 4. Dlx-cKO mice show aberrant paired-pulse facilitation. 
 
(A) Schematic of voltage-sensitive dye imaging (VSDI) showing the site of stimulation at the 
perforant path and regions of interest used for quantitative analysis (GCL, granule cell layer; ML, 
molecular layer; HIL, hilus). Snapshots of VSDI responses in a wild-type slice, from left to right: 
baseline, peak response to first stimulus, baseline immediately prior to second stimulus, peak 
response to second stimulus, 100 ms after second peak response (200 μA x 2 stimuli, with 200 
ms inter-stimulus interval).  (B) Averaged VSDI responses (ΔF/F) in the GCL for WT, Nex-cKO, 
and Dlx-cKO mice in response to each of the two stimuli. Depolarization (decrease in ΔF/F) is 
displayed as an upward signal, while hyperpolarization (increase in ΔF/F) is displayed as a 
downward signal. Error envelopes represent mean +/- s.e.m. (C) Peak amplitudes of the GCL 
response to the first stimulus were not different between WT, Nex-cKO, and Dlx-cKO mice (linear 
mixed effect analysis). (D) Peak amplitudes of the GCL response to the second stimulus were 
significantly different between Nex-cKO and Dlx-cKO mice (linear mixed effect analysis with 
Tukey’s correction for multiple comparisons). (E) Ratios of peak responses in the GCL. Nex-cKO 
slices showed significant paired-pulse depression, whereas Dlx-cKO slices showed significant 
paired-pulse facilitation (one-sample t-tests for each of WT, Nex-cKO, and Dlx-cKO, two-tailed). 
Dlx-cKO also showed significantly increased paired-pulse ratio in comparison to Nex-cKO (linear 
mixed effect analysis with Tukey’s correction for multiple comparisons). (F-K) Averaged VSDI 
responses (ΔF/F) in the ML and HIL for WT, Nex-cKO, and Dlx-cKO mice in response to each of 
the two stimuli (linear mixed effect analysis). (H) Peak ratios in ML (one-sample t-test or Wilcoxon 
signed-rank test, two-tailed). (K) Peak ratios in HIL (one-sample t-test or Wilcoxon signed-rank 
test, two-tailed). For all experiments, n=20 slices/5 mice for WT, n=12 slices / 4 mice for Nex-

























Figure 5. VSDI responses in regions of the dentate gyrus at 400μA stimulation intensity. 
 
(A-C) Peak responses are not significantly different between WT, Nex-cKO, and Dlx-cKO (linear 
mixed effect analysis). In all three regions (ML, GCL, and HIL) at this higher stimulation intensity, 
Dlx-cKO show significantly increased facilitation, whereas Nex-cKO shows no significant 
facilitation or depression (one-sample t-test or Wilcoxon signed-rank test, two-tailed). In the GCL, 
Dlx-cKO also showed significantly increased paired-pulse ratio in comparison to Nex-cKO (linear 
mixed effect analysis with Tukey’s correction for multiple comparisons). *p<0.05, **p<0.01, 






Figure 6. Enhanced excitatory synaptic transmission but unaltered inhibitory synaptic 
transmission in Dlx-cKO mice. 
 
(A) Representative mEPSC traces for cells from WT and Dlx-cKO mice. (B) Dlx-cKO mice show 
significantly enhanced mEPSC frequency at CA1 pyramidal neurons (linear mixed effect 
analysis). (C) The cumulative frequency distribution of mEPSC inter-event intervals is also 
significantly shifted in Dlx-cKO mice (linear mixed effect analysis with least-square means post-
hoc testing). (D) The mEPSC median amplitude is unaltered in Dlx-cKO mice (linear mixed effect 
analysis). (E) The cumulative frequency distributions of mEPSC amplitudes are not significantly 
different between Dlx-cKO and WT mice (linear mixed effect analysis). (F) Representative mIPSC 
traces for cells from WT and Dlx-cKO mice. (G) Dlx-cKO mice show unaltered mIPSC frequency 
at CA1 pyramidal neurons (linear mixed effect analysis). (H) The cumulative frequency 
distributions of mIPSC inter-event intervals were not significantly different between Dlx-cKO and 
WT mice (linear mixed effect analysis). (I) The median amplitude of mIPSCs is not significantly 
different between Dlx-cKO and WT mice (linear mixed effect analysis). (J) The cumulative 
frequency distributions of mIPSC amplitudes are not significantly different between Dlx-cKO and 
WT mice (linear mixed effect analysis). For mEPSCs: WT, n = 18 cells / 3 mice; Dlx-cKO, n = 16 
cells / 3 mice; for mIPSCs: WT, n = 18 cells / 3 mice; Dlx-cKO, n = 18 cells / 3 mice. *p<0.05. 






























Figure 7. Unaltered mEPSC and mIPSC kinetics in Dlx-cKO mice. 
 
(A) The median 10-90% rise time of mEPSCs is unaltered in Dlx-cKO mice (linear mixed effect 
analysis). (B) The median 90-10% decay times of mEPSCs is unaltered in Dlx-cKO mice (linear 
mixed effect analysis). (C) The median 10-90% rise time of mIPSCs is unaltered in Dlx-cKO mice 
(linear mixed effect analysis). (D) The median 90-10% decay times of mIPSCs is unaltered in Dlx-






Figure 8. Dlx-cKO mice have an upregulation of NMDA receptors at the postsynaptic 
membrane. 
(A) Representative western blot results for several major ionotropic glutamate receptor subunits 
from postsynaptic density membrane fractions. Samples are from pairs of WT and Dlx-cKO 
littermates. (B-F) Dlx-cKO mice show a selective increase in levels of GluN1 and GluN2B, two of 
the major subunits that compose the NMDA receptor (WT, n = 10 mice; Dlx-cKO, n = 10 mice; 












Figure 9. Acute NMDAR blockade ameliorates autistic-like features in Dlx-cKO mice. 
 
(A) Total grooming in a home cage-like environment is significantly increased in saline-treated 
Dlx-cKO mice in comparison to WT, and memantine at 5 mg kg-1 significantly rescued the 
increased grooming phenotype in Dlx-cKO mice (n = 8 for saline groups; n = 7 for memantine 
groups; one-way ANOVA with Holm-Sidak’s multiple comparisons test). (B) Memantine 
significantly reduces the duration of the longest grooming bout in Dlx-cKO mice. (C) On the 
dyadic social assay, saline-treated Dlx-cKO mice spend significantly less time initiating social 
interaction with a novel stimulus mouse in comparison to WT. Memantine at 5 mg kg-1 resulted in 
a significant increase in time spent in social interaction (n = 8 for saline groups; n = 7 for WT - 
memantine; n = 8 for Dlx-cKO - memantine; one-way ANOVA with Holm-Sidak’s multiple 
comparisons test). (D) For co-tested pairs of Dlx-cKO and WT mice, the ratio of time spent in 
direct interaction was significantly reduced in saline-treated mice. Memantine normalized this 
ratio, indicating a differential effect of this drug on social interaction in WT and Dlx-cKO mice (n=7 






Figure 10. R59X mice have an upregulation of NMDA receptors at the postsynaptic 
membrane. 
(A) Schematic of the R59X non-sense mutation at arginine 59, which results in early truncation of 
the catalytic domain of CDKL5. (B) Representative western blot results for several major 
ionotropic glutamate receptor subunits from postsynaptic density membrane fractions. Samples 
are from pairs of WT and R59X littermates. (C-G) R59X mice show a selective increase in level of 
GluN2B, a major subunit of the NMDA receptor (WT, n = 8 mice; R59X, n = 8 mice; unpaired t-






































Figure 11. Loss of full-length CDKL5 protein in R59X knock-in mice. 
 
Loss of full-length CDKL5 protein in R59X mice, shown with western blots of dissected whole 
cortex lysate in four pairs of WT and R59X littermates. Green arrow indicates band corresponding 
to CDKL5 (note a non-specific band running at approximately the same size). Total EB2 protein 




















Figure 12. Acute NMDAR blockade ameliorates autistic-like features, but not learning and 
memory, in CDKL5-deficient mice. 
 
(A) Spontaneous alternation percentage is significantly reduced in saline-treated R59X mice in 
comparison to WT mice. However, acute memantine administration at either 2.5 or 5 mg kg-1 
doses did not significantly rescue the spontaneous alternation deficit (WT-saline, n = 9; R59X-
saline, n = 11; WT-memantine (5 mg kg-1), n = 6; R59X-memantine (5 mg kg-1), n = 6; WT-
memantine (2.5 mg kg-1), n = 6; R59X-memantine (2.5 mg kg-1), n = 6; Kruskal-Wallis test with 
Dunn’s multiple comparisons test). (B) Total grooming in a home cage-like environment is 
significantly increased in saline-treated R59X mice in comparison to WT, and memantine at 5 mg 
kg-1 significantly ameliorated the increased grooming phenotype in R59X mice (n = 8 for all 
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groups; one-way ANOVA with Holm-Sidak’s multiple comparisons test). (C) The duration of the 
longest grooming bout is significantly increased in saline-treated R59X mice in comparison to 
WT, and memantine also ameliorated this aspect of repetitive behavior (n = 8 for all groups; one-
way ANOVA with Holm-Sidak’s multiple comparisons test). (D) On the dyadic social assay, 
saline-treated R59X mice spend significantly less time initiating social interaction with a novel 
stimulus mouse in comparison to WT. Memantine at 5 mg kg-1 resulted in a significant increase in 
time spent in social interaction (n = 7 for all groups; one-way ANOVA with Holm-Sidak’s multiple 
comparisons test). (E) For co-tested pairs of R59X and WT mice, the ratio of time spent in direct 
interaction was significantly reduced in saline-treated mice. Memantine normalized this ratio, 
indicating a differential effect of this drug on social interaction in WT and R59X mice (n=7 for all 































CHAPTER 3 – CDKL5 IS ESSENTIAL IN THE POST-DEVELOPED BRAIN TO 
MAINTAIN MULTIPLE BEHAVIORAL DOMAINS, HIPPOCAMPAL CIRCUIT 
COMMUNICATION, AND SYNAPTIC MORPHOLOGY 
 
Contributions: Barbara Terzic led this study with help from Sheng Tang and Yu-Ting Liu 
for cellular morphology experiments, and Zhaolan Zhou for the review and interpretation 
of data. Yue Cui managed all mouse husbandry, genotyping, and breeding. Barbara 
Terzic wrote this chapter with input from all authors. 
 
Abstract 
CDKL5 deficiency disorder (CDD) is an early-onset, neurodevelopmental syndrome 
characterized by intractable seizures, intellectual disability, hypotonia, and autistic features. It is 
associated with pathogenic variants in the gene encoding cyclin-dependent kinase-like 5 
(CDKL5), but the specific action of CDKL5 in neuronal development and maintenance remains 
unclear. Although CDD is an early-onset disorder, from both a basic science and therapeutic 
perspective it will be imperative to understand whether CDKL5 also serves a critical role in the 
nervous system after development. In this study, we address this uncertainty by employing a 
conditional adult knockout of Cdkl5 in mice to examine the post-developmental requirement of 
CDKL5. We present, for the first time, that CDKL5 function is required in adult mice to maintain 
proper performance within several behavioral domains, hippocampal circuit communication, and 
dendritic spine morphology. We also demonstrate that CDKL5 continuously regulates 
phosphorylation of the microtubule-associate protein EB2, highlighting disrupted microtubule 
networks as a potential node in CDD pathogenesis. Collectively, these results demonstrate that 
adult neural function requires CDKL5, and expand upon our current understanding of CDKL5 in 
regulating neurological function. Importantly, our results also suggest that chronic treatment may 




Mutations in the X-linked gene encoding cyclin-dependent kinase-like 5 (CDKL5) are 
associated with a devastating neurodevelopmental syndrome known as CDKL5 deficiency 
disorder (CDD)(Fehr et al., 2013; Kalscheuer et al., 2003; Tao et al., 2004; Weaving et al., 2004). 
CDD is characterized by a constellation of phenotypes including intractable seizures, severe 
neurodevelopmental delay, intellectual disability, hypotonia, and autistic features(S. T. Demarest 
et al., 2019; H. E. Olson et al., 2019). The disorder predominantly afflicts young females 
heterozygous for mutations in CDKL5, but hemizygous male cases have also been reported 
(albeit at a significantly lower prevalence)(S. T. Demarest et al., 2019; Liang, Huang, Wang, & Lu, 
2019). With an overall incidence of one per forty-two thousand live births, mutations in CDKL5 
currently comprise one of the most common genetic causes of epilepsy in children(Symonds et 
al., 2019). Despite this strong genetic link, the pathogenesis of CDD remains unclear. Presently, 
there is no cure, and the limited treatment options available have focused on mitigating seizure 
burden using a variety of non-specific anticonvulsants(H. E. Olson et al., 2019).  
In 2012, the first knockout mouse model of CDD was generated and found to recapitulate 
several of the cardinal phenotypes of the human disease including learning and memory 
impairments, motor deficits, and autistic-like behaviors(I. T. Wang et al., 2012). This line carries a 
deletion of Cdkl5 exon 6, mimicking a reported CDD patient splice site mutation resulting in exon 
6 skipping and loss of full-length protein(Archer et al., 2006). Several additional knockout and 
knock-in lines have since been generated with similar behavioral deficits, highlighting the 
reproducibility of CDD-related phenotypes in mice(Amendola et al., 2014; Okuda et al., 2018; 
Tang et al., 2019). Despite the multitude of CDD models, the time course of CDD pathogenesis, 
specific roles for CDKL5 in nervous system development versus maintenance, and reversibility of 
CDD-related phenotypes remain undetermined.  
CDKL5 is a serine-threonine kinase most highly expressed in forebrain neurons and 
enriched at the neuronal post-synaptic density(Kilstrup-Nielsen et al., 2012; Ricciardi et al., 2012; 
Zhu et al., 2013). Recent work has identified microtubule-associated proteins as targets of the 
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kinase, revealing a potential role for CDKL5 in regulating the microtubule network and 
morphology of neurons(Lucas L. Baltussen et al., 2018; Muñoz et al., 2018). Indeed, previous 
studies have reported that shRNA-mediated knockdown of CDKL5 leads to an increased density 
of filipodia-like, or immature, spine protrusions, consistent with observed reductions in the 
frequency of miniature excitatory postsynaptic currents (mEPSCs) in cultured hippocampal 
neurons(Ricciardi et al., 2012). Loss of CDKL5 in vivo in mice results in reduced dendritic spine 
stability and density in somatosensory cortex and visual cortex, but increased spine density in the 
hippocampus. Conditional knockout of CDKL5 selectively from forebrain excitatory neurons also 
results in an increased spine density and frequency of mEPSCs within the hippocampal 
CA1(Della Sala et al., 2016; Lupori L, 2019; Okuda et al., 2018; Tang et al., 2017). Conflicting 
results on these cellular phenotypes are likely due to regional differences within the brain as well 
as in vitro versus in vivo variability on neuronal activity and spine dynamics. Furthermore, the cell-
autonomous versus non cell-autonomous effects of CDKL5 loss on these reported phenotypes, 
particularly in light of developmental compensation that may occur with germline or cell type-
specific Cdkl5 deletion, remain unaddressed. 
Clinical reports illustrating the early, postnatal onset of CDD symptomology support a 
critical role for CDKL5 in the developing nervous system(H. E. Olson et al., 2019; Y. C. Zhu & Z. 
Q. Xiong, 2019). However, from a treatment perspective, it will be important to determine whether 
CDKL5 is also required for the maintenance of neurological function after development. Would 
transient treatment of CDKL5-related functional pathways during early postnatal life be sufficient 
to permanently mitigate disease? With recent advances in precision medicine highlighting 
promising treatment options for CDD patients in the future, it is imperative to establish the 
temporal role of CDKL5 in neuronal development versus maintenance in order to inform 
treatment time windows. 
To address these questions, we have employed a genetic strategy to ablate Cdkl5 
expression in adult mice and evaluate the functional significance of CDKL5 in the mature brain. 
We find that post-developmental deletion of Cdkl5 results in behavioral and circuit deficits in adult 
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mice similar to germline knockout mice, suggesting that CDKL5 is indispensable in adulthood. We 
also demonstrate that adult loss of CDKL5 alters neuronal dendritic spine morphology, but not 
dendrite complexity, in a cell autonomous manner, highlighting a critical role for this kinase in 
synaptic maintenance. These findings are the first to delineate a post-developmental requirement 
for CDKL5, providing critical insight into the endogenous requirements of CDLK5 and informing 
future therapeutic efforts aimed towards the treatment of CDD. 
Results 
Post-developmental loss of CDKL5 results in behavioral deficits similar to germline 
knockout mice 
Several groups have previously reported on the early-developmental expression of 
CDKL5 across different tissues, demonstrating it to be mostly highly enriched in forebrain 
neurons(Kilstrup-Nielsen et al., 2012; Y. C. Zhu & Z. Q. Xiong, 2019). We extended these studies 
by quantifying CDKL5 protein expression in the forebrain at different developmental timepoints, 
using knockout littermates to corroborate antibody specificity. We found that CDKL5 protein was 
detectable in forebrain tissues at postnatal day (P)0, followed by a gradual increase and peak in 
expression around P14 (Figure 1a). After this postnatal peak, CDKL5 remained stably expressed 
in the forebrain throughout adulthood, suggesting that its function may not be exclusively limited 
to developmental processes (Figure 1a). This prompted us to investigate the necessity of CDKL5 
in the maintenance of proper neurological function after development. 
We crossed our previously-reported Cdkl5 floxed mouse line (Cdkl5flox) to transgenic 
mice expressing a Cre-ERT2 fusion gene under the control of the human ubiquitin C promoter 
(UBC-Cre-ERT2, hereafter referred to as CreER)(Tang et al., 2017). This line drives ubiquitous 
Cre-ER expression, and thereby allows for temporal control of gene deletion using 
tamoxifen(Ruzankina et al., 2007). We delivered tamoxifen via oral gavage (0.3mg∙kg-1 every 
other day for a total of 5 doses) to mice beginning at P42, the end of adolescence in C57BL/6 
mice and well after the closure of developmental critical periods in the mouse brain(Hensch, 
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2004). This regiment resulted in successful ablation of CDKL5 protein expression to <5% of wild-
type levels one week after tamoxifen delivery (Figure 2). We then waited approximately two 
months before beginning a battery of behavioral assessments, similar to those examined in 
germline knockout animals, to determine the functional impact of adult loss of CDKL5(I. T. Wang 
et al., 2012). All experiments were performed on the following three groups: Cdkl5flox/y; +/+ (Flx), 
Cdkl5+/y; CreER/+ (Cre), and Cdkl5flox/y; CreER/+ (AKO) where all genotypes received tamoxifen 
in order to minimize potential variability introduced upon tamoxifen administration. Post-hoc 
CDKL5 protein quantification in all experimental mice confirmed a nearly complete loss of CDKL5 
protein in the brains of AKO animals but not Flx or Cre littermate controls (Figure 1b). 
We found that AKO mice exhibit motor and anxiety-related impairments similar to Cdkl5 
germline knockout animals. AKO mice spent significantly more time in the open arm of the 
elevated zeromaze suggestive of decreased anxiety-related behaviors (Figure 1c, Figure 3a), and 
displayed hyperactivity during an open field test (Figure 1d, Figure 3b). They also recapitulate 
several of the autistic-like features observed in germline knockout models of CDD, namely, 
reduced time sniffing and directly interacting with a novel stimulus mouse in the 3-chambered 
social choice test (Figure 1e-f, Figure 3f-g) as well as increased repetitive grooming and digging 
behaviors (Figure 1g) when compared to littermate Flx and Cre controls. Moreover, AKO mice 
displayed significantly impaired contextual- and cue-dependent memory in a Pavlovian fear 
conditioning paradigm when compared to Flx and Cre controls, though working memory 
measured by the Y-Maze assay appeared unaffected (Figure 1h, Figure 3c-e). Interestingly, AKO 
mice show enhanced motor coordination on the rotarod assay, with a significantly increased 
latency to fall from an accelerating, rotating rod, and show no hindlimb clasping when compared 
to Flx and Cre controls (Figure 1i, Figure 3h). This is contrary to Cdkl5 germline knockout mice 
that exhibit significantly impaired motor coordination and a penetrant hindlimb clasping 
phenotype. Importantly, we did not find any significant differences across all examined behavioral 
domains between Flx and Cre controls, suggesting that the presence of the Cre allele alone does 
not induce any abnormal phenotypes. In summary, although two documented germline knockout 
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phenotypes were not recapitulated in AKO mice, our results highlight several major behavioral 
domains disrupted upon adult loss of CDKL5, supporting an indispensable role for CDKL5 in the 
post-developed brain. 
Adult loss of CDKL5 disrupts hippocampal, low-frequency event-related neuronal 
oscillations similar to germline knockout mice 
Auditory or visual event-related potentials (ERPs) have been increasingly leveraged as a 
biomarker for sensory information processing deficits in both patients and animal models of 
various neurodevelopmental disorders(Saby, Peters, Roberts, Nelson, & Marsh, 2020). We 
previously reported that germline loss of CDKL5 resulted in disrupted auditory-evoked ERPs 
recorded from the hippocampus, reflecting an impairment in neural circuit activity(I. T. Wang et 
al., 2012). We thus measured sensory-evoked ERPs in the hippocampus of AKO mice in 
response to an auditory cue. These assessments were performed on nonanesthetized, freely 
mobile mice and are not confounded by the motor and cognitive deficits observed in our CDD 
models. We found that AKO animals displayed an aberrant ERP waveform with a significantly 
decreased amplitude of the canonical N1 (negative) and P2 (positive) polarity peaks as well as a 
significantly increased latency in the P2 polarity peak, similar to Cdkl5 germline knockout animals 
(Figure 4a). The amplitude and latency of these ERP polarity peaks are thought to reflect the 
strength and timing of cognitive processes, thereby suggesting that adult loss of CDKL5 also 
impairs sensory information processing in conjunction with compromised behavioral functions.  
Time-frequency analysis of these ERPs in the hippocampus also demonstrated reduced 
oscillatory strength specifically in the low-frequency delta (δ, 2-4Hz), theta (θ, 4-8Hz), and alpha 
(α, 8-12Hz) oscillations, but no differences in the high-frequency beta (β, 12-30Hz), low gamma 
(γlow, 30-50Hz), and high gamma (γhigh, 70-140Hz) oscillations in AKO mice relative to Flx 
littermate controls (Figure 4b-c). Similarly, event-related phase locking (measured by the phase-
locking factor, PLF), which reflects the reliability and sensitivity of the circuit communication, was 
also significantly decreased in AKO mice compared to Flx littermate controls but selectively in the 
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low-frequency δ and θ (Figure 4b-c). Notably, EEG studies in ASD children have reported 
selective deficits in low-frequency δ, θ, and α oscillations, suggesting similar neural network 
defects in CDD and related syndromic ASDs(Saby et al., 2020). Together, these results indicate 
that adult loss of CDKL5 leads to similar hippocampal network alterations as reported in germline 
knockout animals, and that CDKL5 is required for the maintenance of proper signaling within this 
circuit throughout life. 
Germline, but not adult, loss of CDKL5 disrupts dendritic complexity of hippocampal CA1 
pyramidal neurons 
We next sought to investigate any cellular deficits that may be underlying the circuit and 
behavioral abnormalities that emerge upon loss of CDKL5. In culture models, shRNA knockdown 
of CDKL5 impairs neurite outgrowth in rat primary hippocampal neurons, and several Cdkl5 
knockout mice have been reported to display reduced dendritic complexity in the 
hippocampus(Amendola et al., 2014; Chen et al., 2010; Okuda et al., 2018; Tang et al., 2017). 
However, the direct impact of CDKL5 loss on pyramidal neuron morphology remains 
undetermined. Ablating CDKL5 selectively in adulthood provided us with a unique opportunity to 
examine the consequences of CDKL5 loss independent of developmental confounds or any 
homeostatic compensatory mechanisms that may be occurring. Our present EEG recordings, as 
well as previous studies in various mouse models of CDD, have repeatedly revealed hippocampal 
circuit abnormalities coupled to deficits in hippocampal-dependent learning and memory(Okuda 
et al., 2017; Tang et al., 2019; Tang et al., 2017; I. T. Wang et al., 2012). These data, along with 
the fact that CDKL5 is highly enriched in excitatory cells of this circuit, directed our initial studies 
to pyramidal neurons of the hippocampal CA1(Zeisel et al., 2015). 
We initially examined the effects of germline loss of CDKL5 on dendritic complexity of 
hippocampal pyramidal neurons by crossing Cdkl5 constitutive knock-in mice (Cdkl5R59X, which 
results in early truncation and loss of protein) to Thy1-GFPm transgenic mice. This reporter allele 
allows for in vivo visualization of pyramidal neurons in their entirety, and subsequent analysis of 
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dendritic arborization and complexity(Feng et al., 2000). In comparison to wild-type littermate 
controls (Cdkl5+/y; Thy1-GFPm/+), WT, germline knockout mice (Cdkl5R59X/y; Thy1-GFPm/+), KO, 
displayed a significant decrease in the complexity of both the basal and proximal apical dendrites 
of their CA1 pyramidal neurons as shown by Sholl analysis (Figure 5a & 5c). These data are in 
line with previous studies describing the effects of CDKL5 knockdown and knockout in vitro and in 
vivo. Furthermore, both basal and proximal apical dendrite length were significantly reduced in 
germline knockout mice in comparison to wild-type littermates (Figure 5b & 5d).  
We next wanted to evaluate whether similar morphological deficits might be recapitulated 
upon adult loss of CDKL5. We crossed our AKO mice (Cdkl5flox/y; CreER/+) and Flx littermate 
controls (Cdkl5flox/y; +/+) to mice carrying the Thy1-GFPm reporter allele and delivered tamoxifen 
to all animals at the previously described dosage and regiment beginning at P42. We then 
evaluated cellular morphology at the same age we had previously assessed behavioral 
impairments in AKO mice (P120). Interestingly, dendritic complexity at either the proximal apical 
or basal dendritic tree, measured via Sholl analysis, was not altered between Cdkl5flox/y; CreER/+; 
Thy1-GFPm/+ (AKO) mice and Cdkl5flox/y; +/+; Thy1-GFPm/+ (Flx) littermates at this age (Figure 
5e & 5g). In fact, there were very subtle but significant increases in basal dendrite complexity at 
the 120-150μm distances from the soma. These minor morphological shifts were in stark contrast 
to the reduction in dendrite complexity seen in germline knockout animals. We also saw no 
significant differences in average basal or apical dendrite length (Figure 5f & 5h). These findings 
argue that germline, but not adult, loss of CDKL5 is capable of modulating pyramidal neuron 
dendrite complexity and length in the hippocampal CA1, and suggest a specific developmental 
window for the emergence of this phenotype. 
CDKL5 is required for the maintenance of dendritic spine morphology on hippocampal 
CA1 pyramidal neurons 
Previous studies have also reported that loss of CDKL5 leads to aberrant dendritic spine 
stability/morphology and perturbed miniature excitatory post-synaptic currents (mEPSCs), 
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suggesting an important role for CDKL5 in neuronal synapse maturation(Della Sala et al., 2016; 
Lupori L, 2019; Okuda et al., 2018; Ricciardi et al., 2012; Tang et al., 2017; Zhu et al., 2013). The 
extent to which CDKL5 regulates the formation and/or maintenance of these highly dynamic 
compartments, however, remains inconclusive.  
We examined the effects of germline and adult loss of CDKL5 on dendritic spines of 
pyramidal neurons in the hippocampal CA1 by utilizing the same Thy1-GFPm reporter line 
described above, allowing us to evaluate dendritic spine density and morphology in vivo. We 
found that dendritic spine density was not significantly altered on either basal or proximal apical 
dendritic trees of CA1 pyramidal neurons between germline knockout (Cdkl5R59X/y; Thy1-GFPm/+) 
and wild-type littermate (Cdkl5+/y; Thy1-GFPm/+) animals, or between AKO (Cdkl5flox/y; CreER/+; 
Thy1-GFPm/+) mice and Flx littermate controls (Cdkl5flox/y; +/+; Thy1-GFPm/+). These results 
argue that loss of CDKL5 during either germline or adulthood does not significantly alter dendritic 
spine density in the hippocampal CA1 (Figure 6).  
Aside from spine density and turnover, previous work in cultured neurons and Cdkl5 
knockout animals has also proposed an altered spine morphology in CDD models(Della Sala et 
al., 2016; Lupori L, 2019; Okuda et al., 2018; Ricciardi et al., 2012; Tang et al., 2017). We thus 
evaluated various components of dendritic spine morphology in an in vivo setting using 
reconstruction and analysis of the three-dimensional confocal image stacks taken for spine 
density quantifications. We found that, on average, spine length was significantly increased on 
both basal and apical dendrites of pyramidal CA1 neurons of AKO mice compared to Flx controls 
(Figure 7a,d). This phenotype, coupled to a trending decrease in spine head diameter, is 
reflective of a filipodia-like state typically associated with immature spines(Harris KM, 1989). 
Given that the total density of dendritic spines remained unchanged, these findings suggest a 
significantly increased representation of morphologically immature spines on both apical and 
basal trees of CA1 pyramidal neurons in AKO mice, resembling similar findings seen upon loss of 
CDKL5 in cultured hippocampal neurons(Ricciardi et al., 2012). 
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Our adult knockout allows for an evaluation of neuronal morphological deficits resulting 
from CDKL5 loss in vivo independent of developmental confounds, yet, it remained uncertain 
whether this spine phenotype was indeed a cell autonomous effect of CDKL5 loss or a 
compensatory phenotype due to ablation of CDKL5 in every cell. Sparse, conditional deletion 
isolates the single-neuron consequences of CDKL5 loss while also bypassing pre- versus post-
synaptic effects of mutant cells on spine dynamics. We therefore performed a conditional, sparse 
deletion of CDKL5 in adult mice by crossing Cdkl5 floxed mice to SLICK transgenic mice. The 
Single-neuron Labeling with Inducible Cre-mediate Knockout technique (or SLICK) utilizes two 
copies of the Thy1 promoter to simultaneously drive sparse expression CreER and yellow 
fluorescent protein (YFP), thereby allowing for conditional knockout and simultaneous labeling of 
individual neurons to assess cell autonomous-driven morphology(Young et al., 2008). Cdkl5flox/y; 
SLICK/+ mice and wild-type controls (Cdkl5+/y; SLICK/+) received tamoxifen beginning at P42, 
and their spine morphology was subsequently analyzed at P70. We found that sparse, conditional 
deletion of CDKL5 in adulthood amplified the increased spine length of both apical and basal 
dendritic spines on CA1 pyramidal neurons seen in AKO animals (Figure 8b & 8f). Remarkably, 
we also observed a significantly decreased spine head diameter and decreased spine volume, on 
average, of basal and apical CA1 dendritic spines on knockout neurons in comparison to wild-
type control neurons (Figure 8c-d, 8g-h). Again, there was no change in spine density on both 
apical and basal dendritic arbors between Cdkl5 sparse knockout and wild-type control neurons 
(Figure 8a & 8e).  
Taken together, these results demonstrate an increased proportion of filipodia-like, or 
morphologically immature, dendritic spines on CA1 pyramidal neurons of the hippocampus with 
loss of Cdkl5, and highlight a key role for CDKL5 in the maintenance of dendritic spine 
morphology in a cell autonomous manner.  
73 
 
CDKL5 continuously regulates phosphorylation of the microtubule end-binding 2 protein 
Previous work in Cdkl5 knockout mice has reported disruptions of AKT–mTOR signaling 
with reduced phosphorylation of AKT Ser473 and mTOR Ser2448, specifically, but no 
concomitant alteration in total AKT or mTOR protein levels(I. T. Wang et al., 2012). 
Phosphorylation of these residues normally promotes AKT activation and mTOR complex 1 
(mTORC1) assembly, respectively, likely reflecting decreased AKT and mTORC1 activity upon 
Cdkl5 loss-of-function(Bhaskar & Hay, 2007; Rosner, Siegel, Valli, Fuchs, & Hengstschläger, 
2010). To profile whether similar molecular signaling disruptions were also occurring upon post-
developmental deletion of CDKL5, we harvested forebrain cortical tissues from AKO mice and 
FLX littermate controls and evaluated the phosphorylation of key AKT pathway members, 
including AKT, mTOR, S6, GSK-3β, and β-catenin. In contrast to what is reported in germline 
Cdkl5 knockout mice, adult loss of CDKL5 did not lead to any significant changes in the 
phosphorylation of pAKT Ser473, pmTOR Ser2448, pS6 Ser240/244, pGSK-3β Ser9, and β-
catenin compared to their respective total protein levels (Figure 9). These results raise the 
possibility that loss of CDKL5 may indirectly disrupt these cell growth/proliferation transduction 
cascades during a critical time window in development, or that they are simply a compensatory 
by-product of germline loss of CDKL5. Regardless, our findings highlight the potential for CDKL5 
loss-of-function behavioral, circuit, and cellular phenotypes to emerge without a concomitant 
disruption of AKT/mTOR signaling. 
Notably, recent studies have suggested a role for CDKL5 in microtubule dynamics 
through its direct phosphorylation of microtubule-associated proteins such as end-binding 2 (EB2) 
protein(Lucas L. Baltussen et al., 2018; Muñoz et al., 2018). Interestingly, we found that 
phosphorylation of endogenous EB2 Ser222 (pS222) was significantly reduced in forebrain 
tissues of AKO mice to a similar magnitude as observed in germline knockout mice (Figure 10). 
This suggests that this microtubule-associated substrate remains modulated by CDKL5 in 
adulthood, and highlights that similar microtubule network disruptions may occur upon post-
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developmental loss of CDKL5. Given the expression pattern of CDKL5 is developmentally 
regulated (Figure 1a), it will be informative to determine whether EB2 phosphorylation is also 
dynamically regulated with CDKL5 throughout critical periods of brain development. 
To investigate this, we harvested forebrain cortical tissues from wild-type mice at various 
developmental and adult ages: postnatal day (P)0, P7, P14, P21, P30, and P60 and subsequently 
examined the protein levels of CDKL5, phospho-EB2 (Ser22), and total EB2. CDKL5 protein 
expression was developmentally regulated as previously shown (Figure 1a), with a postnatal 
peak in expression ~P14 (Figure 11a-b). Interestingly, we found pEB2 Ser222 levels to also be 
developmentally regulated and correlating with CDKL5, with phosphorylation levels peaking ~P14 
and subsequently declining into adult ages (>P21) (Figure 11a, c). Total levels of EB2 protein 
remained unchanged throughout the time points examined, and CDKL5 and pEB Ser222 levels 
were significantly ablated in Cdkl5 knockout brain tissues (Figure 11a). These findings suggest 
that phosphorylation of EB2 at Ser222 correlates with the expression levels of CDKL5. 
We next profiled CDKL5, phospho-EB2 (Ser22), and total EB2 protein levels across the 
same ages in Cdkl5 knockout forebrain cortical tissues (P0-P60). As expected, CDKL5 protein 
levels were undetectable at every age in Cdkl5 knockout cortices, however, phosphorylation of 
EB2 Ser22 was still detectable at each age (Figure 11a, d). We examined the relative 
developmental progression of EB2 phosphorylation in Cdkl5 knockout brain tissues across 
various ages. Intriguingly, pEB2 Ser222 levels still reflected a developmental regulation: peaking 
early postnatally and subsequently declining into adulthood (Figure 11a, d). However, the peak 
pEB2 level occurred at P7, rather than at P14 as observed in Cdkl5 wild-type animals (Figure 
11a, e). A comparison of EB2 phosphorylation across all ages between Cdkl5 wild-type and 
Cdkl5 knockout brains reflects an overall reduction in pEB2 as previously shown (Figure 10), but 
also demonstrates this shift in the peak levels of pEB2 Ser222 to an earlier age (Figure 11e). 
These results highlight that CDKL5 dynamically regulates phosphorylation of EB2 throughout 
development and adulthood, and perhaps plays a role in continuously regulating microtubule 
dynamics via its regulation of microtubule-associated proteins such as EB2. The synaptic 
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morphological deficits reported in our AKO, coupled with an impaired regulation of EB2, represent 
a potential cellular basis for the behavioral and circuit phenotypes exhibited by AKO animals. 
 
Discussion 
Several mouse models of CDD have been characterized to date, and although they 
recapitulate many of the hallmark phenotypes of the human disorder, it remains unclear whether 
these deficits are solely a consequence of detrimental changes occurring in the developing 
nervous system or also due to loss of CDKL5 function in mature neurons(Amendola et al., 2014; 
Okuda et al., 2018; I. T. Wang et al., 2012; Yennawar et al., 2019). Furthermore, from a 
therapeutic perspective, it will be imperative to delineate the temporal requirement of CDKL5 
action needed to establish as well as maintain proper neurological function. Prior to this study, it 
was uncertain if providing CDKL5 function, or abrogating kinase pathway dysfunction, exclusively 
during critical periods of development would be sufficient to significantly mitigate disease 
pathology for life or whether chronic treatment would be required in CDD. Along this line, our 
adult knockout experiments comprise a seminal foundation for future studies aiming to dissect the 
temporal requirement of CDKL5 in various circuits and behavioral domains, informing future 
therapeutic endeavors aimed at treating CDD.  
Adult neural function requires CDKL5 
Our results demonstrate that multiple features of disease-associated behavioral and 
circuit phenotypes in mouse models of CDD can be recapitulated following adult deletion of 
Cdkl5. Since Cdkl5 germline knockout mice have been reported to present with a constellation of 
behavioral deficits, we began by testing various behavioral domains in our adult knockout 
animals. We found that adult loss of CDKL5 resulted in similar deficits in anxiety-related 
behaviors, locomotion, sociability, repetitive behaviors, and context- and cue-dependent fear 
conditioning as previously reported in germline knockout mice(I. T. Wang et al., 2012). Adult 
knockout of Cdkl5 also resulted in perturbation of auditory-evoked ERPs recorded from the 
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hippocampus, reflective of gross circuit abnormalities that can arise even upon post-
developmental CDKL5 loss. Specifically, auditory-evoked ERP recordings in the hippocampus of 
these AKO mice displayed significant decreases in amplitude and increases in latency of the 
canonically-elicited polarity peaks, suggesting perturbed sensory processing in these animals (a 
hallmark feature of several ASDs in both humans and mouse models)(Gandal et al., 2010; Jeste 
& Nelson, 2009; Riva et al., 2018; Roberts et al., 2010). Furthermore, our expression data reflect 
a peak in CDKL5 protein levels during the critical period of synaptogenesis for several brain 
regions followed by stable expression throughout adulthood, further highlighting that the kinase’s 
functional roles are likely not sequestered to developmental processes. Collectively, these results 
demonstrate that adult neural function still requires CDKL5, and suggest that early postnatal 
expression of the kinase, or transient, early-developmental treatments, would offer little protection 
against the disease. Rather, our findings argue that either chronic treatment of CDD or gene-
replacement therapy will comprise viable avenues(Gao et al., 2020). These data also contend 
that many of the phenotypes associated with CDD may be unrelated to any stage-restricted 
functions of CDKL5, at least in mice. Notably, similar results have been highlighted with loss of 
MECP2 in Rett syndrome as well as postnatal deletion of various synaptic proteins, and may 
reflect a unifying theme for synaptopathies and related ASDs(Chabbert et al., 2019; Djurisic, 
Brott, Saw, Shamloo, & Shatz, 2018; Huang et al., 2019; McGraw, Samaco, & Zoghbi, 2011; 
Spratt et al., 2019; X. Wang et al., 2016). 
Interestingly, working memory (measured via spontaneous alternations in a Y-Maze 
assay) was not significantly affected by adult loss of CDKL5. This effect could be governed by 
specific circuits that, after proper establishment, are resilient to later loss of CDKL5 or carry the 
ability to more readily compensate to kinase loss at these later ages. The dorsolateral prefrontal 
cortex plays a known role in working memory functions thought to be executed by the basal 
ganglia. The fact that working memory was not affected in AKO mice in spite of concomitant 
motor and anxiety-related deficits suggests that the working memory impairment reported in 
germline Cdkl5 knockout animals is not simply a byproduct of other phenotypic confounds. 
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Rather, loss of CDKL5 may directly modulate this circuitry during a critical time window in 
development. In contrast, context- and cue-dependent memory retrieval were both sensitive to 
adult loss of CDKL5, further emphasizing these hippocampal-mediated memory domains as 
distinct in their circuit-origins from working memory. Furthermore, the sensitivity of hippocampal-
mediated behaviors and hippocampal circuit function to loss of CDKL5 at both ages reflects a 
likely critical maintenance role for the kinase in this brain region throughout life. In the future, it 
will be interesting to dissect the temporal role of CDKL5 in the various circuits that underlie these 
behavioral domains, and to perhaps delineate a critical time window of CDKL5 action in 
regulating these behaviors. 
Surprisingly, adult knockout of Cdkl5 resulted in a significantly enhanced motor 
coordination phenotype in contrast to the deficit in motor coordination typically reported in 
germline knockout animals and severe hypotonia reported in CDD patients(S. Demarest et al., 
2019). It is unlikely that the concomitant hyperactivity or repetitive behavior phenotypes present in 
AKO animals influence this enhanced motor coordination given germline knockout mice mirror 
similar deficits yet still carry impaired motor coordination. Although motor coordination and 
learning are strongly associated with proper cerebellar functioning, CDKL5 is minimally 
expressed in this brain region suggesting additional circuitry may drive this phenotype(Lein et al., 
2007; I. T. Wang et al., 2012). Furthermore, a recent, pilot gene therapy study in Cdkl5 knockout 
mice utilizing AAV-CDKL5 vectors revealed only partial rescue of motor coordination deficits on 
the rotarod assay. This is likely due to the fact that vector expression was mostly limited to the 
hindbrain regions of treated mice (including cerebellum) but not forebrain or midbrain regions 
where CDKL5 is most highly expressed(Gao et al., 2020). This incomplete rescue further 
highlights the importance of additional, extra-cerebellar circuitry to the motor phenotypes 
regulated by CDKL5. Notably, the basal ganglia (where CDKL5 is highly expressed) also play a 
known role in motor control and learning, and have been highlighted as common node for ASD 
pathophysiology(Fuccillo, 2016). We previously reported that loss of CDKL5 exclusively from 
forebrain GABAergic neurons (including the striatum) selectively recapitulates the autistic-like 
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features present in Cdkl5 constitutive knockout models, including aberrant repetitive behaviors. 
However, this conditional deletion of CDKL5 from forebrain inhibitory neurons did not elicit any 
changes in locomotor activity, anxiety-related behaviors, or motor coordination(Tang et al., 2019). 
This may suggest that aberrant striatal circuitry does not autonomously drive the motor 
coordination phenotypes seen across CDD mouse models, including our AKO mice, yet it is 
important to highlight that the Dlx5/6 Cre driver used in this study does not encompass the 
entirety of basal ganglia circuitry. Namely, the midbrain and subthalamic nuclei of the 
diencephalon are not targeted in this conditional knockout(Monory et al., 2006). Thus, loss of 
CDKL5 may still be affecting proper motor output of this circuitry via 1) a critical function in basal 
ganglia subregions not affected upon Dlx5/6 conditional knockout or 2) the synergistic action of 
CDKL5 across the basal ganglia and additional forebrain circuits not modeled by conditional 
deletion. Alternatively, CDKL5 may regulate motor coordination and learning through a different 
circuit or mechanism including contributions from the spinal cord (where CDKL5 expression is 
detectable). How loss of CDKL5 in adulthood leads to improved motor coordination and learning 
remains uncertain, but represents an interesting future avenue to investigate temporally-distinct 
influences of CDKL5 loss of the same behavioral output.  
Loss of CDKL5 influences dendritic arborization of CA1 pyramidal neurons during a 
critical time window in development 
Impaired dendritic arborization and complexity, particularly within the hippocampus, has 
been reported across multiple Cdkl5 knockout models(Amendola et al., 2014; Okuda et al., 2018; 
Tang et al., 2017). These morphological deficits were initially postulated to contribute to the 
impaired hippocampal-dependent memory phenotypes robustly seen in various CDD mouse 
models. Thus, we were surprised when we saw no significant alterations in dendrite length or 
complexity with post-developmental deletion of Cdkl5, yet observed similar behavioral 
phenotypes such as impaired context-dependent memory retrieval. These findings suggest that 
impaired dendrite arborization or outgrowth of hippocampal CA1 neurons is not necessary for the 
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impaired learning and memory phenotypes seen with CDKL5 loss. In fact, the majority of 
behavioral impairments reported for germline Cdkl5 knockout animals were recapitulated upon 
post-developmental deletion of CDKL5, highlighting alternative cellular mechanisms as likely 
driving loss-of-function behavioral impairments. 
Our findings argue that CDKL5 either modulates dendritic complexity during a specific 
time window during development, or that this phenotype is a compensatory mechanism in 
response to loss of CDKL5. For example, the reduction in dendritic complexity reported in 
germline Cdkl5 knockout models could be a secondary, homeostatic response to altered spine 
morphology and synaptic activity. Activity-dependent dendritic retraction is known to occur both in 
vivo and in vitro, and elevated GSK-3 activity, which is associated with activity-dependent 
shrinkage of dendrites, has been reported in mouse models of CDKL5 deficiency(Fuchs et al., 
2014; Krey et al., 2013; Rui et al., 2013; Wong & Ghosh, 2002). Alternatively, CDKL5 may simply 
regulate dendrite and synapse formation through distinct mechanisms at distinct periods of 
development. This idea is consistent with recent findings in which neuronal activity in immature 
neurons leads to the induction of CDKL5 protein levels, whereas neuronal activity in mature 
neurons leads to the degradation of CDKL5(P. La Montanara et al., 2015). CDKL5 may therefore 
have distinct functions during stages of development that uniquely affects the processes of 
dendrite growth, spine generation, and activity-dependent pruning. One such example of a family 
of kinases that serve two contrasting cellular functions is the doublecortin-like kinases (DLCKs), 
which promote dendrite growth but suppress synapse maturation(Shin et al., 2013). 
Concomitant with a significant reduction of dendritic arborization and length of pyramidal 
neurons, germline Cdkl5 knockout mouse models also have reported AKT/mTOR/GSK-3β 
signaling disruptions(Amendola et al., 2014; I. T. Wang et al., 2012). These findings aligned with 
the known importance of mTOR as a regulator of cell growth, proliferation, and neuronal 
plasticity, and motivated a subsequent study to administer IGF-1 to juvenile Cdkl5 knockout mice 
as a treatment for dendritic spine instability(Della Sala et al., 2016). However, the efficacy of this 
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therapy in CDD patients remains uncertain, especially since these signaling changes may be an 
indirect effect of Cdkl5 loss(Costales & Kolevzon, 2016).  
Surprisingly, adult loss of CDKL5 did not lead to significant disruption of AKT-mTOR 
signaling in spite of recapitulated germline knockout behavioral, circuit, and synaptic deficits. 
These data suggest that disrupted AKT-mTOR signaling is not required for the emergence of 
several CDD-related phenotypes, but may be a compensatory, or developmentally-specific 
outcome of CDKL5 loss. The two, germline knockout-specific phenotypes highlighted in this 
chapter (dendritic arborization and AKT/mTOR signaling) may be regulated by a developmental-
specific function of CDKL5 on neuronal outgrowth and arborization, and align with the known 
importance of AKT/mTOR signaling in cell growth and proliferation.  
CDKL5 is required for the maintenance of hippocampal dendritic spine morphology 
The direct impact of CDKL5 loss on pyramidal neuron morphology has been contentious, 
likely due to context-dependent variability. In our initial findings, we observed no significant 
differences in dendritic spine density upon CDKL5 loss on either the basal or apical dendritic 
arbors of hippocampal CA1 pyramidal neurons. This is in contrast to previous studies that have 
reported either increased dendritic spine density with CDKL5 shRNA-mediated knockdown in 
vitro, or decreased dendritic spine density in somatosensory and visual cortex of Cdkl5 knockout 
mice(Della Sala et al., 2016; Ricciardi et al., 2012). These discrepancies are likely due to in vitro 
versus in vivo circuit differences that can alter spine signaling and dynamics, as well as potential 
regional differences of CDKL5 action across different circuits. We sought to overcome these 
confounds by harnessing an adult deletion of CDKL5 to observe more direct effects of kinase 
loss. However, adult knockout of CDKL5 did not result in significant changes in dendritic spine 
density on pyramidal cells within the hippocampal CA1. Taken together, we suggest that there 




Interestingly, however, we did notice significant morphological changes for the dendritic 
spines we imaged upon adult deletion of Cdkl5. Overall, dendritic spines on both the apical and 
basal dendritic trees of hippocampal CA1 pyramidal neurons were significantly longer upon adult 
knockout of Cdkl5. We found that sparse, conditional deletion of CDKL5 in adulthood 
recapitulated this increased spine length phenotype we saw in our constitutive AKO, and also 
resulted in a significantly decreased head diameter and decreased total volume of analyzed 
spines. Taken together, these filipodia-like structures are suggestive of a more morphologically 
immature spine state that, when combined with no change in overall spine density, reflect a 
greater proportion of morphologically immature spines on hippocampal CA1 pyramidal 
neurons(Arellano, 2007). Collectively, these results suggest that CDKL5 is required for the 
maintenance of dendritic spine maturation or morphology within the hippocampal CA1, and align 
with the deficits in hippocampal-dependent behavioral domains and hippocampal circuit 
communication presented in our AKO model. Future work will aim to dissect the causal role of 
these spine phenotypes in relation to the hippocampal behavioral and circuit abnormalities 
resulting from CDKL5 loss. It will also be relevant to examine whether CDKL5 plays a similar 
spine maintenance role across various brain regions, particularly those implicated in the 
behavioral domains disrupted in our AKO mice. 
Our sparse, conditional deletion addresses the cell-autonomous effects of CDKL5 loss on 
pyramidal neuron spines, however, it is still possible that these results are a compensatory or 
secondary effect of CDKL5 loss within excitatory neurons of the hippocampus. We show that 
CDKL5 is capable of regulating EB2 phosphorylation, a member of the end-binding protein family, 
even during adulthood. End-binding proteins are plus-end-tracking proteins that accumulate at 
the growing microtubule end, and play pivotal roles in microtubule dynamics that mediate cellular 
architecture, cargo trafficking, and spine stability. Thus, it is appealing to hypothesis that CDKL5 
may play a role in continuously regulating microtubule dynamics, particularly those related to 
receptor trafficking at the post-synaptic density, via its continuous regulation of microtubule-
associated proteins such as EB2(Baltussen, Rosianu, & Ultanir, 2018; Barbiero, De Rosa, & 
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Kilstrup-Nielsen, 2019; Jaworski et al., 2009; Merriam et al., 2013). However, the extent to which 
CDKL5 regulation of EB2 activity, specifically, can affect cellular morphology and synaptic 
maturation remains uncertain. This target’s well-characterized family member, EB3, has 
previously been implicated in regulating dendritic spine morphology within hippocampal neurons, 
but whether EB2 itself is essential for similar functions remains undetermined(Leterrier et al., 
2011; Pchitskaya et al., 2017; Straube & Merdes, 2007). In our future work, we are focused on 
delineating the specific role of CDKL5 in regulating synaptic turnover and maturation through the 
microtubule network. 
 
Materials and Methods 
Regulatory approval. Experiments were conducted in accordance with the ethical guidelines of 
the National Institutes of Health and with the approval of the Institutional Animal Care and Use 
Committee of the University of Pennsylvania. Mice were group-housed in cages of two to five in a 
twelve-hour light/dark cycle with food and water provided ad libitum. 
 
Mouse strains and genotyping. The Cdkl5 conditional (Cdkl5flox) and R59X knock-in (Cdkl5R59X) 
lines were generated as previously described, and are available from the Jackson Laboratories 
(Cdkl5flox: Stock No. 030523; R59X: Stock No. 028856)(Tang et al., 2019; Tang et al., 2017). 
UBC-CreER (Stock No. 007001), Thy1-GFP line M (Thy1-GFPm; Stock No. 007788), and SLICK 
(Stock No. 007610) mice were all obtained from the Jackson Laboratories. All lines have been 
maintained in the C57BL/6J background. 
Experimental cohorts were all weaned at 3 weeks of age and littermates housed 
together. Cdkl5flox, Cdkl5R59X, and Thy1-GFPm mice were genotyped using previously-reported 
PCR-based strategy or with qPCR by Transnetyx, Inc. For genotyping of UBC-CreER and SLICK 





Tamoxifen preparation and administration. Tamoxifen (Sigma, T5648) was dissolved in corn 
oil (Sigma, C8267) at a concentration of 20mg∙ml-1 by vortexing and slowly heating the solution at 
40°C for approximately one hour. Freshly prepared tamoxifen was protected from light by 
aluminum foil and stored at 4°C for a maximum of one week. Animal feeding needles from Roboz 
Surgical Store (20 gauge, 1.5” length, curved; FN-7910) were used for oral gavage delivery of 
0.3mg∙kg-1 of tamoxifen every other day for a total of five doses. All genotypes received tamoxifen 
within each experimental cohort. 
 
Behavioral assessments. All animal behavioral studies were carried out blinded to genotype. 
Mice were allowed to habituate to the testing room for at least 1 hr before the test, and testing 
was performed at the same time of day. All animal behaviors were performed on adult male mice 
between postnatal days 120-160, and the analysis of behavioral data was carried out by a 
researcher blinded to genotype.  
Elevated zeromaze. The elevated zeromaze (San Diego Instruments; California, USA) consists of 
a circular-shaped platform elevated 3 feet above the floor. Two opposite quadrants of the maze 
are enclosed (wall height, 12 inches), whereas the other two are open (wall height, 0.5 inches). 
Mice were placed in one of the closed quadrants and their movement traced over the course of 5 
min. Analysis, including the quantification of percent of time spent in open arms and the number 
of entries, was performed manually using a stopwatch. An entry was defined as a transition from 
a closed to open arm, or vice versa, that involves all four paws. Total distance traveled over the 
entire assay was measured by a ceiling-mounted camera coupled to a video-tracking software 
(SmartScan 3.0), allowing for real-time analysis of all movements. 
Open-field test. Locomotor activity was measured via an open-field test where mice were 
individually placed into, and allowed to explore, a 15” x 15” arena for a total of 60 min. A ceiling-
mounted camera allowed for a video-tracking software (SmartScan 3.0) to real-time analyze the 
total distance traveled as well as the percent time spent in the center of the arena (defined as the 
central 25% of the total area).  
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Y-maze. Spontaneous alternation behavior was measured on a Y-maze apparatus (San Diego 
Instruments; California, USA), composed of three arms (Arm A: 8in. x 5in. x 3in.; Arms B and C: 
6in. x 5in. x 3in.). For testing, the mouse was placed in Arm C, facing the center, and allowed to 
freely explore the maze for 5 min. A spontaneous alternation was defined an entry into the arm 
less recently explored. Percent spontaneous alternation was calculated as the number of 
spontaneous alternations over the total number of entries. For example, the sequence 
C,B,A,B,C,B,A,C (starting in arm C) resulted in a percent spontaneous alternation of 4/6 = 67%. 
Three-chambered social approach assay. The social choice test was carried out in a three-
chambered apparatus that consisted of a center chamber and two end chambers. Before the start 
of the test and in a counter-balanced sequence, one end chamber was designated the social 
chamber, into which a stimulus mouse would be introduced, and the other end chamber was 
designed the nonsocial chamber. Two identical, clear Plexiglas cylinders with multiple holes to 
allow for air exchange were placed in each end chamber. In the habituation phase of the test 
(Phase I), the test mouse was placed in the center chamber and allowed to explore all three 
chambers for 10 min. During this acclimation period, baseline measurements of how much time 
the mouse spent in each of the three chambers and the distance traveled by the test mouse were 
collected. In the social choice phase of the test (Phase II), an age-matched stimulus mouse 
(adult, gonadectomized A/J mice) was placed in the cylinder in the social chamber while a novel 
object was simultaneously placed into the other cylinder in the nonsocial chamber. During the 
subsequent 10 min social choice period, chamber times and numbers of transitions among 
chambers were again recorded as well as the percent time spent sniffing the social cylinder. In 
the direct social interaction test, the cylinders were removed simultaneously following the social 
choice test, and the amount of time test and stimulus mice spent in direct contact (sniffing, 
allogrooming) was measured for a total of 5 min. If fighting persisted for more than several 
seconds, the mice were removed from the apparatus and excluded from the study.  
Accelerating rotarod assay. Mice were placed on an accelerating rotarod apparatus (Harvard 
Apparatus) for 16 trials (four trials a day for four consecutive days) with at least 15 min of rest 
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between the trials. Each trial lasted for a maximum of 5 min, during which the rod accelerated 
linearly from 4 to 40 rpm. The amount of time for each mouse to fall from the rod was recorded for 
each trial.  
Context- and cue-dependent fear conditioning. For the training day, mice were placed in 
individual chambers (Med Associates) for 2 min followed by a loud tone (85 dB, 2 kHz) lasting 30 
s that coterminated with a 2-s, 1.25-mA foot shock. Mice were left undisturbed for an additional 
30 s in the chamber and then immediately placed back into their home cage. Freezing behavior, 
defined as no movement except for respiration, was determined before and after the tone-shock 
pairings and scored by FreezeScan NI version 2.00. To test for context-dependent learning, we 
placed mice back into the same testing boxes 24 hr later for a total of 5 min without any tone or 
shock, and again measured the total time spent freezing. After 4 hrs, we tested for cue-
dependent fear memory by placing the mice into a novel chamber consisting of altered flooring, 
wall-panel inserts, and vanilla scent. After 2 min in the chamber, the cue tone (85 dB, 2 kHz) was 
played for a total of 3 min, and the total time spent freezing during the presentation of this cue 
tone was recorded. 
Olfaction. Mice were tested for whether they could detect and differentiate odors in a habituation-
dishabituation protocol modified from Yang and Crawley(Yang & Crawley, 2009). Mice were 
presented with cotton-tipped wooden applicators dipped in either water, vanilla, or swiped across 
the bottom of an unfamiliar social cage. Each stimulus was presented for 2 min with a 1-min inter-
trial interval. Time spent sniffing was defined as when the animal was oriented with its nose 2 cm 
or closer toward the cotton tip.  
Repetitive behavior. Mice were individually placed into a clean, home-cage like environment lined 
with bedding. After allowing 5 min for habituation, 10 min of activity was videotaped for each 
mouse. The duration of repetitive behavior, defined as grooming or digging, was scored manually 
using a stopwatch.  
Hindlimb clasping. Mice were suspended by the base of their tail at least 6 inches above a flat 
surface for up to 1 min. If the hindlimbs were consistently splayed outward, away from the 
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abdomen, the mouse was assigned a score of 0. If one hindlimb was retracted towards the 
abdomen for more than 50% of the time, the score was 1. If both hindlimbs were partially 
retracted for greater than 50% of the time, the score was 2. Finally, if both hindlimbs were entirely 
retracted and touching the abdomen for more than 50% of the time suspended, the mouse 
received a score of 3. 
 
Event-related potentials. ERP surgeries, recordings, and analyses were performed as 
previously described(Goffin et al., 2012; I. T. Wang et al., 2012). 
Surgery. Mice underwent stereotaxic implantation of tripolar electrode assemblies (PlasticsOne) 
for nonanesthetized recording of auditory ERPs. Mice were anesthetized with isoflurane (4% for 
induction (vol/vol), 1.5-2% for surgery with 1 L·min−1 O2). Three stainless steel electrodes, 
mounted in a single pedestal were aligned to the sagittal axis of the skull. A stainless steel 
recording electrode was placed 2.0 mm posterior, 2.0 mm left lateral relative to bregma, and at -
1.8 mm depth. Ground and reference electrodes were placed posterior of the hippocampal 
electrode at 1.0 mm and 2.0 mm distances, respectively. The electrode pedestal was secured to 
the skull with ethyl cyanoacrylate and dental cement. Postoperative analgesia was supplied using 
the opioid analgesic, buprenorphine (buprenex, subcutaneous, 0.1 μg ∙ gram-1 of body weight). 
Mice were allowed to recover for 7 days before EEG recordings.  
Recordings. EEG recordings were performed on freely mobile, nonanesthetized mice in their 
home cage environment after a 20 min acclimation to the recording room. Recordings were 
performed using Spike2 software connected to a Power 1401 II interface module (CED) and high 
impedance differential AC amplifier (A-M Systems). Signals were acquired at 1,667 Hz and band-
pass filtered between 1 and 500 Hz with a 60-Hz notch filter and gain of 1,000. 
Event-related potentials (ERPs) were recorded by presentation of auditory stimuli 
consisting of a series of 250 white-noise clicks of 10 ms duration, 85 dB sound pressure, and 4 s 
interstimulus intervals. Stimuli were presented through speakers on the recording chamber ceiling 
(model 19-318A, 700-10,000 Hz frequency response; Radio Shack) connected to a digital audio 
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amplifier (RCA model STAV3870; Radio Shack). ERP traces were generated by averaging 
across single trial epochs centered at t = 0 ± 2 s. Single trials were baseline corrected by 
subtracting the temporal mean at t = −1 s to t = 0.5 s. Altering the baseline closer to sound 
presentation had no effect on the results shown. The mean ERP amplitudes were subsequently 
calculated across 250 trials.  
Time-frequency analysis of EEG. For each recording in which mice were presented with 250 
white-noise clicks (10 ms duration, 85 dB sound pressure, 4 s interstimulus intervals), we 
computed event-related power and phase as a function of frequency and time. Time-frequency 
calculations were performed as previously described(Goffin et al., 2012; I. T. Wang et al., 2012).  
 
Brain microdissection. To assess CDKL5 protein expression in various brain regions, adult 
male mice were sacrificed by cervical dislocation. After decapitation, brains were removed and 
sectioned into 1mm coronal slices using a mouse brain matrix. Tissue was dissected from the 
somatosensory cortex, striatum, hippocampus, and cerebellum and homogenized in RIPA lysis 
buffer (150mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate [DOC], 0.1% sodium dodecyl 
sulfate [SDS], 25mM Tris [pH7.4] with protease inhibitors [Roche, cOmplete, EDTA-free protease 
inhibitor cocktail tablets; 5056489001]). To prepare protein extracts, homogenized lysates were 
incubated on ice for 15 min, and then centrifuged at 21,000 x g for 15min at 4°C. The supernatant 
fraction was removed and sonicated using a Biorupter for 3 alternating session at max frequency 
for 15 sec, each followed by a 60 sec cooldown period. The lysate was then centrifuged at 21,000 
x g for 15min at 4°C, and the top aqueous layer carefully removed and collected as the total 
protein fraction. 
 
Western blot. Protein concentration was measured using a Bradford assay. Purified synaptic 
density membrane proteins or protein lysates were prepared for gel electrophoresis by adding 4X 
LDS Sample Buffer (NuPAGE, NP0008) to a final concentration of 1X and β-mercaptoethanol to 
a final concentration of 5%. Samples were heat-denatured at 75°C for 20 min, and 25 µg of 
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protein was loaded into each well of a 4–12% Bis-Tris gradient gel (Invitrogen, 10-well, 1.5mm; 
NP0335) for brain lysate quantification, respectively. Protein gels were run for 2hr at 125V at 
room temperature on a XCell SureLock mini-cell electrophoresis box (ThermoFisher; EI001) 
using a PowerPac HC High-Current Power Supply (BioRad; 1645052), then transferred onto a 
polyvinylidene fluoride (PVDF) membrane (0.45µm pore-size; Biorad 162–0115) at 27V for 1hr 
and 10min at room temperature. The resulting membrane was blocked with a 1:1 solution of 
Odyssey blocking buffer (LICOR; 927-40100) and 1X PBS for 1hr at room temperature.  
Primary antibodies used were rabbit anti-N-terminal CDKL5 (in house; diluted 1:500), 
mouse anti-β-Actin (Abcam; ab8226; diluted 1:10,000), rat anti-EB2[K52] (Abcam, ab45767; 
diluted 1:10,000), and rabbit anti-phospho-EB2[S222] (generously shared by Dr. Sila Ultanir at 
the Francis Crick Institute; London, UK; diluted 1:1000). For AKT/mTOR signaling studies, the 
primary antibodies used were rabbit anti-AKT (CST4691P), rabbit anti-pAKT S473 (CST4060), 
rabbit anti-mTOR (CST2983), rabbit anti-p-mTOR S2448 (ab109268), rabbit anti-S6 (CST2217), 
rabbit anti-pS6 S240/244 (CST5364), rabbit anti-GSK-3β (CST9315), rabbit anti-pGSK-3β S9 
(CST5558), rabbit anti-β-Catenin (CST9562), and anti-β-Actin. Secondary antibodies (LI-COR) 
used were goat anti-rabbit IgG IRDye800CW, rabbit anti-mouse IgG IRDye680LT, and goat anti-
rat IRDye680LT, all incubated for 50min at room temperature at dilutions of 1:10,000. Standard 
protocols were used for the Odyssey Infrared Imaging System (LI-COR) for protein visualization 
and quantification.  
 
Dendritic branching and dendritic spine analysis. All steps of sectioning, imaging, and data 
analysis were performed by a researcher blinded to genotype. Adult male mice at postnatal day 
120 (Cdkl5R59X/y; Thy1-GFPm/+ versus Cdkl5R59X/y; +/+ or Cdkl5flox/y; +/+ ; Thy1-GFPm/+ versus 
Cdkl5flox/y; UBC-CreER; Thy1-GFPm/+ or Cdkl5flox/y; SLICK/+ versus Cdkl5+/y; SLICK/+) were 
transcardially perfused with 4% paraformaldehyde. Brains were extracted and postfixed 
additionally for 1hr (for dendritic branching analysis) or overnight at 4°C (for dendritic spine 
analysis). For dendritic branching analysis, brains were embedded in 2% agar and sectioned 
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coronally at 200μm on a Leica VT1000S vibratome. For dendritic spine analysis, brains were 
cryoprotected upon overnight fixation by sinking in 15% sucrose and subsequently 30% sucrose 
in PBS, and then frozen in OCT (Sakura Finetek). Frozen brains were sectioned coronally at 
50μm on a Leica CM3050S cryostat. For both dendrite and spine imaging, unstained sections 
were mounted with ProLong™ Glass Antifade Mountant (Thermo Fisher; P36982).  
GFP-positive pyramidal neurons located in the hippocampal CA1 region (approximately 
between bregma coordinates -1.34 to -1.94) with well-preserved morphology were chosen for 
imaging. For dendritic branching, confocal image stacks were taken on a laser scanning confocal 
microscope (Leica TCS SP8, 488 laser) with a 20X/0.75 NA immersion objective at 1X zoom. 
Each neuron was oriented diagonally and centered in a field of view with dimensions 553.57 X 
553.57 μm, with a step size of 0.5 μm. For dendritic spines, secondary and tertiary dendritic 
branches of basal and proximal apical dendrites, excluding the apical tuft, of CA1 pyramidal 
neurons were imaged. Image stacks were taken with a 63X/ 1.40 NA oil-immersion objective at 
4X zoom. Each dendritic segment was centered in a field of view with dimensions 43.93 X 10.95 
μm, with a step size of 0.22 μm and total depth spanning a depth of <7 μm.  
All image analysis was performed by a researcher blinded to genotype. For dendritic 
branching analysis, the dendrites of each neuron were traced in a supervised manner using 
Imaris FilamentTracer (Bitplane; RRID: SCR_007366). Each branch was individually traced using 
a combination of the Autopath and Autodepth functions, with the center of the soma designated 
as the dendrite beginning point. The basal and apical dendritic trees were separately traced. Sholl 
analysis was automatically performed by Imaris, and the statistics were exported for analysis. 
 For spine analysis, three-dimensional blind deconvolution was first performed on 
confocal image stacks with an iterative constrained Tikhonov-Miller algorithm (DeconvolutionLab, 
ImageJ) using a pointspread function generated from the imaging parameters (PSF Generator, 
ImageJ). The deconvolved image stack was imported into Imaris and analyzed. The dendritic 
backbone of each segment was first traced using the Autopath function and a cone-type dendrite 
diameter was built using a contrast threshold of 0.2 and dendrite maximum diameter of 1 μm. 
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Spines were manually traced on each dendrite using the Autopath function, with a cutoff of a 
maximum distance of 3 μm from the dendritic backbone. Automated spine reconstruction of 
manually-traced spines was performed using the Imaris Bitplane Wizard builder. Imaris performed 
automated computation of spine density and estimation of morphometric parameters for individual 
spines, including spine length, terminal point (head) diameter, and volume. 
 
Statistical Analysis. For behavioral assays, we chose similar sample sizes for all behavioral 
experiments based on previous published studies of Cdkl5 constitutive knockout mice and Cdkl5 
conditional knockout mice(Tang et al., 2019; Tang et al., 2017; I. T. Wang et al., 2012). 
Importantly, the number of mice used was pre-determined prior to the start of each experiment. 
Statistical analyses were performed using Prism (GraphPad). All data sets were analyzed using 
the Shapiro-Wilk test for normality. For one-sample comparisons, data sets with normal 
distributions were analyzed for significance using the one-sample t-test, whereas data sets with 
non-normal distributions were analyzed using the Wilcoxon signed-rank test. For two-sample 
comparisons, data sets with normal distributions were analyzed for significance using the 
unpaired Student’s t-test, whereas data sets with non-normal distributions were analyzed using 
the Mann-Whitney test. Two-way repeated measures ANOVA or the Kruskal-Wallis test was 
conducted for the appropriate data sets with post hoc Sidak’s or Dunn’s multiple-comparisons 
tests. All one-sample, two-sample, and multiple-comparison tests were two-tailed.  
All other assays that involved sub-sampling of animals were analyzed using R (The R 
Project for Statistical Computing). Each data set was analyzed using a linear mixed effect model, 
where Genotype was modeled as a fixed effect term and Animal was modeled as a random effect 
term. This model accounts for both between-animal and between-cell variation. For each assay, 
null and alternative models were constructed using the lmer function in the lme4 package in the 
following format:  
m0 = lmer(Outcome ~ (1|Animal), REML = TRUE) 




To make statistical comparisons, the KRmodcomp function from the pbkrtest package 
(Halekoh and Højsgaard, 2014) was used:  
KRmodcomp(m0, m1) 
The KRmodcomp function reports a modified F-test statistic based on the Kenward and 
Roger approximation, which accounts for the small sample sizes in our study, modified numerator 
and denominator degrees of freedom, and a p-value. The estimated effect of Genotype is 
obtained from the alternative model constructed using the lmer function from lme4.  
All graphs are plotted using Prism (GraphPad). Bolded center lines reflect the mean, and 
all error bars indicate s.e.m. For boxplots, the limits indicate the minimum and maximum with 
boxplot center line indicating the median. In our figures, p-values between 0.05 and 0.1 are 
shown explicitly, * is used to denote all 0.01 < p < 0.05, ** for 0.001 < p < 0.01, *** for 0.0001 < p 









































Figure 1: Post-developmental loss of CDKL5 disrupts multiple behavioral domains in mice 
 
(a) Top: Representative western blot showing CDKL5 protein expression from forebrain tissues of 
wild-type mice across multiple ages (Postnatal Day (P)0, P4, P7, P10, P14, P21, P60, P120) with 
Actin protein as a loading control and forebrain tissue from Cdkl5 knockout mice as a reference 
for antibody specificity; Bottom: Quantification of western blot results for CDKL5 protein 
expression across multiple ages demonstrates a postnatal increase in CDKL5 forebrain 
expression and peak ~P14, with stable expression detectable into adulthood. Normalized to Actin 
loading control and plotted relative to P0 levels (n=4). (b) Top: Tamoxifen administration scheme 
and experimental schedule; Bottom: Representative western blot and quantification for CDKL5 
protein expression in all experimental mice demonstrates significant reduction of CDKL5 protein 
in AKO over Flx and Cre forebrain tissues collected after undergoing behavioral evaluation. Actin 
protein served as a loading control, and Cdkl5 knockout and wild-type brain tissues were used as 
a reference for antibody specificity with all values normalized to Cre-only control CDKL5 levels. 
(c) AKO mice spent significantly more time in the open arm of the elevated Zeromaze assay over 
Flx and Cre littermate controls suggestive of decreased anxiety. (d) AKO mice travel significantly 
more distance than Flx littermates in the open-field assay suggesting hyperactivity. (e) AKO mice 
spent significantly less time than Flx and Cre littermates sniffing and (f) directly interacting with a 
novel stimulus mouse during the 3-chambered social choice test, suggestive of deceased 
sociability. (g) AKO mice carry aberrant repetitive behaviors demonstrated by increased time 
spent grooming or digging in a homecage-like environment when compared to Flx and Cre 
littermates. (h) AKO mice freeze in response to a mild footshock similarly to Flx and Cre 
littermates, but show decreased percent time freezing compared to Flx and Cre littermates when 
returned to the testing chamber (contextual) and upon hearing the testing tone (cue), 
demonstrating impaired learning and memory. (i) AKO mice take significantly more time to fall 
from an accelerating, rotating rod than Flx and Cre littermates, indicating enhanced motor 
coordination. For all panels: Flx, n=13; Cre, n=19; AKO, n=23 where all genotypes received 
tamoxifen; Kruskal-Wallis test with Dunn’s multiple comparisons test (except Open-field: Mann-
Whitney test & Rotarod: 2-way repeated measures ANOVA with Sidak’s multiple comparisons 


























Figure 2. Timecourse of CDKL5 protein knockdown with tamoxifen 
 
Top: tamoxifen administration scheme and experimental schedule; Bottom: representative 
western blot results and quantification demonstrating significant reduction in CDKL5 protein in 
forebrain tissues of Cdkl5flox/y; CreER/+ (AKO) mice compared to Cdkl5flox/y; +/+ (Flx) littermate 
controls after tamoxifen administration. Forebrain tissues were collected and analyzed for CDKL5 
protein 9, 13 and 16 days after the first tamoxifen dose, and all experimental mice were sacrificed 
after behavioral assessment for post-hoc protein quantification. Actin protein was a loading 














Figure 3. Additional behavioral domains analyzed upon adult deletion of Cdkl5 
 
(a) Total distance traveled in the elevated Zeromaze assay was similar between AKO and Flx 
mice (Mann-Whitney test). (b) AKO mice traveled significantly more in an open-field assay 
relative to Flx littermates over the course of one hour (distance traveled binned in 5min intervals; 
two-way, repeated measures ANOVA with Sidak’s multiple comparisons test). (c) AKO mice 
showed no difference in percentage of spontaneous alternations in a Y-Maze assay, and no 
difference in the (d) total number of alternations or (e) total difference traveled when compared to 
Flx and Cre littermate controls (Kruskal-Wallis test). (f) Flx, Cre, and AKO mice all spent 
significantly more time in the chamber containing a social stimulus (S; novel mouse) over a non-
social stimulus (NS; rock) during the 3-chambered social choice test (paired t test). (g) Flx, Cre, 
and AKO mice all spent significantly more time sniffing a social scent over either water or almond 
scents, with no significant difference detected between genotypes (two-way ANOVA with 
Dunnett’s multiple comparisons test). (h) No Flx, Cre, or AKO animals displayed any hindlimb 
clasping phenotypes (Kruskal-Wallis test). For all panels: Flx, n=13; Cre, n=19; AKO, n=23 where 
all genotypes received tamoxifen; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Bars represent 
































Figure 4: Post-developmental loss of Cdkl5 disrupts hippocampal event-related potentials. 
 
(a) Top: grand-average hippocampal CA1 ERP waveform following presentation of auditory 
stimuli in Cdkl5flox/y; +/+ (Flx) and Cdkl5flox/y; CreER/+ (AKO) mice demonstrates abnormal ERP 
waveform in AKO mice. Traces represent mean amplitude ± SEM. Characteristic polarity peaks 
P1, N1, and P2 in Flx control are labeled (scale bar: 100ms [horizontal] and 20mV [vertical]); 
Bottom: quantification of the amplitude and latency of ERP peaks shows significantly decreased 
amplitude of the canonical N1 and P2 peaks and increased latency in the P2 polarity peak 
(unpaired, two-tailed t test). (b) Time-frequency plots showing changes in event-related power 
(top) and phase-locking factor (PLF; bottom) following auditory stimulus. Color represents mean 
power/PLF, where warmer colors correspond to increased power/PLF and cooler colors 
correspond to decreased power/PLF relative to prestimulus baseline. (c) Changes in event-
related mean power (top) and PLF (bottom) averaged across δ (2-4Hz), θ (4-8Hz), α (8-12Hz), β 
(12-30Hz), γlow (30-50Hz), and γhigh (70-140Hz) oscillation frequencies demonstrate a selective 
disruption of power and phase-locking in the low-frequency oscillations in AKO mice over Flx 
littermate controls (unpaired, two-tailed t test). Bars represent mean ± SEM; n=7 Flx and n=7 
























Figure 5: Germline, but not adult, loss of Cdkl5 results in decreased dendrite length and 
complexity of CA1 pyramidal neurons. 
 
(a) Reduced complexity of the basal dendritic tree of hippocampal CA1 neurons in Cdkl5R59X/y; 
Thy1-GFPm (KO) mice compared to Cdkl5+/y; Thy1-GFPm (WT) littermate control mice measured 
via Sholl analysis. (b) Total basal dendrite length is significantly decreased in KO animal CA1 
neurons compared to WT neurons. (c) Reduced complexity of the apical dendritic tree of 
hippocampal CA1 neurons in KO mice compared to WT littermate control mice measured via 
Sholl analysis. (d) Total apical dendrite length is significantly decreased in KO animal CA1 
neurons compared to WT neurons. (n=18 cells/3 mice for WT; n=21 cells/3 mice for KO). (e) 
There was no significant difference in basal tree dendritic complexity of hippocampal CA1 
neurons between Cdkl5flox/y; CreER/+; Thy1-GFPm (AKO) mice and Cdkl5flox/y; +/+; Thy1-GFPm 
(Flx) littermate control mice measured via Sholl analysis. (f) Total basal dendrite length was 
unchanged in AKO animal neurons compared to Flx littermate controls. (g) There was no 
significant difference in apical tree dendritic complexity of hippocampal CA1 neurons between 
AKO mice and Flx littermate control mice measured via Sholl analysis. (h) Total apical dendrite 
length was unchanged in AKO animal neurons compared to Flx littermate controls. Basal: n= 24 
cells/6 mice for WT, n= 40 cells/8 mice for cKO; Apical: n=23 cells/6 mice for WT, n=26 cells/8 








































Figure 6. Germline or post-developmental deletion of Cdkl5 does not alter dendritic spine 
density on hippocampal CA1 neurons. 
 
(a) Cdkl5 germline knock-in mice (Cdkl5R59X/y; Thy1-GFPm/+), KO, show no significant difference 
in spine density compared to wild-type littermate controls (Cdkl5+/y; Thy1-GFPm/+), WT, on either 
basal or (b) apical dendritic arbors of hippocampal CA1 pyramidal neurons (Basal: n=23 cells/5 
mice for WT; n=32 cells/5 mice for KO. Apical: n=23 cells/5 mice for WT; n=28 cells/5 mice for 
KO). (c) Cdkl5flox/y; CreER/+; Thy1-GFPm/+ (AKO) mice similarly show no significant change in 
spine density compared to Cdkl5flox/y; +/+; Thy1-GFPm/+ (Flx) littermate controls on either basal 
or (d) apical dendritic arbors of hippocampal CA1 pyramidal neurons (Basal: n= 22 cells/8 mice 
for Flx, n= 30 cells/7 mice for AKO. Apical: n=25 cells/8 mice for Flx; n=36 cells/7 mice for AKO). 



























Figure 7. Post-developmental deletion of Cdkl5 disrupts hippocampal CA1 dendritic spine 
morphology. 
 
(a) Cdkl5flox/y; CreER/+; Thy1-GFPm/+ (AKO) neurons have increased spine length compared to 
Cdkl5flox/y; +/+; Thy1-GFPm/+ (Flx) littermate control neurons on both basal and (d) apical 
dendritic arbors. Spine head diameter [(b) basal; (e) apical] and spine volume [(c) basal; (f) 
apical] were not significantly different between AKO neurons and Flx neurons. For all spine 
analyses: Basal: n= 22 cells/8 mice for Flx; n= 30 cells/7 mice for AKO. Apical: n=25 cells/8 mice 






Figure 8: Post-developmental loss of Cdkl5 results in cell-autonomous disruption of 
dendritic spine morphology on CA1 pyramidal neurons. 
 
(a) Cdkl5flox/y; SLICK/+ (cKO) mice show no significant change in spine density on (a) basal or (e) 
apical dendritic arbors of CA1 pyramidal neurons compared to Cdkl5+/y; SLICK/+ (WT) littermate 
control neurons. cKO neurons have increased spine length compared to WT controls on both (b) 
basal and (f) apical dendritic arbors as well as significantly reduced head diameter [(c) basal; (g) 
apical] and reduced volume [(d) basal; (h) apical]. Basal: n= 24 cells/6 mice for WT, n= 40 cells/8 
mice for cKO; Apical: n=19 cells/6 mice for WT, n=33 cells/8 mice for cKO. Linear mixed effects 









































Figure 9. AKO mice do not demonstrate disrupted AKT-mTOR pathway signaling 
(a) Representative western blot results for several major proteins within the AKT-mTOR signal 
cascade including phospho-protein levels and total protein levels for each. Samples are from 
pairs of Cdkl5flox/y; +/+ (FLX) and Cdkl5flox/y; CreER/+ (AKO) littermates. (b-f) AKO mice do not 
show significant changes in levels of pAKT S473, p-mTOR S2446, pS6 S240/244, and pGSK-3β 
S9 over respective total protein levels, or changes in total levels of β-catenin compared to FLX 






Figure 10. Germline and post-developmental deletion of Cdkl5 abrogate EB2 
phosphorylation. 
 
(a) Left: representative western blot demonstrating CDKL5, phospho-EB2 (S222), and total EB2 
protein levels in wild-type (WT) versus Cdkl5 germline knock-in (Cdkl5R59X/y; KO) forebrain 
tissues. Two bands present for EB2 represent two isoforms detectable in brain tissue (both 
containing Ser222); Right: quantification of phospho-EB2 (S222) western blot results 
demonstrates a nearly total loss of EB2 phosphorylation at Ser222 in KO forebrains compared to 
WT, normalized to total EB2 protein levels (n=4 per genotype). (b) Left: representative western 
blot demonstrating CDKL5, phospho-EB2 (S222), and total EB2 protein levels in Cdkl5flox/y; +/+ 
(Flx) versus Cdkl5flox/y; CreER/+ (AKO) forebrain tissues (both genotypes receiving tamoxifen); 
Right: quantification of phospho-EB2 (S222) western blot results demonstrates a nearly total loss 
of EB2 phosphorylation at Ser222 in AKO forebrains compared to Flx, normalized to total EB2 

















Figure 11. EB2 phosphorylation is developmentally regulated and correlates with CDKL5. 
(a) Representative western blot results for CDKL5, pEB2 Ser222, and total EB2 protein levels 
from forebrain cortices of Cdkl5 wild-type (left) and Cdkl5 knockout (right) mice at various ages 
(Postnatal Day (P)0, P7, P14, P21, P30, P60). Two bands present for EB2 represent two 
isoforms detectable in brain tissue (both containing Ser222). (b) Quantification of total CDKL5 
protein levels in wild-type mice across various ages, normalized to Cdkl5 knockout, demonstrates 
a postnatal increase and expression peak ~P14. (c) Quantification of phospho-EB2 Ser222 
levels, normalized to total EB2 levels, in Cdkl5 wild-type mice across various ages demonstrate a 
developmental regulation that correlates with CDKL5 expression, including a peak ~P14. (d) 
Quantification of phospho-EB2 Ser222 levels, normalized to total EB2 levels, in Cdkl5 knockout 
mice across various ages reflects a shift in the peak phosphorylation levels of EB2 from P14 to 
P7. (e) Overlay of pEB2 Ser222 protein quantifications from Cdkl5 wild-type and knockout mice 
demonstrates the overall reduction in EB2 phosphorylation in knockout mice at each timepoint, 








CHAPTER 4 – LATE RESTORATION OF CDKL5 EXPRESSION IS SUFFICIENT TO 




Contributions: Barbara Terzic led this study with help from M. Felicia Davatolhagh for 
electrophysiological experiments, Joshua Ross for data analysis, and Marc V. Fuccillo 
and Zhaolan Zhou for the review and interpretation of data. Yue Cui and Erin Nugent 
managed all mouse husbandry, genotyping, and breeding. Barbara Terzic wrote this 
chapter with input from all authors. 
 
Abstract 
CDKL5 deficiency disorder (CDD) is an early-onset, neurodevelopmental syndrome 
associated with pathogenic variants in the gene encoding cyclin-dependent kinase-like 5 
(CDKL5). CDKL5 has been implicated in neuronal synapse maturation and NMDA receptor 
subunit trafficking at the post-synaptic membrane, however, the reversibility of these and other 
CDD-associated impairments remain unknown. We genetically manipulated endogenous Cdkl5 
expression in mice, and found adult restoration of CDKL5 in hemizygous male knockout mice 
significantly ameliorates CDD-related behavioral impairments, NMDA-induced seizure 
susceptibility, and aberrant NMDA receptor signaling. We have further extended these findings 
into a novel, independent conditional rescue line to corroborate that late rescue of CDKL5 also 
reverses several behavioral deficits in heterozygous female models of CDD. These findings 
underscore the potential for disease reversal in both male and female CDD patients, and suggest 





Mutations in the X-linked gene encoding cyclin-dependent kinase-like 5 (CDKL5) are 
associated with a devastating neurodevelopmental syndrome known as CDKL5 deficiency 
disorder (CDD)(Fehr et al., 2013; Kalscheuer et al., 2003; Tao et al., 2004; Weaving et al., 2004). 
CDD is characterized by a constellation of phenotypes including intractable seizures, severe 
neurodevelopmental delay, intellectual disability, hypotonia, and autistic features(S. T. Demarest 
et al., 2019; H. E. Olson et al., 2019). The disorder predominantly afflicts young females 
heterozygous for mutations in CDKL5, but hemizygous male cases have also been reported 
(albeit at a significantly lower prevalence)(S. T. Demarest et al., 2019; Liang et al., 2019). Despite 
this strong genetic link, the pathogenesis and treatability of CDD remains unclear. Presently, 
there is no cure, and the limited treatment options available have focused on mitigating seizure 
burden using a variety of non-specific anticonvulsants(H. E. Olson et al., 2019).  
In 2012, the first knockout mouse model of CDD was generated and found to recapitulate 
several of the cardinal phenotypes of the human disease including learning and memory 
impairments, motor deficits, and autistic-like behaviors(I. T. Wang et al., 2012). Several additional 
knockout and knock-in lines have since been generated with similar behavioral deficits, 
highlighting the reproducibility of CDD-related phenotypes in mice(Amendola et al., 2014; Okuda 
et al., 2018; Yennawar et al., 2019). Intriguingly, Cdkl5 knockout mouse models have also 
demonstrated a robust sensitivity to NMDA-induced seizures concomitant with an increased 
postsynaptic localization of NMDA receptors (NMDARs), specifically GluN2B-containing 
NMDARs(Okuda et al., 2017). These results were supported by our recent study which 
demonstrated that acute, NMDAR blockade was capable of selectively ameliorating autistic-like 
phenotypes in CDKL5-deficient mice (see Chapter 2)(Tang et al., 2019). Despite these multitude 
of CDD models, however, the extent of reversibility of the remaining heterogeneous constellation 
of CDD-related phenotypes, particularly at later ages, remains undetermined. 
Clinical reports illustrating the early, postnatal onset of CDD symptomology support a 
critical role for CDKL5 in the developing nervous system(H. E. Olson et al., 2019; Y. C. Zhu & Z. 
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Q. Xiong, 2019). However, it remains unknown whether restoration of the kinase after critical 
periods of brain development can reverse any CDD-related deficits. With recent advances in 
precision medicine highlighting promising treatment options for CDD patients in the future, it is 
imperative to establish the temporal role of CDKL5 in neuronal development versus maintenance, 
and the potential for symptom amelioration in patients who may have already passed a specific 
developmental time window(Benke & Kind, 2020). 
To address these questions, we have employed a genetic strategy to investigate the 
reversibility of CDD-associated symptoms by generating conditional rescue mice enabling 
temporal control of Cdkl5 re-expression at its endogenous locus. We find that the majority of 
CDD-related behavioral deficits, as well as aberrant NMDA receptor signaling, are significantly 
mitigated with late restoration of CDKL5 expression. We corroborate these findings an 
independent conditional rescue model, demonstrating that several CDD-related behavioral 
impairments are also reversible in heterozygous female Cdkl5 knockout mice with late Cdkl5 re-
expression. These findings, in conjunction with our adult knockout studies highlighted in Chapter 
3, are the first to delineate a post-developmental requirement for CDKL5, and the first to 
demonstrate the potential for disease reversal in CDD. Importantly, our results also uncover a 
broad therapeutic time window for numerous CDD-related deficits, supporting future therapeutic 
efforts aimed towards the treatment of CDD. 
Results 
Adult restoration of CDKL5 rescues numerous CDD-related behavioral deficits in 
hemizygous male knockout mice 
Our previous findings support that post-developmental loss of CDKL5 induces similar 
phenotypes as germline knockout (see Chapter 3). However, the reversibility of CDD-associated 
symptoms remains a long-standing question in the field, especially since the disorder presents 
very early in life. Given that CDD patients do not normally experience neurodegeneration, the 
viability of mutant neurons in CDD patients opens up the prospect that re-expression of CDKL5 
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(or therapeutic intervention) may restore CDKL5-dependent signaling pathways and thereby 
alleviate some of the disorder phenotypes(H. E. Olson et al., 2019). If a critical time window of 
CDKL5 function does exist, then delayed treatment (or gene replacement) may have little effect 
or even contravening outcomes in a system that has partially compensated for its loss. 
To address this, we created a mouse line in which the endogenous Cdkl5 gene is 
conditionally silenced by the insertion of a loxP-flanked transcriptional STOP cassette, and where 
physiological levels of Cdkl5 expression can be restored upon Cre-mediated cassette deletion 
(Cdkl5STOP, hereafter referred to as STOP; Figure 1a). This is particularly relevant as human 
genetic studies have reported that duplication of CDKL5 is associated with neurological 
impairments(Szafranski et al., 2015). A preliminary characterization of STOP mice demonstrated 
that they do not express detectable levels of CDKL5 protein and display similar phenotypes to 
Cdkl5 germline knockout mice by P42 when we began tamoxifen administration (Figure 2). We 
delivered tamoxifen to four experimental groups of mice: Cdkl5+/y; +/+ (WT), Cdkl5+/y; CreER/+ 
(Cre), Cdkl5STOP/y; +/+ (STOP), and Cdkl5STOP/y; CreER/+ (rescue, Res) beginning at P42 using 
the same regiment applied in our adult knockout experiments (0.3mg∙kg-1 every other day for a 
total of 5 doses). We observed significant restoration of CDKL5 protein expression in forebrain 
tissues of Res mice, but not STOP mice, that was comparable to WT and Cre-only littermate 
controls within two weeks of tamoxifen delivery. Unexpectedly, however, we noticed significant 
lethality at this dosage selectively in Res mice, but not WT, Cre, or STOP animals (Figure 3a). 
These findings suggest there may be toxicity associated with rapid Cdkl5 reactivation, even at 
endogenous levels of CDKL5 expression. We therefore optimized our tamoxifen administration 
protocol and found that a more gradual Cdkl5 re-expression (1 tamoxifen dose of 0.3mg∙kg-1 
every week for a total of 3 weeks, followed by 2 booster treatments) was able to eliminate this 
toxicity while restoring CDKL5 expression to nearly WT levels (Figure 1b, Figure 3b). 
Consequently, we adhered to this gradual Cdkl5 activation protocol for subsequent rescue 
experiments. Remarkably, phosphorylation of EB2 Ser222 was also restored to control levels 
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upon adult reversal of Cdkl5 expression, highlighting that CDKL5-dependent signaling pathways 
are likely rescued with Cdkl5 re-expression (Figure 1b). 
Using this gradual gene reversal strategy, we next examined the extent to which late 
restoration of CDKL5 expression could mitigate CDD-related behavioral deficits. We again 
administered tamoxifen to a cohort of Cre, STOP, and Res littermates beginning at P42 (the age 
at which most behavioral deficits have arisen in STOP mice, Figure 2) and then beginning at 
P140 evaluated multiple behavioral domains known to be disrupted in Cdkl5 germline and adult 
knockout animals. We found that Res animals showed significant improvement over STOP 
littermates in hyperactivity and anxiety-related behaviors. STOP mice spent significantly more 
time exploring the open arm of the elevated zeromaze in comparison to Cre-only controls, 
suggestive of decreased anxiety (Figure 1c). However, adult restoration of Cdkl5 resulted in a 
significant decrease in open-arm time compared to STOP mice, with Res animals behaving 
comparable to Cre controls (Figure 1c, Figure 4a). STOP mice also moved significantly more over 
the course of one hour in an open field test when compared to Cre-only controls, whereas Res 
mice exhibited activity levels closer to Cre control littermates (Figure 1d, Figure 4b). Adult 
restoration of CDKL5 also ameliorated several of the autistic-like phenotypes frequently reported 
upon Cdkl5 deletion. During the three-chambered social choice assay, Res animals spent similar 
amounts of time to Cre-only controls sniffing the social cylinder and directly interacting with a 
novel stimulus mouse, while STOP mice spent significantly less time sniffing the social cylinder 
and directly interacting with a novel stimulus mouse, suggestive of decreased sociability (Figure 
1e-f, Figure 4f-h). STOP mice also exhibited aberrant repetitive behaviors, illustrated by an 
increased time spent grooming/digging in a home cage-like environment when compared to Cre 
controls, whereas Res mice displayed control-level grooming/digging behaviors (Figure 1g).  
Similar to other Cdkl5 knockout models, STOP mice recapitulate impaired motor learning 
on the rotarod assay, as demonstrated by a decreased latency to fall from an accelerating, 
rotating rod as well as a penetrant hindlimb clasping phenotype. Adult rescue of CDKL5 
significantly ameliorated these motor deficits, with Res mice performance on the rotarod assay 
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comparable to littermate Cre-only controls and no hindlimb clasping present in any of the 17 Res 
animals tested (Figure 1h-i). Finally, normal context- and cue-dependent learning and memory 
were also restored to nearly control levels in Res animals, while STOP mice displayed significant 
impairment in both of these memory domains (Figure 1j). Interestingly, working memory, as 
measured by spontaneous alternations during the Y-Maze assay, was not significantly improved 
in Res animals when compared to STOP-only littermate mice (Figure 4c). However, total activity 
during the Y-Maze assay (measured by the total number of alternations) was significantly 
restored to Cre control levels in Res animals which aligns with the ameliorated hyperactivity 
phenotype illustrated by the open field test (Figure 4d-e). Collectively, these findings support that 
adult restoration of CDKL5 is sufficient to reverse or ameliorate the majority of loss-of-function 
behavioral impairments; namely, the hyperactivity, anxiety-related phenotypes, autistic-like 
behaviors, motor impairments, and learning and memory deficits appear to remain amenable to 
post-developmental restoration of CDKL5 expression. Additionally, post-hoc examination of 
CDKL5 restoration revealed that several rescue mice showed only 20-50% of wild-type protein 
expression (Figure 5). The rescue of numerous behavioral domains in these mice underscores 
the potential that even partial restoration of CDKL5 expression may show notable therapeutic 
benefit, at least in mice. 
 
Adult restoration of CDKL5 abrogates NMDA-induced hyperexcitability and aberrant 
NMDAR-mediated synaptic responses 
The significant rescue of behavioral phenotypes upon re-expression of endogenous 
Cdkl5 in adult mice raises the possibility that the molecular and cellular deficits caused by loss of 
CDKL5 are also reversible. To investigate this, we focused on the aberrant NMDA receptor 
(NMDAR) signaling phenotypes previously found to be altered in Cdkl5 knockout and knock-in 
mice. Specifically, CDD mouse models display an increase in the ratio of NMDA-mediated to 
AMPA-mediated synaptic responses (NMDA/AMPA EPSC ratio) in the CA1 region of the 
hippocampus that correlates with an increased susceptibility to NMDA-induced seizures(Okuda et 
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al., 2017; Tang et al., 2019). The NMDA-mediated synaptic responses in CDD mouse models 
also display significantly larger decay times, suggestive of a higher contribution of GluN2B-
containing NMDARs. 
Consistent with our previous studies in Cdkl5 knockout and knock-in models, we found 
that the levels of membrane-associated GluN2B in postsynaptic density fractions purified from 
STOP mice were significantly elevated compared to littermate controls, but detected no change in 
several other major ionotropic glutamate receptor subunits such as GluA1, GluA2, and GluN2A 
(Figure 6a-e). Correspondingly, STOP mice also recapitulated the enhanced susceptibility to 
NMDA-induced seizures as shown in other Cdkl5 knockout lines (Figure 6f)(Okuda et al., 2017; 
Tang et al., 2019). These phenotypes were further supported by an increase in the NMDA/AMPA 
ratio onto CA1 pyramidal neurons of the hippocampus. Additionally, the NMDA-mediated currents 
displayed a significantly larger decay time constant, highlighting that our STOP mice carry similar 
NMDAR signaling deficits to other CDD models (Figure 6g-i)(Okuda et al., 2017). Remarkably, we 
found that late restoration of Cdkl5 expression was able to reverse these NMDAR synaptic 
phenotypes. Adult reversal of Cdkl5 expression, using our established tamoxifen regiment 
beginning at P42, restored GluN2B expression to Cre-only levels, and consistently attenuated the 
enhanced susceptibility to NMDA-induced seizures exhibited by STOP-only mice (Figure 6a-f). 
Furthermore, the ratio of NMDA/AMPA currents and NMDAR-current kinetics were rescued as a 
result of restoring Cdkl5, suggesting reestablishment of control-level NMDAR subunit composition 
(Figure 6g-i). Together, these findings demonstrate that late restoration of CDKL5 expression 
attenuates the aberrant NMDAR signaling deficits in the hippocampus that result from CDKL5 




Adult restoration of Cdkl5 expression ameliorates CDD-related behavioral deficits in 
heterozygous female mouse models of CDD 
 Given the variability introduced from X-chromosome inactivation and mosaic Cdkl5 
expression in females, we confined our initial experiments to hemizygous male knockout animals. 
However, the majority of carriers for this X-linked disorder are heterozygous females(H. E. Olson 
et al., 2019). Thus, we expanded upon our initial findings to also examine the reversibility of CDD-
related deficits in adult, heterozygous female mouse models of CDD. We generated an 
independent conditional rescue line, Cdkl5FLEX, that, similar to our Cdkl5STOP animals allows for 
temporal control of Cdkl5 re-expression at its endogenous locus upon Cre-mediated 
recombination. Cdkl5FLEX mice carry an inverted Cdkl5 exon 4 flanked by two pairs of loxP sites 
that allow for proper cassette re-orientation and gene expression upon tamoxifen delivery (Figure 
7a). We crossed this novel conditional rescue line to a second, inducible Cre allele, CAG-CreER. 
We next delivered tamoxifen to three experimental groups of mice: Cdkl5+/+; CreER/+ (Cre), 
Cdkl5FLEX/+; +/+ (FLEX), and Cdkl5FLEX/+; CreER/+ (rescue, Res) beginning at P90 using the same 
regiment applied in our adult knockout experiments (0.3mg∙kg-1 every other day for a total of 5 
doses). We subsequently assayed a similar battery of behavioral test as in our male rescue 
studies 3 months later. 
 An open-field test demonstrated significant hyperactivity of FLEX heterozygous 
knockouts compared to Cre littermate controls, similar to what is reported for hemizygous Cdkl5 
knockout male mice (Figure 7b). Interestingly, although Res females appeared to also be slightly 
hyperactive, there was no significant activity change between Cre-only controls and Res mice, 
suggesting reduced hyperactivity with late Cdkl5 re-expression (Figure 7b). We also examined 
sociability behaviors, known to be disrupted in Cdkl5 knockout male mice, using a 3-chambered 
social choice test. FLEX female mice spent significantly less time sniffing and directly interacting 
with a novel stimulus mouse compared to Cre littermate controls, reflecting impaired sociability 
upon heterozygous Cdkl5 loss similar to male knockouts (Figure 7c-d). In contrast, Res mice 
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spent similar amounts of time sniffing and directly interacting with a stimulus mouse as their Cre 
littermate controls, demonstrating rescued sociability with late Cdkl5 restoration (Figure 7c-d). 
FLEX heterozygous females also carry impaired context-dependent memory retrieval in a 
Pavlovian fear-conditioning paradigm highlighted by reduced time spent freezing upon return to 
the foot-shock chamber (Figure 7e). Res mice show significantly increased time freezing 
compared to FLEX knockouts, suggesting improved contextual memory retrieval (Figure 7e). 
These results suggest that the hyperactivity, sociability, and learning and memory deficits 
exhibited by hemizygous Cdkl5 knockout male mice are also recapitulated upon heterozygous 
loss of Cdkl5. More importantly, we demonstrate that these domains appear to be amenable to 
late kinase rescue in female models of CDD, similar to what we report for hemizygous male mice. 
Discussion 
Adult restoration of CDKL5 ameliorates several loss-of-function deficits 
 
Several models have been putatively proposed for CDKL5’s role in nervous system 
function, including neuronal signaling, PSD stability, and microtubule dynamics(Lucas L. 
Baltussen et al., 2018; Fuchs et al., 2014; Ricciardi et al., 2012). However, the absence of a 
unifying hypothesis likely explains the scarcity of effective therapeutics currently available to 
reverse or ameliorate CDD. Therefore, gene replacement has been recently explored as a viable 
strategy for treatment(Gao et al., 2020). A key question along this avenue, however, is whether 
later restoration of CDKL5 is sufficient to restore normal neurological function or if the absence of 
CDKL5 results in irreversible abnormalities. If a critical time window of CDKL5 does exist, then 
later treatment (or gene replacement) may have little effect or even contravening outcomes in a 
system that has partially compensated for its loss.  
Our adult rescue study of CDKL5 highlights the capability of late reversal of Cdkl5 
expression in ameliorating several loss-of-function deficits in mice. Namely, we see significant 
rescue of anxiety-related behaviors, hyperactivity, autistic-related phenotypes, motor 
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coordination, hindlimb clasping, and learning and memory impairments, suggesting that the 
underlying circuitry essential for these behavioral domains is amenable to later kinase restoration. 
Notably, working memory was not rescued with adult restoration of CDKL5, which aligns with our 
adult knockout study (Chapter 3) where we accordingly saw no impairment of this behavior upon 
adult loss of CDKL5. This further reinforces that this behavioral domain and its underlying circuitry 
may be modulated by CDKL5 during a critical developmental time widow in development. 
Importantly, rescue mice exhibited working memory deficits in spite of their ameliorated 
hyperactivity phenotype (demonstrated both by the open-field test and total number of 
alternations on the Y-Maze assay), again suggesting that this behavioral domain is impaired upon 
loss of CDKL5 independent of motor confounds. These findings also suggest that the reported 
working memory phenotypes in germline Cdkl5 knockout animals likely exist independent of any 
motor activity confounds. Regardless, the promise of late restoration of CDKL5 mitigating several 
CDD-associated deficits in patients represents an exciting development for the field. 
In 2016, IGF-1 treatment in juvenile Cdkl5 knockout mice was shown to partially rescue 
dendritic spine instability, and although preliminary clinical trials have demonstrated some 
success for this therapy in Rett syndrome, its efficacy in CDD patients remains 
undetermined(Costales & Kolevzon, 2016). CDKL5 protein substitution therapy in knockout mice 
was also reported to rescue neurological phenotypes, but only with continuous administration. 
Furthermore, this study exclusively reported on short-term outcomes, and, analogous to IGF-1 
therapies, its feasibility and efficacy in CDD patients is untested(Trazzi et al., 2018). Finally, as 
the majority of these studies were performed in juvenile animals, the reversibility of CDKL5 loss-
of-function phenotypes at later ages remains to be addressed. These results, combined with the 
monogenetic nature of CDD, highlight the pertinence of gene replacement therapy for viable 
treatment in this highly heterogeneous disease. Previous studies have applied the concept of late 
gene reversal in rodents to attempt phenotypic rescue in various disease models(Chandran et al., 
2017; Guy, Gan, Selfridge, Cobb, & Bird, 2007; James et al., 2012; Y. Mei et al., 2016). Notably, 
late restoration of Mecp2 expression in knockout mouse models has been reported to alleviate 
117 
 
impairments associated with Rett syndrome, and adult restoration of Shank3 is capable of 
rescuing selective autistic-like phenotypes(Guy et al., 2007; Y. Mei et al., 2016).  However, no 
study to date in rodent models of neurodevelopmental disorders other than CDD has reported 
rescue of autistic phenotypes using AAV gene therapy(Gadalla et al., 2017; Garg et al., 2013; 
Gholizadeh, Arsenault, Xuan, Pacey, & Hampson, 2014). This pernicious lack of effective gene 
therapy treatments for neurodevelopmental syndromes highlights the potential for gene 
replacement in CDD to set the stage for future attempts at widespread CNS delivery of gene 
vectors to treat the heterogeneous assortment of symptoms associated with these disorders. As 
mentioned, a preliminary gene therapy study in Cdkl5 knockout mice achieved successful AAV-
hCDKL5 development and expression of CDKL5, but only in hindbrain regions(Gao et al., 2020). 
Although this was capable of partially restoring some motor coordination deficits in this model, 
further work is needed to improve upon forebrain and CNS-wide delivery of CDKL5. Nevertheless 
this study, together with our findings, highlights the promise of late gene restoration in 
successfully alleviating CDD-associated impairments. 
CDKL5 and NMDA receptor signaling 
Our results suggest that loss of CDKL5 is capable of regulating post-synaptic localization 
of NMDA receptor subunits, namely GluN2B, with resultant behavioral effects on NMDA-induced 
hyperexcitability. During development, the canonical switch from predominantly GluN2B-
containing to GluN2A-containing NMDA receptors across the CNS is thought to be a regulatory 
mechanism involved in shaping circuit plasticity during the critical period of synaptogenesis for 
several brain regions(Paoletti, Bellone, & Zhou, 2013). Interestingly, the peak expression of 
CDKL5 in mouse forebrain appears to coincide with this subunit composition switch during a time 
window also associated with circuit refinement and acquisition of learning abilities(Shipton & 
Paulsen, 2014). Our results in STOP mice are unable to demonstrate whether this phenotype is a 
result of a failed switch from GluN2B to GluN2A early in development, or a continual role of 
CDKL5 in maintaining receptor subunit composition at the post-synaptic membrane. Our gene 
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reversal study demonstrates that this aberrant GluN2B expression and NMDA hyperexcitability 
phenotype is reversible upon late restoration of CDKL5, arguing that CDKL5 may continuously 
regulate NMDA receptor composition rather than carry a specific function early in development. 
However, the direct role of the kinase within this domain remains to be dissected. Interestingly, 
CDKL5 has been reported to target EB2 pS222 via an NMDAR-dependent mechanism, providing 
a potential link between disrupted NMDAR signaling, microtubule dynamics, and CDKL5 loss-of-
function phenotypes(Lucas L. Baltussen et al., 2018). While we see a significant reduction in EB2 
phosphorylation at Ser222 in STOP mice, this reduction is restored to nearly Cre control levels 
upon adult rescue of CDKL5. Still, a more mechanistic examination of the role of EB2 
phosphorylation, and its effects on synaptic maturation, is needed before a direct role for CDKL5 
in this pathway can be corroborated. 
Modeling and treating CDD-related phenotypes in heterozygous female mice 
The final component of this study demonstrates that several behavioral domains 
disrupted in hemizygous knockout mouse models of CDD are also impaired in heterozygous 
females of our second, novel knockout line (Cdkl5FLEX). These findings further confirm that 
heterozygous Cdkl5 knockout female mice can serve as a viable pre-clinical model for CDD. 
Importantly, we also demonstrate that late restoration of Cdkl5 expression in these females 
ameliorates several CDD-related deficits, similar to what we reported in hemizygous male rescue 
mice. Our future work aims to provide a more in-depth analysis on the reversibility of additional 
CDKL5 loss-of-function phenotypes in this female model, however, these initial results provide 
promising evidence that the findings of our hemizygous male studies may also extend to female 
CDD models. 
In contrast to the pervasive epilepsy in CDD patients, the absence of an overt seizure 
phenotype in Cdkl5 knockout male mice could contribute to the success of phenotypic reversibility 
found in this study. This is particularly pertinent given that in the subsequent chapter (Chapter 5), 
we report the occurrence of spontaneous and disturbance-associated seizures exclusively in 
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heterozygous Cdkl5 knockout female mice. This epilepsy phenotype appears to increase in 
frequency and severity with age, with a median age of onset around 28-30 weeks. Although our 
behavioral testing was confined to heterozygous females within 21-25 weeks of age (prior to 
seizure development), we cannot exclude the fact that an altered seizure susceptibility or circuit 
hyperexcitability may affect the reversibility of certain deficits in heterozygous female models, 
particularly after seizure onset. In the future, it will be necessary to extend these experiments to 
aged (seizing), heterozygous female mouse models of CDD, determine the minimum and 
maximum levels of CDKL5 expression required for safe phenotypic reversal, and define the latest 
time window allowable for rescue, at least in mouse models. In the subsequent chapter, we 
expand upon this analysis of heterozygous female models of CDD, and provide promising 
insights into the treatability of these seizure-like phenotypes specifically. 
Materials and Methods 
Regulatory approval. Experiments were conducted in accordance with the ethical guidelines of 
the National Institutes of Health and with the approval of the Institutional Animal Care and Use 
Committee of the University of Pennsylvania. Mice were group-housed in cages of two to five in a 
twelve-hour light/dark cycle with food and water provided ad libitum. 
 
Mouse strains and genotyping. Cdkl5STOP mice were generated in collaboration with 
Biocytogen using CRISPR-mediated genomic editing techniques. A selected gRNA 
(TGCAACTACAGCATTAGCTCTGG) was chosen upon screening of 12 candidates for targeting 
specificity and efficacy at intron 3 of the Cdkl5 locus. The DNA repairing template constituted a 
loxP-flanked transcriptional STOP cassette, flanked by 817bp of DNA as the 5’ homologous arm 
and 1453bp of DNA as the 3’ homologous arm. Synthesized gRNA, purified and linearized DNA 
repairing template, as well as Cas9 mRNA were co-injected into a one-cell zygote of C57BL/6 
background to allow for homology-directed repair, followed by implantation. PCR primers specific 
to the 5’ and 3’ integration sites flanking the gRNA sequence at Cdkl5 intron 3 were used to 
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screen for positively targeted pups. Southern blotting was finally conducted to confirm the correct 
targeting of the F1 generation, followed by establishment a Cdkl5 floxed-STOP (STOP) colony in 
a C57BL/6J genetic background.  
Cdkl5FLEX mice were generated in collaboration with Biocytogen using CRISPR-mediated 
genomic editing techniques. A pair of gRNAs (TGCAACTACAGCATTAGCTCTGG & 
TTTCACAGTAGGTTACCCAGGGG) were chosen upon screening of 22 candidates for targeting 
specificity and efficacy at introns 3 and 4 of the Cdkl5 locus. The DNA repairing template 
constituted the endogenous Cdkl5 exon 4 flanked by a pair of mloxP and loxP sites, all flanked by 
888bp of DNA as the 5’ homologous arm and 1800bp of DNA as the 3’ homologous arm. 
Synthesized gRNA, purified and linearized DNA repairing template, as well as Cas9 mRNA were 
co-injected into a one-cell zygote of C57BL/6 background to allow for homology-directed repair, 
followed by implantation. PCR primers specific to the 5’ and 3’ integration sites flanking the gRNA 
sequence at Cdkl5 exon 4 were used to screen for positively targeted pups. Southern blotting 
was finally conducted to confirm the correct targeting of the F1 generation, followed by 
establishment a Cdkl5 FLEX (FLEX) colony in a C57BL/6J genetic background. 
UBC-CreER (Stock No. 007001) mice and CAG-CreER (Stock No. 004682) mice were 
obtained from the Jackson Laboratories. All lines have been maintained in the C57BL/6J 
background. 
Experimental cohorts were all weaned at 3 weeks of age and littermates housed 
together. For genotyping of UBC-CreER and CAG-CreER transgenics, primers and genotyping 
strategy were identical to that used by Jackson Laboratories. Cdkl5STOP and Cdkl5FLEX mice were 
genotyped using a qPCR based strategy optimized by Transnetyx to detect the presence of a 
loxP-flanked STOP cassette within intron 3 of the endogenous Cdkl5 gene and the inversion of 
exon 4 of the endogenous Cdkl5 gene, respectively. 
 
Tamoxifen preparation and administration. Tamoxifen (Sigma, T5648) was dissolved in corn 
oil (Sigma, C8267) at a concentration of 20mg∙ml-1 by vortexing and slowly heating the solution at 
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40°C for approximately one hour. Freshly prepared tamoxifen was protected from light by 
aluminum foil and stored at 4°C for a maximum of one week. Animal feeding needles from Roboz 
Surgical Store (20 gauge, 1.5” length, curved; FN-7910) were used for oral gavage delivery of 
0.3mg∙kg-1 of tamoxifen every other day for a total of five doses. For adult restoration of Cdkl5, a 
slower dosage timeline was introduced to avoid the lethality associated with rapid reintroduction 
of CDKL5: Cdkl5+/y; CreER/+, Cdkl5STOP/y; +/+, and Cdkl5STOP/y; CreER/+ cohorts all received 
0.3mg∙kg-1 of tamoxifen once a week for a total of three weeks, and then two subsequent booster 
deliveries every other day after the third dose (total of 5 doses). See schematic in Figure 3a for 
details. All genotypes received tamoxifen within each experimental cohort. 
  
Behavioral assessments. All animal behavioral studies were carried out blinded to genotype. 
Mice were allowed to habituate to the testing room for at least 1 hr before the test, and testing 
was performed at the same time of day. All animal behaviors were performed on adult male and 
female mice between postnatal days 120-160, and the analysis of behavioral data was carried out 
by a researcher blinded to genotype.  
Elevated zeromaze. The elevated zeromaze (San Diego Instruments; California, USA) consists of 
a circular-shaped platform elevated 3 feet above the floor. Two opposite quadrants of the maze 
are enclosed (wall height, 12 inches), whereas the other two are open (wall height, 0.5 inches). 
Mice were placed in one of the closed quadrants and their movement traced over the course of 5 
min. Analysis, including the quantification of percent of time spent in open arms and the number 
of entries, was performed manually using a stopwatch. An entry was defined as a transition from 
a closed to open arm, or vice versa, that involves all four paws. Total distance traveled over the 
entire assay was measured by a ceiling-mounted camera coupled to a video-tracking software 
(SmartScan 3.0), allowing for real-time analysis of all movements. 
Open-field test. Locomotor activity was measured via an open-field test where mice were 
individually placed into, and allowed to explore, a 15” x 15” arena for a total of 60 min. A ceiling-
mounted camera allowed for a video-tracking software (SmartScan 3.0) to real-time analyze the 
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total distance traveled as well as the percent time spent in the center of the arena (defined as the 
central 25% of the total area).  
Y-maze. Spontaneous alternation behavior was measured on a Y-maze apparatus (San Diego 
Instruments; California, USA), composed of three arms (Arm A: 8in. x 5in. x 3in.; Arms B and C: 
6in. x 5in. x 3in.). For testing, the mouse was placed in Arm C, facing the center, and allowed to 
freely explore the maze for 5 min. A spontaneous alternation was defined an entry into the arm 
less recently explored. Percent spontaneous alternation was calculated as the number of 
spontaneous alternations over the total number of entries. For example, the sequence 
C,B,A,B,C,B,A,C (starting in arm C) resulted in a percent spontaneous alternation of 4/6 = 67%. 
Three-chambered social approach assay. The social choice test was carried out in a three-
chambered apparatus that consisted of a center chamber and two end chambers. Before the start 
of the test and in a counter-balanced sequence, one end chamber was designated the social 
chamber, into which a stimulus mouse would be introduced, and the other end chamber was 
designed the nonsocial chamber. Two identical, clear Plexiglas cylinders with multiple holes to 
allow for air exchange were placed in each end chamber. In the habituation phase of the test 
(Phase I), the test mouse was placed in the center chamber and allowed to explore all three 
chambers for 10 min. During this acclimation period, baseline measurements of how much time 
the mouse spent in each of the three chambers and the distance traveled by the test mouse were 
collected. In the social choice phase of the test (Phase II), an age-matched stimulus mouse 
(adult, gonadectomized A/J mice) was placed in the cylinder in the social chamber while a novel 
object was simultaneously placed into the other cylinder in the nonsocial chamber. During the 
subsequent 10 min social choice period, chamber times and numbers of transitions among 
chambers were again recorded as well as the percent time spent sniffing the social cylinder. In 
the direct social interaction test, the cylinders were removed simultaneously following the social 
choice test, and the amount of time test and stimulus mice spent in direct contact (sniffing, 
allogrooming) was measured for a total of 5 min. If fighting persisted for more than several 
seconds, the mice were removed from the apparatus and excluded from the study.  
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Accelerating rotarod assay. Mice were placed on an accelerating rotarod apparatus (Harvard 
Apparatus) for 16 trials (four trials a day for four consecutive days) with at least 15 min of rest 
between the trials. Each trial lasted for a maximum of 5 min, during which the rod accelerated 
linearly from 4 to 40 rpm. The amount of time for each mouse to fall from the rod was recorded for 
each trial.  
Context- and cue-dependent fear conditioning. For the training day, mice were placed in 
individual chambers (Med Associates) for 2 min followed by a loud tone (85 dB, 2 kHz) lasting 30 
s that coterminated with a 2-s, 1.25-mA foot shock. Mice were left undisturbed for an additional 
30 s in the chamber and then immediately placed back into their home cage. Freezing behavior, 
defined as no movement except for respiration, was determined before and after the tone-shock 
pairings and scored by FreezeScan NI version 2.00. To test for context-dependent learning, we 
placed mice back into the same testing boxes 24 hr later for a total of 5 min without any tone or 
shock, and again measured the total time spent freezing. After 4 hrs, we tested for cue-
dependent fear memory by placing the mice into a novel chamber consisting of altered flooring, 
wall-panel inserts, and vanilla scent. After 2 min in the chamber, the cue tone (85 dB, 2 kHz) was 
played for a total of 3 min, and the total time spent freezing during the presentation of this cue 
tone was recorded. 
Olfaction. Mice were tested for whether they could detect and differentiate odors in a habituation-
dishabituation protocol modified from Yang and Crawley(Yang & Crawley, 2009). Mice were 
presented with cotton-tipped wooden applicators dipped in either water, vanilla, or swiped across 
the bottom of an unfamiliar social cage. Each stimulus was presented for 2 min with a 1-min inter-
trial interval. Time spent sniffing was defined as when the animal was oriented with its nose 2 cm 
or closer toward the cotton tip.  
Repetitive behavior. Mice were individually placed into a clean, home-cage like environment lined 
with bedding. After allowing 5 min for habituation, 10 min of activity was videotaped for each 
mouse. The duration of repetitive behavior, defined as grooming or digging, was scored manually 
using a stopwatch.  
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Hindlimb clasping. Mice were suspended by the base of their tail at least 6 inches above a flat 
surface for up to 1 min. If the hindlimbs were consistently splayed outward, away from the 
abdomen, the mouse was assigned a score of 0. If one hindlimb was retracted towards the 
abdomen for more than 50% of the time, the score was 1. If both hindlimbs were partially 
retracted for greater than 50% of the time, the score was 2. Finally, if both hindlimbs were entirely 
retracted and touching the abdomen for more than 50% of the time suspended, the mouse 
received a score of 3. 
 
Brain microdissection. To assess CDKL5 protein expression in various brain regions, adult 
male mice were sacrificed by cervical dislocation. After decapitation, brains were removed and 
sectioned into 1mm coronal slices using a mouse brain matrix. Tissue was dissected from the 
somatosensory cortex, striatum, hippocampus, and cerebellum and homogenized in RIPA lysis 
buffer (150mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate [DOC], 0.1% sodium dodecyl 
sulfate [SDS], 25mM Tris [pH7.4] with protease inhibitors [Roche, cOmplete, EDTA-free protease 
inhibitor cocktail tablets; 5056489001]). To prepare protein extracts, homogenized lysates were 
incubated on ice for 15 min, and then centrifuged at 21,000 x g for 15min at 4°C. The supernatant 
fraction was removed and sonicated using a Biorupter for 3 alternating session at max frequency 
for 15 sec, each followed by a 60 sec cooldown period. The lysate was then centrifuged at 21,000 
x g for 15min at 4°C, and the top aqueous layer carefully removed and collected as the total 
protein fraction. 
 
Postsynaptic density protein purification. We adapted a widely used protocol for the 
preparation of PSD fractions that we previously reported on(Bermejo et al., 2014; Tang et al., 
2019). Mice were sacrificed via cervical dislocation, and their brains quickly extracted. Forebrain 
cortical tissues were microdissected and Dounce-homogenized in 10mL of homogenization buffer 
(0.32M sucrose, 4mM HEPES, pH 7.4 with protease inhibitors [Roche, cOmplete, EDTA-free 
protease inhibitor cocktail tablets; 5056489001]). The homogenate was centrifuged at 1000 × g 
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for 10 min at 4°C to pellet cellular debris and nuclei (P1), and the subsequent supernatant (S1) 
was centrifuged for another 15 min at 10,000 × g at 4°C. The resulting pellet (P2, “crude” 
synaptosomes) was re-suspended in another 10mL of homogenization buffer and centrifuged at 
10,000 × g for 15 min at 4°C. The supernatant was discarded, and the resulting pellet (P2’) was 
re-suspended in 10mL of 4mM HEPES (pH 7.4) then homogenized on ice. The lysate was 
incubated at 4°C for 30 min while shaking to hypo-osmotically lyse the synaptosomes, and then 
centrifuged for 20 min at 25,000 × g at 4°C. The resultant pellet (LP1) was re-suspended in 1 mL 
of homogenization buffer and layered on top of a discontinuous sucrose gradient (bottom to top: 
1.5mL of 1.2M sucrose, 1mL of 1.0M sucrose, and 1mL of 0.8M sucrose). The gradient was 
ultracentrifuged at 150,000 × g for 1.5hr at 4 °C. The turbid layer between the 1.0/1.2 M sucrose 
interphase containing the synaptic plasma membranes (~1mL) was collected and re-suspended 
in 5mL of 4mM HEPES to dilute out the sucrose. This fraction was ultracentrifuged again at 
200,000 × g for 30 min at 4°C. The resulting pellet was re-suspended in 1mL of 50mM HEPES 
with 2mM EDTA (pH 7.4), and the membrane proteins extracted by adding Triton X-100 at a final 
concentration of 0.5% and incubating at 4°C while rotating for 15 min. The proteins were 
centrifuged at 32,000 × g for 20 min at 4°C, and the resulting pellet re-suspended in 75µL of 
50mM HEPES with 2 mM EDTA. 
 
Western blot. Protein concentration was measured using a Bradford assay. Purified synaptic 
density membrane proteins or protein lysates were prepared for gel electrophoresis by adding 4X 
LDS Sample Buffer (NuPAGE, NP0008) to a final concentration of 1X and β-mercaptoethanol to 
a final concentration of 5%. Samples were heat-denatured at 75°C for 20 min, and 7.5µg or 25 µg 
of protein was loaded into each well of a 4–12% Bis-Tris gradient gel (Invitrogen, 10-well, 1.5mm; 
NP0335) for PSD protein or brain lysate quantification, respectively. Protein gels were run for 2hr 
at 125V at room temperature on a XCell SureLock mini-cell electrophoresis box (ThermoFisher; 
EI001) using a PowerPac HC High-Current Power Supply (BioRad; 1645052), then transferred 
onto a polyvinylidene fluoride (PVDF) membrane (0.45µm pore-size; Biorad 162–0115) at 27V for 
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1hr and 10min at room temperature. The resulting membrane was blocked with a 1:1 solution of 
Odyssey blocking buffer (LICOR; 927-40100) and 1X PBS for 1hr at room temperature.  
Primary antibodies used were rabbit anti-N-terminal CDKL5 (in house; diluted 1:500), 
mouse anti-β-Actin (Abcam; ab8226; diluted 1:10,000), rat anti-EB2[K52] (Abcam, ab45767; 
diluted 1:10,000), and rabbit anti-phospho-EB2[S222] (generously shared by Dr. Sila Ultanir at 
the Francis Crick Institute; London, UK; diluted 1:1000). For postsynaptic density studies, the 
primary antibodies used were rabbit anti-N-terminal CDKL5, mouse anti-GluN1 (ThermoFisher, 
OMA1–04010; diluted 1:1000), rabbit anti-GluN2A (Frontier Institute, AB_2571605; diluted 1:200), 
rabbit anti-GluN2B (Frontier Institute AB_2571761; diluted 1:200), rabbit anti-GluA1 (Abcam, 
ab31232; diluted 1:5000), rabbit anti-GluA2 (Abcam, ab133477; diluted 1:5000), and anti-β-Actin. 
Secondary antibodies (LI-COR) used were goat anti-rabbit IgG IRDye800CW, rabbit anti-mouse 
IgG IRDye680LT, and goat anti-rat IRDye680LT, all incubated for 50min at room temperature at 
dilutions of 1:10,000. Standard protocols were used for the Odyssey Infrared Imaging System (LI-
COR) for protein visualization and quantification. 
 
NMDA-induced seizure scoring. Seizures were induced in postnatal day 180 mice by 
intraperitoneal administration of 90 mg∙kg-1 NMDA (Sigma-Aldrich; M3262) in sterilize, 0.9% PBS. 
Seizure progression was scored using a modified Racine scale as previously described: (0) no 
abnormality; (1) exploring, sniffing, and grooming ceased, animal becomes motionless; (2) 
forelimb and/or tail extension, appearance of rigid posture; (3) myoclonic jerks of the head and 
neck, with brief twitching movement, or repetitive movements with head bobbing or “wet-dog 
shakes”; (4) forelimb clonus and partial rearing, or rearing and falling; (5) forelimb clonus, 
continuous rearing and falling; (6) tonic-clonic movements with loss of posture tone, often 
resulting in death(Okuda et al., 2017). After drug injection, max seizure scores were recorded 




Electrophysiology recordings. Mice were deeply anesthetized using isoflurane and perfused 
transcardially with ice-cold ACSF (pH 7.3 – 7.4) containing (in mM): 124 NaCl, 2.5 KCl, 1.2 
NaH2PO4, 24 NaHCO3, 5 HEPES, 12.5 glucose, 1.3 MgSO4, 7H2O, 2.5 CaCl2. The brain was 
rapidly removed, and transverse sections (400 uM) were cut on a vibratome (VT 1200s, Leica). 
Slices were incubated in a holding chamber for 12-15 minutes at 32-34°C in a NMDG-based 
recovery solution (pH 7.3-7.4, pH adjusted with HCl) (in mM): 92 NMDG, 2.5 KCl, 1.2 NaH2PO4, 
30 NaHCO3, 20 HEPES, 25 glucose, 5 sodium ascorbate, 2 thiourea, 3 sodium pyruvate, 10 
MgSO4, 7H2O, 0.5 CaCl2. Osmolarity for the NMDG-based solution and ACSF was kept between 
300-310 mOsm. Following incubation, slices were moved to a second holding chamber 
containing ACSF at room temperature (20-22°C) for at least 1 hr. prior to recording. For 
recording, slices are transferred to the recording chamber (Scientifica) fully submerged in 
oxygenated (95% O2, 5% CO2) ACSF at a perfusion rate of 1.4-1.6 mL/min, bath temperature of 
29-30°C, and secured using a slice anchor (Warner Instruments). Electrophysiology data were 
acquired using custom-built Recording Artist software version (Rick Gerkin), Igor Pro 6.37 
(Wavemetrics). All recordings were sampled at 20kHz, filtered at 2.8kHz. 
 
Evoked AMPA/NMDA currents. CA1 pyramidal neurons were visualized using differential 
interference contrast (DIC) video microscopy on an upright microscope (Olympus, BX51). 
Somatic whole-cell recordings were performed using borosilicate glass (World Precision 
Instruments, TW150-3) that had a tip resistance of 3-5 MΩ, filled with cesium-based internal for 
voltage-clamp recordings (in mM): 115 CsMeSO3, 20 CsCl, 10 HEPES, 0.6 EGTA, 2.5 MgCl, 10 
Na-Phosphocreatine, 4 Na-ATP, 4 Na-GTP, 0.1 Spermine, 1 QX-314 (pH adjusted to 7.3-7.4 with 
CsOH). A bipolar theta glass electrode backfilled with ACSF was positioned in the Schaffer 
collaterals for electrical stimulation. Stimulation intensity was adjusted to evoke single component 
EPSCs with a frequency of 0.1Hz. Voltage-clamp traces were recorded at a holding potential of -
70 mV (for AMPA-EPSCs) or +40 mV (for NMDA-EPSCs) in the presence of 100μM picrotoxin 
(Sigma-Aldrich). For each cell, at least 15 traces were averaged to obtain a representative 
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response at each holding potential. The peak EPSC amplitude at -70 mV was taken as the 
magnitude of the AMPA-EPSCs. To isolate the NMDA-mediated current, 10 μM NBQX (Abcam) 
was bath-applied and was blockade of AMPA-mediated currents was confirmed at -70mV. To 
calculate the NMDA/AMPA ratio, the amplitude taken at +40mV in the presence of NBQX was 
divided by the peak amplitude of the AMPA-EPSC at -70mV. The access resistance was 
monitored throughout the experiment and data was excluded if access resistance increased 
above 20 MΩ. The decay time constant of NMDAR-mediated EPSCs was calculated with a 
single-exponential fit in Igor 7. 
 
Statistical Analysis. For behavioral assays, we chose similar sample sizes for all behavioral 
experiments based on previous published studies of Cdkl5 constitutive knockout mice and Cdkl5 
conditional knockout mice(Tang et al., 2019; Tang et al., 2017; I. T. Wang et al., 2012). 
Importantly, the number of mice used was pre-determined prior to the start of each experiment. 
Statistical analyses were performed using Prism (GraphPad). All data sets were analyzed using 
the Shapiro-Wilk test for normality. For one-sample comparisons, data sets with normal 
distributions were analyzed for significance using the one-sample t-test, whereas data sets with 
non-normal distributions were analyzed using the Wilcoxon signed-rank test. For two-sample 
comparisons, data sets with normal distributions were analyzed for significance using the 
unpaired Student’s t-test, whereas data sets with non-normal distributions were analyzed using 
the Mann-Whitney test. Two-way repeated measures ANOVA or the Kruskal-Wallis test was 
conducted for the appropriate data sets with post hoc Sidak’s or Dunn’s multiple-comparisons 
tests. All one-sample, two-sample, and multiple-comparison tests were two-tailed.  
For NMDA seizure induction experiments, we tested a pilot cohort of wild-type and Cdkl5 
knockout animals at various doses of NMDA to establish an effect size in our own hands on this 
reported phenotype. This enabled proper power analysis to determine the appropriate sample 
size for our experimental cohorts (n=10 at 90 mg∙kg-1). Max seizure scores were statistically 
analyzed using the Kruskal-Wallis test and post hoc Dunn’s multiple comparisons test for 
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significance. Similarly, we referenced reported effect sizes for NMDA/AMPA ratio phenotypes 
reported in mouse models of CDD and related models of neurodevelopmental disorders in order 
to determine proper sample sizes for our physiology experiments. To analyze significance, we 
conducted One-way ANOVA with post hoc Tukey’s multiple-comparisons test. 
All graphs are plotted using Prism (GraphPad). Bolded center lines reflect the mean, and 
all error bars indicate s.e.m. For boxplots, the limits indicate the minimum and maximum with 
boxplot center line indicating the median. In our figures, p-values between 0.05 and 0.1 are 
shown explicitly, * is used to denote all 0.01 < p < 0.05, ** for 0.001 < p < 0.01, *** for 0.0001 < p 












Figure 1: Adult restoration of Cdkl5 expression rescues CDD-associated behavioral 
deficits. 
 
(a) Top: schematic of conditional rescue approach in Cdkl5STOP mice where a loxP-flanked 
transcriptional STOP cassette can be removed in the presence of Cre; Bottom: tamoxifen 
administration scheme and experimental schedule. (b) Left: representative western blot 
demonstrating restored CDKL5 protein expression in Cdkl5STOP/y; CreER/+ (Res) mice, but not 
Cdkl5STOP/y; +/+ (STOP) mice, to nearly Cdkl5+/y; CreER/+ (Cre) levels with tamoxifen 
administration concomitant with significant rescue of phosphorylation of EB2 at Ser222 but no 
change in total EB2 levels; Right: quantification of CDKL5 and EB2 pSer222 protein levels in 
forebrain tissues of all genotypes demonstrates significant rescue of both in Res mice upon 
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tamoxifen administration. (c) STOP mice, but not Res mice, spend significantly more time than 
Cre littermates in the open arm of the elevated zeromaze assay suggestive of decreased anxiety 
that is rescued in Res animals. (d) STOP mice travel significantly more distance in the open-field 
assay than Cre and Res littermates, demonstrating rescued hyperactivity in Res animals. (e) 
STOP mice spent significantly less time sniffing and (f) directly interacting with a stimulus mouse 
during the 3-chambered social choice test compared to Cre and Res littermates, highlighting 
rescued sociability phenotypes in Res animals. (g) STOP mice, but not Res mice, spend 
significantly more time grooming and digging in a home cage-like environment, demonstrating 
aberrant repetitive behaviors that are rescued in Res animals. (h) STOP mice take significantly 
less time to fall from an accelerating, rotating rod, suggestive of impaired motor coordination, 
whereas Res mice fall at a similar latency to Cre littermate controls demonstrating rescue of 
motor coordination. (i) STOP mice present with hindlimb clasping behaviors, whereas no Cre or 
Res mice were observed to carry hindlimb clasping phenotypes. (j) STOP and Res mice freeze in 
response to a mild footshock similarly to Cre littermates, but STOP mice show decreased percent 
time freezing compared to Cre and Res littermates when returned to the testing chamber 
(contextual) and upon hearing the testing tone (cue), demonstrating impaired learning and 
memory selectively in STOP mice that is restored in Res mice. For all panels: Cre, n=23; STOP, 
n=20; Res, n=17 where all genotypes received tamoxifen; Kruskal-Wallis test with Dunn’s multiple 
comparisons test (except Rotarod: 2-way repeated measures ANOVA with Sidak’s multiple 



































Figure 2. STOP mice are behaviorally similar to Cdkl5 germline knock-in mice by postnatal 
day 42. 
 
(a) STOP and KO mice move significantly more in the open-field test compared to Cre controls 
suggestive of hyperactivity. (b) STOP and KO mice show a trending decrease in percentage of 
spontaneous alternations during the Y-Maze assay compared to Cre controls suggestive of 
impaired working memory. STOP and KO mice also (c) travel significantly more and (d) make 
more total alternations compared to Cre controls in the Y-Maze assay. (e) STOP mice spend less 
time directly interacting with a novel stimulus mouse during a dyadic social test, demonstrating 
decreased sociability as reported for other Cdkl5 knockout and knock-in lines. For all panels: 
n=14 Cre (Cdkl5+/y; CreER/+); n=7 STOP (Cdkl5STOP/y; +/+); n=7 KO (Cdkl5R59X/y) all at postnatal 
day 42. Kruskal-Wallis test with Dunn’s multiple comparisons test (except dyadic social: Mann-


















Figure 3. Rapid, but not gradual, reversal of Cdkl5 expression is associated with 
significant lethality. 
 
(a) Top: tamoxifen administration schematic (rapid); Bottom: survival curve demonstrating 
significant lethality in Cdkl5STOP/y; CreER/+ mice, exclusively, with tamoxifen delivery suggesting 
rapid Cdkl5 reintroduction could be detrimental (n=8 Cdkl5+/y; +/+; n=11 Cdkl5+/y; CreER/+; n=8 
Cdkl5STOP/y; +/+; n=6 Cdkl5STOP/y; CreER/+). (b) Top: tamoxifen administration schematic 
(gradual); Bottom: survival curve demonstrating no significant difference in lethality between 
Cdkl5STOP/y; CreER/+ mice and other genotypes with tamoxifen delivery, suggesting that gradual 
Cdkl5 reintroduction mitigates lethality associated with its re-expression (n=23 Cdkl5+/y; CreER/+; 
n=20 Cdkl5STOP/y; +/+; n=17 Cdkl5STOP/y; CreER/+). For all panels: all genotypes received 
























Figure 4. Additional behavioral domains analyzed upon adult rescue of Cdkl5. 
 
(a) Total distance traveled during the elevated Zeromaze assay was similar between Cre, STOP, 
and Res mice. (b) STOP, but not Res, mice traveled significantly more in an open-field assay 
relative to Cre littermates over the course of one hour (distance traveled binned in 5min intervals) 
suggestive of rescued hyperactivity in Res mice. (c) STOP and Res mice show a significant 
decrease in percentage of spontaneous alternations in a Y-Maze assay compared to Cre 
littermates, suggestive of impaired working memory. (d) STOP, but not Res, mice make 
significantly more total number of alternations and (e) travel more distance during the Y-Maze 
when compared to Cre littermate controls further highlighting rescued hyperactivity in Res 
animals. (f) Cre, STOP, and Res mice all spent equal time exploring chamber 1 and chamber 2 
during Phase I of the 3-chambered social choice test (prior to any social/non-social stimulus 
presentation). (g) Cre, STOP, and Res mice all spent significantly more time in the chamber 
containing a social stimulus (S; novel mouse) over a non-social stimulus (NS; rock) during Phase 
II of the 3-chambered social choice test. (h) Cre, STOP, and Res mice all spent significantly more 
time sniffing a social scent over either water or almond scents, with STOP mice spending 
significantly less time than Cre or Res animals sniffing the social scent. For all panels: Cre, n=23; 
STOP, n=20; Res, n=17 where all genotypes received tamoxifen; Kruskal-Wallis test with Dunn’s 
multiple comparisons test (except open field & olfaction: two-way, repeated measures ANOVA 
with Dunnett’s multiple comparisons test & social choice test: paired t test); *p<0.05, **p<0.01, 





































Figure 5. Partial restoration of CDKL5 protein is capable of rescuing multiple behavioral 
domains. 
 
All panels reference data from Figure 1 with four partial rescue (Res) animals highlighted in blue. 
(a) Quantification of western blot results for CDKL5 protein levels in forebrain tissues of all 
genotypes demonstrates significant rescue of CDKL5 protein to nearly Cre-only levels in most 
Res, but not STOP, mice upon tamoxifen administration except for four animals (highlighted in 
blue) demonstrating between 20-60% CDKL5 protein restoration. Results from the (b) elevated 
zeromaze assay, (c) open-field assay, (d-e) 3-chambered social choice test, (f) repetitive 
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behavior assay, and (g) fear conditioning paradigm highlight that the four Res animals not 
showing full CDKL5 protein restoration (blue diamond) still cluster with the remaining Res animals 
versus STOP mice, demonstrating rescue on most behavioral domains evaluated. For all panels: 
Cre, n=23; STOP, n=20; Res, n=17; partial rescue Res, n=4 where all genotypes received 
tamoxifen; Kruskal-Wallis test with Dunn’s multiple comparisons test; *p<0.05, **p<0.01, 











Figure 6: Adult restoration of CDKL5 abrogates aberrant NMDAR-mediated synaptic 
responses. 
 
(a) Representative western blots showing several major ionotropic glutamate receptor subunits 
from postsynaptic density membrane fractions in Cre, STOP, and Res mice. (b-e) STOP, but not 
Res, mice show a selective increase in levels of GluN2B, a major subunit of the NMDA receptor 
compared to Cre littermate controls (n=8 per genotype). (f) STOP, but not Res, mice show a 
significantly increased susceptibility to NMDA-induced seizures compared to Cre littermate 
controls (Cre, n=9; STOP, n=10; Res, n=9). (g-i) STOP, but not Res, mice show an increased 
ratio of NMDA-mediated to AMPA-mediated synaptic responses in the hippocampal CA1 (g) 
concomitant with a significantly larger decay time constant of NMDAR-mediated EPSCs (i), 
suggestive of a higher contribution of GluN2B-containing NMDARs (representative traces shown 
in (h)) and demonstrating an attenuation of aberrant NMDAR signaling deficits in Res mice. For 
all panels: Kruskal-Wallis test with Dunn’s multiple comparisons test (except for (g) and (i): one-
way ANOVA with Tukey’s multiple comparisons test). *p<0.05, **p<0.01, ***p<0.001. Bars 








































Figure 7: Adult restoration of Cdkl5 expression ameliorates several CDD-associated 
behavioral deficits in heterozygous female CDD mice 
 
(a) Cdkl5FLEX mice carry an inverted exon 4 of the endogenous Cdkl5 locus, flanked by two pairs 
of loxP sites that allow for proper cassette re-orientation and gene expression upon tamoxifen 
delivery. All female mice received tamoxifen beginning at postnatal day 90, and behavioral 
analysis was performed 3 months later. (b) Open-field test demonstrating significant hyperactivity 
in heterozygous female Cdkl5 knockout mice (Cdkl5FLEX/+; +/+, or FLEX), but no significant activity 
change between Cre-only controls (Cdkl5+/+; CreER, or Cre) and rescue mice (Cdkl5FLEX/+; 
CreER, or Res) suggesting reduced hyperactivity. (c) Examination of sociability behaviors during 
a 3-chambered social choice test demonstrates reduced sociability in FLEX females mice 
compared to Cre littermate controls indicated by reduced (c) time spent sniffing and (d) directly 
interacting with a novel stimulus mouse. Res mice spent similar amounts of time sniffing and 
directly interacting with a stimulus mouse as their Cre littermate controls, demonstrating rescued 
sociability. (e) FLEX heterozygous females carry impaired context-dependent memory retrieval in 
a Pavlovian fear-conditioning paradigm highlighted by reduced time spent freezing upon return to 
the foot-shock chamber. Res mice show significantly increased time freezing compared to FLEX, 





CHAPTER 5 – X-LINKED CELLULAR MOSAICISM UNDERLIES AGE-DEPENDENT 
SEIZURE OCCURRENCE IN MOUSE MODELS OF CDKL5 DEFICIENCY DISORDER 
 
Contributions: Barbara Terzic, Yolanda Cui, and Andrew C. Edmondson co-led this 
study with help from Nicolas Sarmiento and Dasha Zaitseva for data analysis, Erin 
Nugent for seizure monitoring, and Zhaolan Zhou for the review and interpretation of 
data. Yue Cui and Erin Nugent managed all mouse husbandry, genotyping, and 
breeding. Barbara Terzic wrote this chapter with input from all authors. 
Abstract 
CDKL5 Deficiency Disorder (CDD) is an infantile epileptic encephalopathy presenting 
with early-onset seizures, intellectual disability, motor impairment, and autistic features. The 
disorder has been linked to mutations in the X-linked CDKL5, and mouse models of the disease 
recapitulate several aspects of CDD symptomology including learning and memory impairments, 
motor deficits, and autistic-like features, but not spontaneous seizures. Here, we report the first 
observation of disturbance-associated and spontaneous seizure-like events in heterozygous 
female mice across two independent mouse models of CDD: Cdkl5 knockout mice and CDKL5 
R59X knock-in mice. We find that both the prevalence and severity of this phenotype increase 
with aging, with a median onset around 28 weeks of age. Similar seizure-like events are not 
observed in hemizygous knockout male or homozygous knockout female littermates, suggesting 
that X-linked cellular mosaicism is a driving factor underlying these epileptic events. Furthermore, 
we successfully demonstrate significant prevention of seizure activity upon early (pre-epilepsy) 
Cdkl5 expression restoration, and a significant abatement of seizure activity upon late (post-
epilepsy) Cdkl5 expression restoration across 2 independent, conditional rescue mouse lines. 
Together, these findings not only contribute to our understanding of the effects of CDKL5 loss on 
seizure susceptibility, but also strengthen the face validity of current CDD mouse models for 




Pathogenic variants in the X-linked gene encoding cyclin-dependent kinase-like 5 
(CDKL5) have been associated with the severe childhood epileptic encephalopathy known as 
CDKL5 Deficiency Disorder (CDD)(Bahi-Buisson & Bienvenu, 2012; Fehr et al., 2013; Kalscheuer 
et al., 2003; Tao et al., 2004; Weaving et al., 2004). CDD is characterized by a heterogeneous 
array of clinical symptoms including early-onset seizures, marked hypotonia, autistic features, 
and severe neurodevelopmental impairment(S. Demarest et al., 2019; H. E. Olson et al., 2019). 
The disorder predominantly affects young females heterozygous for mutations in the X-linked 
CDKL5, with an overall incidence of one per forty-two thousand live births, making it one of the 
most common genetic causes of epilepsy in children(S. Demarest et al., 2019; Symonds et al., 
2019). Despite the constellation of phenotypes presented in CDD, the severe, early-onset 
seizures in particular drastically impact quality of life, with ninety percent of patients displaying 
seizures by three months of age. Eighty percent of children with CDD have daily seizures, and 
fewer than half report more than two months of seizure freedom(H. E. Olson et al., 2019). 
Furthermore, children with epilepsy that presents before 3 years of age have been shown to carry 
a high burden of behavioral and cognitive comorbidities, and this risk increases with increased 
seizure incidence(Berg et al., 2008; Berg, Zelko, Levy, & Testa, 2012). This high burden of 
refractory seizures in CDD make it a particularly debilitating aspect of the disorder for both 
patients and their families, highlighting the pressing need to develop effective therapeutics for 
seizure management. 
Several mouse models of CDD have been established and exhibit many of the cardinal 
phenotypes of the disorder, including autistic-like behaviors, impaired motor control, and poor 
learning and memory(Zhou, Han, & Zhou, 2017; Y.-C. Zhu & Z.-Q. Xiong, 2019). The first Cdkl5 
knockout mouse was generated and characterized in 2012, mimicking a reported CDD splice-site 
mutation resulting in skipping of exon 6 and loss of CDKL5 function(Archer et al., 2006; I. T. 
Wang et al., 2012). Although hippocampal electroencephalographic (EEG) recordings in postnatal 
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day (P) 70-90 male mice of this line demonstrated disruptions in event-related neuronal 
oscillations in response to auditory stimuli, chronic video-EEG recordings revealed no 
spontaneous seizure activity. Furthermore, basal EEG patterns and power distribution across 
various oscillation frequencies were unchanged in hemizygous knockout male mice compared to 
littermate controls. In 2014, Amendola et al. developed and characterized another Cdkl5 knockout 
mouse (exon 4 deletion) in which EEG recordings also revealed no spontaneous epileptiform 
activity in hemizygous male knockouts(Amendola et al., 2014). More recently, an exon 2 deletion 
mouse of Cdkl5 as well as the CDKL5 R59X knock-in, mimicking a CDD-associated nonsense 
mutation resulting in loss of CDKL5 function, were created. Although these animals display an 
increased sensitivity to NMDA-induced seizures, no overt spontaneous seizure activity was 
initially reported(Okuda et al., 2017; Tang et al., 2019). Recently, aged heterozygous female mice 
from the first Cdkl5 knockout (exon 6 deletion) and CDKL5 R59X knock-in mouse lines were 
reported to exhibit spontaneous epileptic spasms (Mulcahey, et al. 2020) 
The lack of a robust seizure phenotype in CDD mouse models has so far been attributed 
to neural network differences between human and mouse brains(Zhou et al., 2017). EEG 
recordings in loss-of-function models of CDD have not revealed spontaneous seizures, but the 
majority of these studies have been limited to hemizygous male mice(Amendola et al., 2014; I. T. 
Wang et al., 2012). Despite the lack of overt, behavioral seizures in animal models of CDD 
reported to date, several groups have observed synaptic and circuit-level hyperexcitability in 
various brain regions as well as altered sensitivity to specific chemoconvulsants. CDKL5 is most 
highly expressed in neurons of the forebrain, and selective loss of CDKL5 from forebrain 
excitatory neurons results in increased frequency of miniature excitatory post-synaptic currents 
(mEPSC) in the hippocampal CA1 region(Tang et al., 2017). Interestingly, selective loss from 
GABAergic forebrain neurons also recapitulates this increased mEPSC frequency coupled with 
circuit hyperexcitability in the form of aberrant paired-pulse facilitation(Tang et al., 2019). In this 
same region, loss of CDKL5 was found to result in enhanced long-term potentiation by a 
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misregulation of postsynaptic GluN2B-containing NMDA receptor localization, and in line with 
this, knockout mice exhibit significant hyperexcitability to NMDA(Okuda et al., 2017; Tang et al., 
2019). Although high-dose kainic acid induces overt seizures in Cdkl5 hemizygous knockout 
males at similar latency to wild-type littermates, the mean duration of the resultant epileptic EEG 
bursts is reported to be longer(Amendola et al., 2014). Cdkl5 knockout mice have also been 
reported to display decreased latency to the first stages of seizure progression upon low-dose 
pentylenetetrazol administration(Yennawar et al., 2019). These findings suggest that seizure 
susceptibility may in fact be altered in the absence of CDKL5, but perhaps only under certain 
environmental conditions or specific periods of development and aging.   
Here, we report the occurrence of overt, myoclonic and tonic-clonic behavioral seizure-
like events in two distinct mouse models of CDD: a Cdkl5 knockout carrying a deletion of exon 6 
and the CDKL5 R59X knock-in, both resulting in loss of CDKL5 function. These events are 
specific to female mice heterozygous for mutations in Cdkl5, and not seen in hemizygous 
knockout males, homozygous knockout females, or wild-type littermates. Both the frequency and 
severity of this seizure-like activity increased with aging, with a median age of onset around 28 
weeks of age. The lack of overt similar seizure-like events in hemizygous male knockout and 
homozygous female knockout mice suggests that X-linked mosaicism of Cdkl5 deficiency likely 
drives the seizure phenotype in mouse models of CDD. Importantly, we demonstrate for the first 
time that these seizure-like events in CDD mouse models are preventable and reversible with 
restoration of Cdkl5 expression, providing a positive outlook for seizure management and 
treatment in CDD patients. 
Results 
Female mice heterozygous for mutations in Cdkl5 exhibit seizure-like events in an age-
dependent manner 
The severity and prevalence of seizures in patients with CDD has motivated numerous 
efforts to model and examine seizure-related phenotypes in Cdkl5-deficient mice(Amendola et al., 
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2014; Okuda et al., 2018; Tang et al., 2019; Tang et al., 2017; I. T. Wang et al., 2012; Yennawar 
et al., 2019). Initial reports in several mouse models of CDD failed to recapitulate the 
spontaneous seizure phenotype commonly presented in CDD patients. However the majority of 
these studies, including our own, have focused on hemizygous knockout male mice. Furthermore, 
the majority of these behavioral or functional assays have been confined to young adult mice 
(postnatal days (P) 50-90). 
Given that Cdkl5 is X-linked, we maintain and generate experimental mice by crossing 
wild-type males to females heterozygous for Cdkl5 mutations (e.g., R59X). In the process of 
breeding R59X heterozygous females (Cdkl5R59X/+ or R59X/+), we observed that numerous aged 
(>P200) females displayed abnormal movements following cage opening/disturbance. Upon 
observing these abnormal movements, which we felt resembled seizure-like behaviors, we 
sought to establish a methodology to consistently and quantitatively score these events. We 
modified the Racine scale widely used to describe the progress and severity of chemoconvulsant-
induced seizures (Table 1), and set up a process of regular monitoring (3 minutes per cage, 2-3 
times a week) and seizure scoring along this scale for our R59X/+ breeder and non-breeder 
females as well as wild-type littermate controls(Velíšková, Velíšek, Mareš, & Rokyta, 1990). Over 
the span of fourteen months, upon cage opening or handling, we have documented behavioral 
events that we believe resemble seizures beginning as early as 17 weeks of age. 
The most frequent seizure-like events observed consisted of myoclonic jerks involving 
sudden and repetitive movement of the head and neck with or without tail stiffening (Racine 
Stage 1, Supplementary Video 1A, 1B, 1C). Tonic-clonic seizures with an initial appearance of 
wild running followed by loss of the righting reflex (Racine Stage 4, Supplementary Video 4A, 4B, 
4C) were the second most frequent seizure type observed. On rare occasions, the tonic-clonic 
seizures would progress into extension of fore- and hind-limbs, reaching Racine Stage 5 
(Supplementary Video 5). Clonic seizures with forelimb clonus and rearing were also relatively 
rare (Racine Stage 3, Supplementary Video 3A, 3B, 3C). To streamline data collection, analysis, 
and presentation, all seizures ranging from Racine stages 1 to 2 were termed ‘myoclonic 
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seizures-like events’ and events resembling Racine stages 3 to 5 were grouped as ‘severe 
seizure-like events.’ Mice were defined as being epileptic only after a second seizure-like event 
had been observed (typically Racine Stage 1). By 20 weeks of age, we found that 12% of R59X/+ 
females had displayed a second seizure-like event, and this increased to 70% of R59X/+ females 
exhibiting at least 2 seizures-like events by 40 weeks of age. We never observed similar events 
(or similar behaviors of any type) in wild-type (+/+) females, hemizygous knockout male mice 
(R59X/y), or wild-type male mice (+/y) across any of the age groups (Figure 1A).  
As no laboratory had previously documented seizures in any CDD mouse model at the 
time, we attempted to confirm our findings in an independent Cdkl5 knockout line lacking Cdkl5 
exon 6 (hereafter referred to as KO). Indeed, by 12 weeks of age we had observed at least two of 
these similar events in 8.7% of KO/+ females, and this increased to 65% of KO/+ females by 40 
weeks of age. Again, no seizure-like activity was observed in wild-type (+/+) females, hemizygous 
knockout male mice (KO/y), or wild-type male mice (+/y) across any of the age groups (Figure 
1B). 
To rule out the possibility that this epilepsy phenotype is exclusive to the CDKL5 colonies 
we have maintained in our laboratory, we obtained additional R59X/+ females (Stock No. 028856) 
and KO/KO females (Stock No. 003724) from the Jackson Laboratory, crossed them to newly 
obtained C57BL/6J males (Stock No. 000664), and subsequently monitored their progeny twice a 
week for seizure-like events as described above. 10 out of 13 R59X/+ females (77%), but no +/+ 
female or R59X/y male littermates, were observed to have at least one seizure-like event by 30 
weeks of age. Similarly, KO/+ females, but no +/+ female or KO/y male littermates, displayed 
seizure-like events by 30 weeks of age. We therefore concluded that the phenotype we had 
detected was indeed due to loss of Cdkl5 function. 
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Seizure-like event frequency and severity in Cdkl5 heterozygous females increases with 
age with a concomitant reduced life span 
While monitoring R59X/+ female mice, we observed that several mice reaching Racine 
Stage 5 seizures would die after reaching the tonic phase of the seizure. We found that on 
average, R59X/+ females have a significantly decreased lifespan compared to their wild-type 
littermate (+/+) females with significantly more R59X/+ females dying between 40-50 weeks of 
age (Figure 1C), possibly as a result of infrequent but lethal seizures. In contrast, no significant 
change in life span was found between R59X/y males and their wild-type (+/y) littermates (Figure 
1D). These results suggest that the seizure-like events occurring in R59X/+ females may 
decrease life span. 
Of the R59X/+ females observed starting at 12 weeks of age, the median age of onset of 
a second observed myoclonic seizure-like event (Racine Stages 1 to 2) was 28 weeks. More 
severe seizure-like events (Racine Stages 3 to 5) also occurred more frequently with increasing 
age, with a median onset of 47 weeks of age (Figure 2A). In addition to this increasing seizure-
like event severity, the frequency of all observed seizure-like events also increased with age 
(Figure 2B). 
It should be noted that there is significant individual variability within R59X/+ females for 
both the onset and the frequency of these seizure-like events. During our observations, some 
females displayed their first disturbance-associated seizure-like event as early as 17 weeks of 
age while others did not display an overt seizure-like event until 49 weeks of age or ever. For 
some R59X/+ mice, disturbance-associated seizure-like events occurred every week for a time 
span of a few months, while for other mice no events were observed after two initial seizure-like 
events. A summary of 20 R59X/+ females monitored from 12 to 45 weeks of age for all seizure-
like events demonstrates this trend of age-dependency and variability (Figure 2C).  
We similarly tracked the age-dependent development of seizure-like events in our second 
Cdkl5 knockout line to validate our findings. In KO/+ females, the median age of onset of a 
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second observed myoclonic seizure-like event (Racine Stages 1 to 2) was 32 weeks, with a first 
seizure-like event observed as early as 16 weeks of age in some mice. More severe seizure-like 
events (Racine Stages 3 to 5) occurred in KO/+ females with a median age of onset of 57 weeks 
(Figure 3A). Similar to the R59X/+ females, the likelihood of both myoclonic seizure-like events 
and a severe seizure-like events in KO/+ females increased with age (Figure 3B). We monitored 
17 KO/+ females from 12 weeks until 42-45 weeks of age and recorded all seizure-like events, 
and found similar individual variability in both age-of-onset and seizure frequency as reported 
above for R59X/+ (Figure 3C). 
We recognize that this variability may also be a result of our sampling method of only 
observing seizure-like events 2-3 times a week upon cage disturbance, and that our incomplete 
reported penetrance of ~70% may not accurately reflect the actual incidence of seizure-like 
events amongst heterozygous female carriers of Cdkl5 mutations. To investigate whether the 
seizure-like events we were observing only occur with cage opening/disturbance, we continuously 
video recorded R59X/+ females mice that had previously displayed a disturbance-associated 
seizure-like event for >72 hours to determine whether events can also occur spontaneously. Both 
myoclonic seizure-like events (Supplementary Video 6A, 6B) and tonic-clonic seizure-like events 
(Supplementary Video 7) were observed during this recording session. These events occurred 
spontaneously without any disturbances or environmental changes, suggesting that loss of 
CDKL5 leads to spontaneous seizure-like events as well as the disturbance-associated seizure-
like events we reported above.  
In an attempt to capture EEG correlates of these seizure-like events, we performed EEG 
implantation surgery utilizing 2 cortical surface electrode and video monitoring in R59X/+ female 
mice as described in the methods section (n=13). Mice under EEG surveillance with time-locked 
video were mildly disturbed by a gentle touch of the hand at varying times and intervals 
throughout the monitoring period to mimic the seizure monitoring interactions. No Racine stage 4 
or 5 handling-provoked generalized tonic-clonic seizures were evoked. We also watched the 
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recorded video and analyzed the EEG tracing using integrated seizure detection software without 
observing any unprovoked Racine stage 4 or 5 seizures. Over 1,574 hours of video-EEG data 
across 13 R59X/+ female mice (roughly 121 hours/mouse) we were only able to observe one 
female displaying a stage 1 handling-associated seizure-like event (Supplemental Videos 8A, 
8B), characterized by brief movements involving neck extension and body stiffening temporally 
associated with bilaterally synchronous slow-wave discharges on EEG. We also recorded over 
145 hours of video-EEG data across 4 wild-type female and wild-type male mice without 
detection of similar seizure-like events as reported prior to surgery and implantation. Using this 
technique, we did detect epileptic spasms as recently described in the same mouse 
lines(Mulcahey et al., 2020). 
Given the concern that inability to observe these seizure-like behaviors could be due to a 
possible blunting effect from the surgery itself, we utilized a different EEG implantation technique 
with 2 cortical surface electrodes and a double-depth electrode in right hippocampus in 7 R59X/+ 
and 9 KO/+ heterozygous females mice, as well as 8 wild-type female mice. Each mouse 
underwent video-EEG recording for at least 11 days as described in the methods. Over the entire 
duration of over 2,300 hours of video-EEG monitoring for all 24 mice, the technicians who 
handled the mice observed no Racine stage 4 or 5 handling-provoked generalized tonic-clonic 
seizures. We also utilized a third EEG implantation technique with 8 electrodes (hippocampal, 
bilateral parietal, bilateral motor, bilateral visual electrodes) and failed to detect any Racine stage 
4 or 5 handling-provoked generalized tonic-clonic seizures while working with these mice. 
Interestingly, a recent publication reported spontaneous epileptic spasms, associated with 
generalized, slow-wave activity on EEG, in identical strains of KO/+ and R59X/+ female mice at 
similar ages(Mulcahey et al., 2020). Our findings of disturbance-associated myoclonic and tonic-
clonic seizure-like events, therefore, complement the previous findings and suggest that multiple 
seizure semiologies exist in mouse models of CDD. 
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Heterozygous mosaic, but not homozygous or hemizygous, loss of CDKL5 underlies 
spontaneous seizure development 
We were intrigued by the sex-specificity of our observed seizure-like phenotype and 
wanted to dissect the contributing factors that may underlie this segregation of seizure 
presentation to R59X/+ and KO/+ females but not R59X/y or KO/y hemizygous male knockouts. 
Since sex hormones are well known to affect the seizure threshold of both epileptic humans and 
mice, we examined whether estrous cycle or androgen hormones may be contributing to the sex-
specificity of this phenotype(Tauboll, Sveberg, & Svalheim, 2015). We collected vaginal lavage 
samples from R59X/+ and KO/+ females immediately upon observing disturbance-associated 
seizure-like events in order to test for estrous cycle stage at the time of seizure occurrence. We 
identified seizing females in all four stages of the mouse estrous cycle (Figure 4A), suggesting 
that the levels of sex hormones or estrous cycle stage are unlikely to be triggering factors for the 
seizure-like events we observed. We also compared the median age of seizure onset between 
breeder and nulligravid R59X/+ females and did not observe any significant differences (Figure 
4B). 
An additional factor that differs between our seizing heterozygous knockout females and 
hemizygous males is the X-linked mosaicism exclusively present in heterozygous female 
knockouts. To investigate whether mosaicism may be underlying the seizure-like phenotype 
segregation between our male and female CDD mice, we have been generating a cohort of mice 
by breeding R59X/+ females to +/y and R59X/y males. To date, we have monitored 14 
homozygous knockout females (R59X/R59X) together with 16 heterozygous knockout females 
(R59X/+) and 9 wild-type (+/+) littermate controls beginning at 12 weeks of age. 12 out of 16 
(75%) R59X/+ females have been observed to display at least two disturbance-associated 
seizure-like events with a median age-of-onset of 32 weeks, while no seizure-like events have 
been seen in +/+ littermate controls and only one seizure-like event being observed in a single 
R59X/R59X female littermate (Figure 4C). This supports the idea that X-linked mosaicism of 
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Cdkl5 deficiency may be a driving factor of the disturbance-associated and spontaneous seizure-
like events observed in female models of CDD. 
Restoration of Cdkl5 expression prevents and reverses the evolution of seizure-like 
events in heterozygous female models of CDD 
Our unexpected seizure phenotype finding provoked a unique insight into genetic models 
of CDD, and led us to examine the reversibility of this epileptic phenotype in our Cdkl5STOP and 
Cdkl5FLEX heterozygous female mice. We began by examining Cdkl5STOP heterozygous females 
(Cdkl5STOP/+, hereafter referred to as STOP/+) for the occurrence of any seizure-like events 
similar to what we reported in R59X/+ and KO/+ females. STOP/+ females developed age-
dependent seizure-like events by a median age of 31 weeks, confirming our seizure phenotype in 
an independent Cdkl5 knockout model (Figure 5). Similar events were not detected in UB-CreER-
only control littermates (Cdkl5+/+, CreER/+). We first tested the potential for prevention or 
mitigation of this epilepsy phenotype with early Cdkl5 expression restoration (i.e. prior to epilepsy 
onset). 
We subsequently raised up a cohort of STOP/+; +/+ and STOP/+; CreER/+ female 
littermates, and administered tamoxifen to all genotypes beginning at P90 (13 weeks of age) 
using the same regiment applied in our conditional knockout experiments in Chapter 3 (0.3mg∙kg-
1 every other day for a total of 5 doses). This regiment restores Cdkl5 expression in STOP/+; 
CreER/+ mice, but not STOP/+ mice, prior to the onset of any seizure phenotype. Using the same 
bi-weekly-monitoring method as described in previous sections, we noticed that STOP/+, but not 
STOP/+; CreER/+ mice, developed seizure-like behaviors by 31 weeks of age. These results 
demonstrate a successful prevention (or at least significant mitigation) of seizure-like events with 
early Cdkl5 restoration (Figure 5), and align with our previous behavioral rescue studies in 
females (Chapter 4, Figure 7). 
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We next tested whether late Cdkl5 expression restoration (i.e. after epilepsy onset) was 
also capable of mitigating the occurrence of seizure-like events in heterozygous Cdkl5 knockout 
female models. In an independent cohort, we report that STOP/+ mice and their STOP/+; 
CreER/+ littermates all develop seizure-like events by a median age of 28.5 weeks (Figure 6). We 
subsequently delivered tamoxifen (0.3mg∙kg-1 every other day for a total of 5 doses) to all animals 
beginning at 33 weeks of age in order to test the reversibility of this epileptic phenotype. While 
STOP/+ mice continued to present with seizure-like events even after tamoxifen administration, 
no subsequent seizure-like events were detected in STOP/+; CreER/+ littermates (Figure 6). 
These results suggest that Cdkl5 expression restoration can reverse or significantly mitigate the 
occurrence of seizure-like events even in mice that were previously seizing. Importantly, we 
corroborated these findings in our independent conditional rescue line, the Cdkl5FLEX/+ (FLEX/+) 
crossed to a distinct inducible Cre (CAG-CreER). We demonstrate that FLEX/+ females and their 
FLEX/+; CreER/+ littermates all develop seizure-like events at a median age of onset of 37 and 
28.5 weeks, respectively (Figure 7). Importantly, late Cdkl5 expression restoration (33 weeks of 
age) using our same tamoxifen regiment successfully mitigated the occurrence of seizure-like 
events in FLEX/+; CreER/+ females, but not FLEX/+ littermates (Figure 7). Together, these 
results demonstrate the potential for seizure prevention and reversal in heterozygous female 
mouse models of CDD. 
 
Discussion 
Despite the presence of multiple behavioral and neurophysiological impairments, the 
spontaneous seizures that are a hallmark feature of CDD have not been reported across four 
independent Cdkl5 knockout mouse models(Amendola et al., 2014; Okuda et al., 2018; I. T. 
Wang et al., 2012; Yennawar et al., 2019). It is therefore imperative to establish animal models 
with stronger face validity in order to dissect the mechanisms underlying the epilepsy associated 
with mutations in CDKL5 as well as to facilitate future development of targeted therapeutics. This 
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is the first report of disturbance-associated and spontaneous seizure-like phenotypes in mouse 
models of CDD. Both the disturbance-associated and spontaneous seizure-like activity appear to 
be specific to female mice heterozygous for mutations in Cdkl5, with no hemizygous male 
knockout, homozygous female knockout, or wild-type littermate control mice displaying epileptic 
activity to our knowledge. In contrast to humans with CDD, we find that our female CDD mice 
display a delayed seizure phenotype onset, at a median age around 30 weeks (averaged across 
our two independent loss-of-function lines). We speculate that this delayed-onset as well as the 
variable presentation between individual animals (Figures 2C and 3C) may account for the 
absence of previous reports of seizures across various heterozygous female models of CDD.  
 Our initial observations in R59X/+ females led us to investigate and validate our seizure-
like findings across three additional, independent Cdkl5 knockout lines (KO/+, STOP/+, and 
FLEX/+) with similar age-of-onset and incidence, suggesting that this phenotype is indeed linked 
to mutations in Cdkl5 and will likely be shared across additional mouse models of CDD. 
Myoclonic seizures, as well as generalized tonic-clonic seizures, have been widely described in 
CDD patients, reflecting a potential similarity between human CDD epilepsy and the events we 
observe in our mice(H. E. Olson et al., 2019). Furthermore, we find that the segregation of this 
seizure-like phenotype exclusively to heterozygous female knockouts (and not hemizygous males 
or homozygous females) highlights X-linked mosaicism as a potential driving factor for seizure 
presentation in mouse models of CDD. 
Late-onset of epilepsy phenotype in female CDD mouse models 
The delayed onset of seizure-like events in our CDD mice reflects a key distinction 
between the human CDD patient seizure phenotype and that of our models. The median age of 
onset for a second observed seizure-like event in our R59X/+ and KO/+ females was 28 weeks 
and 32 weeks of age, respectively; considered well into the middle-aged stage of the lifespan of 
C57BL/6 mice(Flurkey et al., 2007). In contrast, CDD patients display early-onset seizures with a 
median age of onset at six weeks of age and with 90% developing seizures by three months of 
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age(Fehr et al., 2013; H. E. Olson et al., 2019). As previously discussed, one factor that could be 
underlying this variability between human and mouse CDD seizure onset in this study is the 
behavioral method of observation for seizure-like events. By sampling events in our mouse 
models 2-3 times a week, it is possible we may have missed any spontaneous seizure-like events 
occurring at earlier ages, especially given the frequency of seizure-like events appears to 
increase with age. It is also plausible that earlier-occurring seizures in our mice may not have had 
recognizable behavioral correlates. The prevalence, frequency, and semiology of spontaneous 
epileptic spasms are characterized in a recent publication using chronic video-EEG recording in 
aged, Cdkl5 mutant mice(Mulcahey et al., 2020). In future studies, a more detailed 
characterization of seizure progression and onset in younger animals via chronic, video-EEG will 
allow for a more fine dissection of the temporal progression of this seizure phenotype. 
In CDD patients, typical seizure progression appears to follow a pattern progressing from 
early onset and at times pharmacoresponsive seizures (Stage I; onset 1-10 weeks), to epileptic 
encephalopathy with infantile spasms (Stage II; onset 6 months to 3 years), and subsequently 
refractory, multifocal and myoclonic epilepsy (Stage III; onset 5-7 years)(Bahi-Buisson, Kaminska, 
et al., 2008). This final stage of refractory epilepsy appears to continue long-term in most 
patients, highlighting an increasing seizure severity with age that human CDD patients also 
appear to display. Developmental differences between human and mouse brains may underlie 
these phenotypic differences in age of onset. As such, a more in-depth focal analysis of the cell 
type or circuit of origin for these epileptic events in the future will provide clarity on the nature of 
this delayed-onset phenotype in mice. Our findings of a second seizure type in addition to the 
recently described epileptic spasms complements the previous findings and suggest that similar 




Disturbance-associated nature of CDD mouse seizure phenotypes 
Seizures are known to be precipitated by a myriad of factors including stress, menses, 
photic stimulation, etc.(Engel Jr., 2012). Our initial observances of seizure-like events in our aging 
CDD female mice occurred upon cage opening or disturbance, suggesting that specific 
environmental triggers may precipitate seizure presentation in our model. Although mice were 
often gently separated by hand for easier observation, disturbance by touching was not required 
for seizure-like events to occur. These events may have been invoked by the movement of the 
cage during transfer to the changing station, sound from the ventilation of the changing station 
hood, brighter light, exposure to human odor, or a combination of multiple of the above factors. 
Even though it remains unclear what aspects of cage disturbance specifically trigger the 
associated seizure-like events we observed in our R59X/+ and KO/+ females, it is important to 
note that we have also observed spontaneous seizure-like events during chronic video 
monitoring, in the absence of any discernible external stimuli (Supplementary Videos 7A, 7B, 7C, 
8), highlighting that this environmental disturbance is not required for seizure onset. Interestingly, 
some CDD patients have been reported to have reflex seizures, or seizures that are predictably 
triggered by specific stimuli, suggesting a precedence for this phenotype in humans(Peikes, 
Hartley, Mhanni, Greenberg, & Appendino, 2019; Solazzi et al., 2018). While we are convinced 
these observed events are seizures, we were unfortunately unable to electrographically capture 
these events despite using three different EEG implantation techniques since the nature of the 
behavioral phenotype changed upon EEG electrode implantation. Failing to capture these events 
could be due to the rarity and unpredictability of the events in individual mice, a possible blunting 
effect from the surgery itself, altered semiology of seizure-like events, or inability to replicate a 
more consistent environmental trigger while in our video-EEG system. The unpredictability of 
seizure events in chronic epilepsy is cited as a major factor affecting quality of life, thus, further 
work into the potential triggering factors for CDD-associated seizures could provide valuable 
insight into environmental influences on seizure development and potential avenues for 
155 
 
mitigation(Devinsky et al., 1995). Our findings, together with those of Mulcahey et al., suggest 
that multiple seizure semiologies likely exist in mouse models of CDD(Mulcahey et al., 2020). 
Mosaic loss of CDKL5 drives the overt presentation of spontaneous seizures  
CDD affects both male and female patients, albeit at varying frequencies, and 
hemizygous male Cdkl5 knockout mice have been able to recapitulate several of the cardinal 
phenotypes presented in CDD patients(Akamine et al., 2018; Amendola et al., 2014; Liang et al., 
2019; Mirzaa et al., 2013; Okuda et al., 2018; Sartori et al., 2009; Szafranski et al., 2015; Van 
Esch, Jansen, Bauters, Froyen, & Fryns, 2007; I. T. Wang et al., 2012; Yennawar et al., 2019). 
However, in our study, no overt seizure-like activity was observed in either R59X/y or KO/y male 
mice, at least at the ages we focused on, and previously reports in various hemizygous CDD 
knockout males have also not observed spontaneous seizures(Amendola et al., 2014; Okuda et 
al., 2018; I. T. Wang et al., 2012; Yennawar et al., 2019). Both of our loss-of-function CDD lines 
(Cdkl5R59X and Cdkl5 knockout) have been generated and maintained in the C57BL/6 strain for at 
least 10 generations – an inbred strain of mouse known to confer increased seizure resistance, 
thus potentially occluding the presentation of spontaneous seizures in other Cdkl5 knockout 
mice(Ferraro et al., 2010; McKhann, Wenzel, Robbins, Sosunov, & Schwartzkroin, 2003). Despite 
this, previous attempts by our group and others at backcrossing our Cdkl5 lines to less seizure-
resistant strains (e.g., DBA/2J, FVB, 129) have not precipitated the manifestation of any 
spontaneous seizure events in hemizygous Cdkl5 knockout males (data not shown)(Amendola et 
al., 2014). This suggests that genetic background is likely not causal to the lack of overt 
behavioral seizures in hemizygous male CDD models.  
We propose the differences we observe between hemizygous male and heterozygous 
female mouse models of CDD may be due to the mosaicism of CDKL5 loss caused by X-
chromosome inactivation in R59X/+ and KO/+. This hypothesis is supported by the lack of an 
overt seizure-like phenotype in either hemizygous male knockout (R59X/y; KO/y) or homozygous 
female knockout (R59X/R59X; KO/KO) mice. Furthermore, estrous cycle and androgen hormone 
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levels appear to be unrelated to event incidence across seizing female mice. Interestingly, 
another epileptic encephalopathy, caused by mutations in the X-linked PCDH19, is well known for 
causing seizures predominantly in heterozygous females and mosaic males(Kolc et al., 2019). 
The mechanism underlying PCDH19-related epilepsy has been traced to abnormalities in cellular 
adhesion and consequent cell sorting in animal models(Bartnik et al., 2011; Pederick et al., 
2018). While it remains unclear whether epilepsy in CDD is definitively related to mosaicism, 
mosaic exon deletions and mosaic de novo point mutations have been reported in both male and 
female CDD patients and may be an underappreciated phenomenon(Stosser et al., 2018). 
Seizure treatment in mouse models of CDD 
Collectively, our gene rescue findings successfully demonstrated significant prevention of 
seizure activity upon early (pre-epilepsy; Figure 5) Cdkl5 expression restoration and a significant 
abatement of seizure activity upon late (post-epilepsy; Figure 6 & Figure 7) Cdkl5 expression 
restoration across 2 independent rescue lines. These results highlight the potential not only for 
inhibition of CDD-associated seizure onset with early gene replacement or treatment, but also 
demonstrate the reversibility of seizure occurrence with late Cdkl5 restoration. Again, due to a 
possible blunting effect from the surgery itself, altered semiology of seizure-like events, or inability 
to replicate a more consistent environmental trigger while in our video-EEG system, the nature of 
this seizure-like phenotype changes upon EEG implantation, making it difficult to 
electrographically capture these events. However, as mentioned, a recent study in collaboration 
with our group also identified epileptic spasms that were associated with generalized slow-wave 
activity on EEG specific to heterozygous female CDD mice(Mulcahey et al., 2020). Our current 
endeavors include attempting to capture correlates of these distinct epileptic spasms using video-
EEG in STOP/+ and FLEX/+ mice, and subsequently evaluating their evolution upon early and 
late Cdkl5 restoration. Early-onset epilepsy is a cardinal phenotype within CDD, therefore, these 
seminal results are a critical development for future examinations into the reversibility, treatment, 
and pathogenesis of epilepsy associated with CDD. Our results also highlight the potential for 
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mouse models of CDD, especially our novel, conditional reversal line, to serve as a valuable tool 
to dissect the circuit and EEG progression of childhood epilepsy more generally. 
Together, our findings demonstrate the first report of overt, disturbance-associated and 
spontaneous seizure-like events in Cdkl5 deficient mice, a second, distinct seizure phenotype, 
and provide the community with newfound face validity for existing CDD models. Although we 
were not able to capture the events described in this study on video-EEG, our video records 
suggest that they closely resemble the spectrum of behavioral seizure phenotypes described by 
the Racine scale. Our current and future work aim to more extensively dissect both the focal 
circuits (or multi-focality) and continuum of severity underlying seizures presented in these CDD 
mouse models as well as the mechanism of seizure reversal with late gene restoration. 
Investigating the circuit origin/nature of this epilepsy phenotype in mice will continue to highlight 
mechanisms by which loss of CDKL5 drives network imbalance and circuit hyperexcitability, and 
will provide the CDD community with crucial insights towards the development of seizure 
therapeutics. 
 
Materials and Methods 
Mouse strains. The CDKL5 R59X knock-in(Tang et al., 2019) and Cdkl5 knockout(I. T. Wang et 
al., 2012) lines were generated as previously described, and have since been deposited at 
Jackson Laboratories (R59X: Stock No. 028856; Cdkl5 KO: Stock No. 021967). UBC-CreER 
(Stock No. 007001) mice and CAG-CreER (Stock No. 004682) mice were obtained from the 
Jackson Laboratories. Cdkl5STOP and Cdkl5FLEX mice were generated as described in Chapter 4 
(‘Materials and Methods’). All lines have been maintained in the C57BL/6J background. 
 
Animal husbandry. Experiments were conducted in accordance with the ethical guidelines of the 
National Institutes of Health and with the approval of the Institutional Animal Care and Use 
Committee of the University of Pennsylvania. Mice were group-housed in cages of two to five in a 
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twelve-hour light/dark cycle with food and water provided ad libitum.  Each breeding cage 
contains one male (C57BL/6J or Cdkl5R59X/y, R59X/y) and one to two females (Cdkl5R59X/+, 
R59X/+, or Cdkl5KO/+, KO/+). All progeny were genotyped either with the previously reported PCR 
strategies or with qPCR by Transnetyx, Inc(Tang et al., 2019; I. T. Wang et al., 2012). Male 
littermates (Cdkl5R59X/y with Cdkl5+/y; Cdkl5KO/y with Cdkl5+/y) and female littermates (Cdkl5+/+ 
and/or Cdkl5R59X/R59X with Cdkl5R59X/+; Cdkl5KO/+ with Cdkl5+/+) were weaned at 3 weeks of age 
and housed together.  
 
Seizure monitoring. Mice were monitored for disturbance-associated seizures two to three times 
over the course of each week (every other day), during varying times between 8AM to 7PM. 
Times of day with no extra disturbances occurring (such as cage changing) were chosen. Cages 
were swiftly and gently pulled out of the rack and moved onto the cage changing station, one 
cage at a time. Cage lids were immediately removed and mice were mildly disturbed by a gentle 
touch of the hand. Mice in the cage were then closely observed for 3 minutes for the occurrence 
of any seizure events and scored according to the modified Racine scale (see Table 1, adapted 
from Velíšková et al., 1990). Stage 0: no changes in behavior; Stage 1: myoclonic jerks with 
sudden and repetitive movement of the head and neck with or without tail stiffening; Stage 2: 
atypical (unilateral or incomplete) clonic seizure; Stage 3: clonic seizure with forelimb clonus and 
rearing; Stage 4: tonic-clonic seizure with an initial wild run and subsequent loss of righting reflex; 
Stage 5: tonic-clonic seizure with full extension of fore- and hind-limbs. To streamline data 
collection, analysis, and presentation, all seizures ranging from Racine stages 1 to 2 were termed 
‘myoclonic seizures’ and events resembling Racine stages 3 to 5 were grouped as ‘severe 
seizures.’ 
 
Determination of estrous cycle stage. Mice observed having disturbance-associated seizures 
underwent vaginal lavage immediately after they resumed normal activities to check for estrous 
cycle stage. Each mouse was picked up by the base of the tail and 20ul of saline was gently 
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expelled into the vaginal cavity using a pipette, aspirated back five times, and then dispensed 
onto a microscopic slide. Dry smears were then evaluated under the microscope and scored for 
the estrous cycle stage according to the presence/absence and percentage of neutrophils, 
nucleated epithelial cells and cornified epithelial cells(Caligioni, 2009). Proestrus stage: 
predominance of nucleated epithelial cells; Estrus stage: predominance of cornified epithelial 
cells; Metestrus stage: predominance of leucocytes with a small amount of nucleated and/or 
cornified epithelial cells; Diestrus stage: predominance of leucocytes. 
 
Two-Channel EEG implantation surgery. Experiments were conducted in accordance with the 
approval of the Institutional Animal Care and Use Committee of the University of Pennsylvania. 
Mice were stereotaxically implanted with an electrode assembly under continuous isoflurane 
anesthesia. The electrode assembly consisted of 4 leads: 2 surface electrodes attached to 
miniature skull screws placed over the left and right frontal cortices (from Bregma: A/P + 1.0 mm, 
M/L ± 1.5 mm); and a reference and a ground electrode also attached to miniature skull screws 
directly behind Lambda on either side of midline (from Bregma: A/P − -5.2 mm, M/L ± 1.5 mm);. 
Silver wires (0.13 mm diameter) were attached to each electrode and connected to an 8-pin 
headmount (Pinnacle Technology Inc, Lawrence, KS). The entire assembly was secured on the 
skull with dental cement (Ortho-Jet, Lang Dental, Wheeling, IL). Mice were given at least 72 
hours post-surgery to recover prior to being placed in a Plexiglas recording cage (Pinnacle 
Technology Inc, Lawrence, KS). EEG waveform was amplified by a preamplifier with a gain of 10 
μV (Pinnacle Technology Inc, Lawrence, KS) at the head of the animal before being passed 
through a low-torque communtator to the Sirenia Acquisition system (Pinnacle Technology Inc, 
Lawrence, KS) for final-stage amplification and filtering. EEG was sampled at 2000 Hz in a 12-
hour light/dark cycle with food and water provided ad libitum. Mice in the monitoring cages were 
mildly disturbed by a gentle touch of the hand at varying times and intervals throughout the 
monitoring period to mimic the seizure monitoring interactions as described above. Video was 
watched by a reviewer familiar with the appearance of the disturbance-associated seizures. EEG 
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traces were also processed with the application of a 1 Hz high-pass filter, 500 Hz low-pass filter, 
and 60 Hz notch filter and analyzed within Serenia Basic (Pinnacle Technology Inc, Lawrence, 
KS) using amplitude and line length individually to identify potential seizure event.  For each 
potential seizure event, time-locked video was used to assess for the presence of motor behavior 
typical of disturbance-associated seizures.  
 
Four-Channel EEG implantation surgery. EEG recordings were performed as previously 
described in Mulcahey et al.(Mulcahey et al., 2020). All experiments were conducted in 
accordance with the approval of the Institutional Animal Care and Use Committee of the 
Children’s Hospital of Philadelphia. Mice were stereotaxically implanted with an electrode 
assembly under continuous isoflurane anesthesia. The electrode assembly consisted of 6 leads: 
2 surface electrodes attached to miniature skull screws placed over the left and right frontal 
cortices (from Bregma: A/P −1.2 mm, M/L ±1.1 mm); a double-depth electrode in right 
hippocampus (A/P −2.2 mm, M/L +1.2 mm, D/V −1.3 mm); and finally a reference and a ground 
electrode directly behind Lambda on either side of midline. Teflon-coated silver wires (0.13 mm 
diameter) were attached to each electrode and connected to a 6-pin pedestal (Plastics One, 
Roanoke, VA). The entire assembly was secured on the skull with dental cement (Ortho-Jet, Lang 
Dental, Wheeling, IL). All surgeries were performed by an experimenter blinded to genotype. 
 
Video-EEG recording. Video-EEG recording was conducted as previously described in 
Mulcahey et al.(Mulcahey et al., 2020). A flexible cable connected each animals headcap 
assembly to a commutator thus allowing the mouse to move freely during the recordings. Mice 
were given at least 72 hours post-surgery to recover prior to being placed in a recording cage and 
were acclimatized for at least 72 hours before recording initiation. Video-monitored EEG 
recordings of awake and behaving mice were performed in custom-made Plexiglas cages using a 
Stellate Harmonie acquisition interface (Natus Medical, Pleasanton, CA) and sampled at 200 Hz 
in a 12-hour light/dark cycle with food and water provided ad libitum. As previously described 
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(Mulcahey et al.), each mouse underwent video-EEG recording for at least 11 days across 8 wild 
type mice, 7 R59X/+ mice, and 9 KO/+ mice. During this period, each mouse underwent a routine 
cage cleaning each week at approximately 9:00-11:00 AM (lights out at 1:00 PM). Cage cleanings 
alternated between “deep” cleans (mouse is removed from recording cage while recording cage 
is cleaned) and “quick” cleans (mouse is lifted, a temporary floor is placed in the recording cage, 
a clean floor and clean bedding are placed in the cage). In addition to cage cleanings, veterinary 
staff checked each recording cage each morning before 11:00 AM. Veterinary staff only opened 
the cages (1) if the mouse needed food or water or (2) if the mouse appeared unhealthy. At the 
conclusion of video-EEG recording, the mice were removed from the recording apparatus. 
 
Eight-channel EEG implantation surgery. Electroencephalographic mouse studies were 
performed as previously described using 8 electrodes (hippocampal, bilateral parietal, bilateral 
motor, bilateral visual electrodes) using the following coordinates (from Bregma – Bilateral motor: 
0.5 mm Anterior-Posterior (A-P) and 1.0 mm medial-lateral (M-L); bilateral parietal: −0.7 mm A-P, 
3.0 mm M-L; bilateral visual −3.5 A-P, 2.0 mm M-L; hippocampus: −2.2 mm A-P, 2.0 mm M-L, 
and 1.7 mm ventral). (Marsh et al., 2009; Simonet et al., 2015). All experiments were conducted 
in accordance with the approval of the Institutional Animal Care and Use Committee of the 
Children’s Hospital of Philadelphia. After 24–48 h of recovery in their home cage the animals 
were transferred to the monitoring cage and recorded using a 32- channel Intan extracellular 
amplifier (RHD2000 USB Interface Board, Intan Technologies) using either DataWave software or 
importing the raw data into Matlab. The recordings were sampled at 2000 Hz, with no on-line 
filtering. Electrode impedances were tested prior to all recordings. All animals were recorded for 
at least 72 h. Other than when being placed in the chambers or removed, mice were not handled 
during the monitoring. 
 
Statistical analyses. Similar sample sizes for all seizure monitoring across genotypes was 
chosen. Statistical analyses were performed using Prism (GraphPad). All data sets were 
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analyzed using the Shapiro-Wilk test for normality. All survival curves were compared using a log-
rank (Mantel-Cox) test to test for significance. All graphs are plotted using Prism (GraphPad). In 
our figures, * is used to denote all 0.01<p<0.05, ** for 0.001<p<0.01, *** for 0.0001<p<0.001, and 


















































0 No changes in behavior   
1 
Myoclonic jerks with sudden and repetitive 
movement of the head and neck with or 
without tail stiffening 
Myoclonic Suppl Video 
1A-C, 6A-B, 8 
2 
Atypical (unilateral or incomplete) clonic 
seizure 
Myoclonic Suppl Video 2 
3 
Clonic seizure with forelimb clonus and 
rearing 
Severe Suppl Video 
3A-C 
4 
Tonic-clonic seizure with an initial wild run and 
subsequent loss of righting reflex 
Severe Suppl Video 
4A-C, 7 
5 
Tonic-clonic seizure with full extension of fore- 
and hind-limbs 


















Figure 1. Disturbance-associated seizure-like events in heterozygous CDD female mice. 
 
(A) Percentage of Cdkl5R59X (R59X) mice and littermates demonstrating seizure-like events at 20, 
30, and 40 weeks of age. Cdkl5R59X/+ (R59X/+): 12% at 20 weeks (n=31); 53% at 30 weeks 
(n=28); 70% at 40 weeks (n=20). Cdkl5+/+ (+/+): 0% at 20 weeks (n=21); 0% at 30 weeks (n=19); 
0% at 40 weeks (n=12). Cdkl5R59/y (R59X/y): 0% at 20 weeks (n=33); 0% at 30 weeks (n=24); 0% 
at 40 weeks (n=10). Cdkl5+/y (+/y): 0% at 20 weeks (n=34); 0% at 30 weeks (n=22); 0% at 40 
weeks (n=10). (B) Percentage of Cdkl5KO (KO) mice and littermates displaying seizure-like events 
at 20, 30, and 40 weeks of age. Cdkl5KO/+ (KO/+): 8.57% at 20 weeks (n=35); 39.39% at 30 
weeks (n=33); 65.22% at 40 weeks (n=23). Cdkl5+/+ (+/+): 0% at 20 weeks (n=34); 0% at 30 
weeks (n=9); 0% at 40 weeks (n=5). Cdkl5KO/y (KO/y): 0% at 20 weeks (n=18); 0% at 30 weeks 
(n=8); 0% at 40 weeks (n=5). Cdkl5+/y (+/y): 0% at 20 weeks (n=20); 0% at 30 weeks (n=8); 0% at 
40 weeks (n=7). (C) Longevity of R59X/+ (gray, dotted line; n=123) and +/+ (black, solid line; 
n=54) females. Mantel-Cox (log-rank) test, p=0.0007. (D) Longevity of R59X/y (gray, dotted line; 
n=36) and +/y (black, dotted line; n=34) males. Mantel-Cox (log-rank) test, ns. *p<0.05, **p<0.01, 
























Figure 2.  Prevalence and severity of disturbance-associated seizure-like events in R59X/+ 
females increases with age. 
 
(A) Percentage of Cdkl5R59X/+ (R59X/+) females presenting with any seizure-like event (Racine 
Stages 1 to 5; black line) and percentage of R59X/+ females presenting with at least one severe 
seizure-like event (Racine Stages 3 to 5; blue line) between 12 weeks to 45 weeks of age (n=20). 
Median age of onset for second observed seizure-like event was 28 weeks; median age of onset 
for severe seizure-like events was 47 weeks of age. (B) Percentage of R59X/+ females observed 
having at least one seizure-like event (Racine Stages 1 to 5; black line) and percentage of 
R59X/+ females observed having at least one severe seizure-like event (Racine Stages 3 to 5; 
blue line) any given week between 12 to 52 weeks of age (n=25). 
(C) Event record of 20 Cdkl5R59X/+ females observed from 12 weeks to 45 weeks of age. Gray: no 
seizure-like events observed during that week. Blue: at least one myoclonic seizure-like event 
(Racine Stages 1 to 2), but no severe seizure-like event, observed during that week. Black: at 























Figure 3.  Prevalence and severity of disturbance-associated seizure-like events in KO/+ 
females increases with age. 
 
(A) Percentage of Cdkl5KO/+ (KO/+) females presenting with any seizure-like event (Racine 
Stages 1 to 5; black line) and percentage of KO/+ females presenting with at least one severe 
seizure-like event (Racine Stages 3 to 5; green line) between 12 weeks to 45 weeks of age 
(n=10). (B) Percentage of KO/+ females observed having at least one seizure-like event (Racine 
Stages 1 to 5; black line) and percentage of KO/+ females observed having at least one severe 
seizure-like event (Racine Stages 3 to 5; green line) any given week between 12 to 50 weeks of 
age (n>=10 at any given time point). Median age of onset for second observed seizure-like event 
was 32 weeks; median age of onset for severe seizure-like events was 57 weeks of age. (C) 
Event record of 17 KO/+ females observed from 12 weeks to 45 weeks of age. Gray: no seizure-
like event observed during that week. Green: at least one myoclonic seizure-like event (Racine 
Stages 1 to 2), but no severe seizure-like event, observed during that week. Black: at least one 



























Figure 4. Seizure-like events are confined to Cdkl5 heterozygous female knockout mice 
and are independent of estrous cycle and parity. 
 
(A) Estrous cycle stages of females displaying disturbance-associated seizures. Proestrus: 
19.35% (n=6); estrous: 9.68% (n=3); metestrus: 29.03% (n=9); diestrus: 41.94% (n=13). (B) 
Percentage of breeder (gray, dotted line; n=16) and nulligravid (black, solid line; n=23) R59X/+ 
females not exhibiting seizure-like events between 12 to 45 weeks of age. Mantel-Cox (log-rank 
test), ns. (C) Percentage of R59X/+ females (gray, dotted line; n=16), R59X/R59X females (gray, 
solid line; n=14), and +/+ females (black line; n=9) not exhibiting seizure-like events between 12 


























Figure 5: Prevention of seizure phenotype in heterozygous Cdkl5 knockout female mice 
with early gene restoration.  
 
Survival curve demonstrating the latency to a second seizure-like event in all mice monitored, 
plotted as percentage of mice without seizures. Cdkl5STOP/+ (STOP/+) heterozygous female mice 
exhibit seizure-like events at a median age of 31 weeks. Tamoxifen delivery (and Cdkl5 
expression restoration) at 12 weeks of age (before seizure onset) prevented the development of 
seizure-like events in STOP/+; CreER/+ females, but not STOP/+; +/+ littermate controls. Cre-
only littermate controls exhibit no similar seizure-like events. This demonstrates the potential for 
seizure prevention with early Cdkl5 expression restoration. n=7 CreER/+, n=12 STOP/+, n=14 

















































Figure 6: Reversal of seizure phenotype in heterozygous Cdkl5 knockout female mice with 
late gene restoration.  
Cdkl5STOP/+ (STOP/+) and STOP/+; CreER/+ heterozygous female mice exhibit seizure-like 
events by a median age of 28.5 weeks (prior to tamoxifen delivery). Tamoxifen delivery (and 
Cdkl5 expression restoration) at 33 weeks of age (after seizure onset) abrogates the occurrence 
of any subsequent seizure-like events in STOP/+; CreER/+ females, but not STOP/+; +/+ 
littermate controls, suggesting a rescued seizure phenotype. Top: survival curve demonstrating 
latency to a second seizure-like event in all observed mice between 10-52 weeks of age. Bottom: 
survival curve demonstrating latency to a second seizure-like event in all observed mice after 
tamoxifen administration (33-52 weeks of age). This demonstrates the potential for seizure 
phenotype rescue with Cdkl5 expression restoration even in mice that were previously displaying 
seizures. n=8 STOP/+; n=20 STOP/+; CreER/+ where all mice received tamoxifen. Mantel-cox 


































Figure 7: Reversal of seizure phenotype in heterozygous females of an independent Cdkl5 
knockout mouse line with late gene restoration.  
Cdkl5FLEX/+ (FLEX/+) and FLEX/+; CreER/+ heterozygous female mice exhibit seizure-like events 
by a median age of 37 and 28.5 weeks, respectively (prior to tamoxifen delivery). Tamoxifen 
delivery (and Cdkl5 expression restoration) at 33 weeks of age (after seizure onset) abrogates 
the occurrence of any subsequent seizure-like events in FLEX/+; CreER/+ females, but not 
FLEX/+; +/+ littermate controls, suggesting a rescued seizure phenotype. Top: survival curve 
demonstrating latency to a second seizure-like event in all observed mice between 10-52 weeks 
of age. Bottom: survival curve demonstrating latency to a second seizure-like event in all 
observed mice after tamoxifen administration (33-52 weeks of age). This demonstrates the 
potential for seizure phenotype rescue with Cdkl5 expression restoration in an independent 
conditional rescue line, even in mice that were previously displaying seizures. n=6 CreER/+, n=9 





Supplemental Video 1. Disturbance-associated seizure-like events of Racine stage 1 in 
Cdkl5R59X/+ 
(a) Cdkl5R59X/+ female at 70 weeks of age displaying a seizure-like event of Racine stage 1.  
(b) Cdkl5R59X/+ female at 59 weeks of age displaying a seizure-like event of Racine stage 1.  
(c) Cdkl5R59X/+ female at 26 weeks of age displaying a seizure-like event of Racine stage 1. 
 
Supplemental Video 2. Disturbance-associated seizure-like event of Racine stage 2 in 
Cdkl5R59X/+ 
Cdkl5R59X/+ female at 56 weeks of age displaying a seizure-like event of Racine stage 2.  
 
Supplemental Video 3. Disturbance-associated seizure-like events of Racine stage 3 in 
Cdkl5R59X/+ 
(a) Cdkl5R59X/+ female at 71 weeks of age displaying a seizure-like event of Racine stage 3.  
(b) Cdkl5R59X/+ female at 63 weeks of age displaying a seizure-like event of Racine stage 3.  
(c) Cdkl5R59X/+ female at 50 weeks of age displaying a seizure-like event of Racine stage 3. 
 
Supplemental Video 4. Disturbance-associated seizure-like events of Racine stage 4 in 
Cdkl5R59X/+ 
(a) Cdkl5R59X/+ female at 60 weeks of age displaying a seizure-like event of Racine stage 4.  
(b) Cdkl5R59X/+ female at 71 weeks of age displaying a seizure-like event of Racine stage 4.  
(c) Cdkl5R59X/+ female at 58 weeks of age displaying a seizure-like event of Racine stage 4. 
 
Supplemental Video 5. Disturbance-associated seizure-like event of Racine stage 5 in 
Cdkl5R59X/+ 
Cdkl5R59X/+ female at 26 weeks of age displaying a seizure-like event of Racine stage 5.  
 
Supplemental Video 6. Spontaneous seizure-like events of Racine stage 1 in Cdkl5R59X/+ 
females  
(a) Cdkl5R59X/+ female at 31 weeks of age with a Racine stage 1 seizure-like event. 
(b) Cdkl5R59X/+ female at 31 weeks of age with a Racine stage 1 seizure-like event. 
 
Supplemental Video 7. Spontaneous seizure-like event of Racine stage 4 in Cdkl5R59X/+ 
female  
Cdkl5R59X/+ female at 43 weeks of age with a Racine stage 4 seizure-like event starting at 8:02:52 
PM 
 
Supplemental Video 8. Video-EEG recording of disturbance-associated seizure in 
Cdkl5R59X/+ 
(a) Cdkl5R59X/+ female at 75 weeks of age displaying a Racine stage 1 seizure. Real-time playback 
of a video-EEG recording clip demonstrating myoclonic jerks with time-locked EEG. 
(b) Manual frame-by-frame viewing of the corresponding myoclonic event captured on video-EEG 
in Supplemental Video 8A. Note that the onset of the behavioral spasm occurs immediately after 
the onset of spike-wave activity. 
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CHAPTER 6 – EXTENDED DISCUSSION AND FUTURE DIRECTIONS 
 
Cellular Origins of CDKL5 Deficiency Disorder-Related Phenotypes 
 The findings presented in Chapter 2 on Cdkl5 conditional knockout mice (Dlx-cKO) 
complement a previous report characterizing behavioral and circuit phenotypes in Nex-cKO 
animals(Tang et al., 2017). Together, these results demonstrate the behavioral segregation of 
Cdkl5 constitutive knockout phenotypes between forebrain glutamatergic (Nex-cKO) and 
GABAergic (Dlx-cKO) Cdkl5 conditional knockout mice, where impaired learning and memory is 
selectively recapitulated in Nex-cKO mice and autistic-like features are selectively recapitulated in 
Dlx-cKO mice. This suggests that CDKL5 is necessary in each of these forebrain neuronal 
populations in order to development and/or maintain proper learning and memory and social 
behaviors, respectively.  
Interestingly, the anxiety-related behaviors, hyperactivity, and motor coordination deficits 
reported in germline Cdkl5 knockout mice were not impaired in either Dlx- or Nex-cKO mouse 
line(Tang et al., 2019; Tang et al., 2017). These phenotypes may be regulated by CDKL5 action 
in cell types and/or brain regions not targeted by either NEX-Cre or Dlx5/6-Cre drivers. 
Alternatively, their disruption may arise via a synergistic disruption across multiple cell types and 
circuits upon loss of CDKL5 that cannot be modeled by conditional knockout. Either way, these 
results present an interesting future avenue to further dissect the cell types and circuits 
underlying these specific CDD-related phenotypes. 
We also highlight aberrant NMDAR signaling as contributing to the autistic-like features of 
Dlx-cKO animals, and selectively rescue these aberrant behaviors in constitutive knockout mice 
using a competitive NMDAR antagonist, memantine(Tang et al., 2019). Together, these findings 
emphasize the importance of further dissecting cell-type-specific functions of CDKL5 within the 
heterogeneous brain, especially in regards to targeted therapies for the constellation of 
phenotypes comorbid in CDD. 
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Given that CDKL5 is a kinase, the identification of CDKL5 substrates and interacting 
proteins remains key to illuminating the etiology of CDD. However, CDKL5 is expressed across 
multiple heterogeneous circuits and cell-types, confounding the identification of reliable targets in 
vivo(Zeisel et al., 2015). Furthermore, the difficulty to date in generating a specific antibody for 
CDKL5 has impeded the visualization and sub-cellular localization of this kinase in the brain. To 
bypass these confounds, we generated genetically modified mice wherein CDKL5 can be labeled 
with biotin in a Cre-dependent manner for future molecular investigations into cell-type-specific 
signaling targets. 
Generation of CDKL5-TAVI knock-in mice for the investigation of CDKL5 molecular 
targets and signaling pathways 
As part of a future direction, we develop and characterize a novel genetic tool, CDKL5-
TAVI, that allows for cell-type-specific biotin tagging of CDKL5 in vivo. We inserted a short affinity 
tag immediately upstream of the endogenous Cdkl5 stop codon, termed TAVI, which comprises a 
TEV protease cleavage site and a 15 amino acid biotinylation consensus motif that can be post-
translationally labeled with biotin by Escherichia coli biotin ligase BirA (Figure 1a). To control 
biotinylation of CDKL5 in a cell-type-specific manner, we crossed these mice to transgenic mice 
carrying a conditional BirA allele (R26cBirA) that allows for Cre-dependent expression of BirA. 
Upon crossing these mice to mice carrying a cell-type-specific Cre allele (e.g., NEX-Cre), we are 
able to restrict BirA expression (and CDKL5 biotinylation) to select cell-types (Figure 1b). 
We crossed our Cdkl5TAVI (hereafter referred to as CDKL5-TAVI) mice to mice carrying 
the conditional BirA allele and NEX-Cre (Cdkl5Tavi/y; BirA/+; NEXCre). These mice carry CDKL5-
TAVI in every cell, but only NEX+ neurons will express Cre, and therefore have BirA-mediated 
biotinylation of CDKL5. We confirmed this result in forebrain cortices of Cdkl5Tavi/y; BirA/+; NEXCre 
mice, demonstrating selective biotinylation of CDKL5, but no biotinylation of CDKL5-TAVI in 
Cdkl5Tavi/y; BirA/+; +/+ littermate controls or wild-type littermates (Figure 1c). The strong affinity 
between biotin and avidin/streptavidin can be harnessed to visualize a biotin-tagged protein (e.g., 
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with streptavidin-conjugated antibodies), or to purify a biotin-tagged protein using streptavidin-
conjugated beads(Deal & Henikoff, 2010). We attempted the latter in order to evaluate the extent 
to which our CDKL5-TAVI tool allowed for successful purification of CDKL5 in vivo. We 
subsequently optimized a condition to successfully enrich biotinylated CDKL5 protein from brain 
tissue extracts of Cdkl5Tavi/y; BirA/+; NEXCre mice via immunoprecipitation with streptavidin-
conjugated beads, but not Cdkl5Tavi/y; BirA/+; +/+ control littermate brain tissues (Figure 1d). The 
details of this immunoprecipitation protocol are outlined in the ‘Materials and Methods’ section 
below. In the future, this novel genetic tool can serve as an invaluable resource for cell-type-
specific in vivo visualization of CDKL5, purification and identification of co-interactors, and sorting 
of biotin-labeled cells for further proteomic or transcriptomic analyses. This advancement 
provides the CDD and CDKL5 research community with a valuable tool for future dissection of 
cell-type-specific CDKL5 interactomes and signaling cascades throughout the brain. This will be 
particularly relevant when considering the cell-type-specific effects and overall efficacy of any 
CDD-targeting drugs or therapeutics.  
Synaptic Convergence of CDKL5 Loss-of-Function Phenotypes 
Several studies to date have highlighted disrupted neuronal arborization and/or dendritic 
spine stability with loss of CDKL5(Amendola et al., 2014; Della Sala et al., 2016; Lupori L, 2019; 
Okuda et al., 2018; Ricciardi et al., 2012; Tang et al., 2017; Zhu et al., 2013). The direct impact of 
CDKL5 loss on pyramidal neuron morphology has been contentious, likely due to context-
dependent variability and confounds of mixing cell and non-cell autonomous cellular effects. 
Interestingly, we find that adult deletion of Cdkl5 can lead to similar behavioral deficits without 
concomitant effects on neuronal morphology or dendritic arborization, bringing into question the 
necessity of these reported arborization phenotypes to CDD-related behavioral deficits. 
Alternatively, we find that both post-developmental and sparse deletion of CDKL5 in mice 
increased dendritic filipodia-like structures suggestive of a morphologically immature spine state 
that, when combined with the absence of changes in overall spine density, reflects a greater 
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proportion of morphologically immature spines on hippocampal CA1 pyramidal neurons(Harris 
KM, 1989).  
These findings are in line with the observation that CDKL5 is responsible for the 
phosphorylation of EB2, a member of the microtubule end-binding protein family. End-binding 
proteins are plus-end-tracking proteins that accumulate at the growing microtubule end, and play 
pivotal roles in microtubule dynamics that mediate cellular architecture, cargo trafficking, and 
spine stability(Akhmanova & Steinmetz, 2015; Komarova et al., 2009). In Chapter 3, we 
demonstrate that EB2 phosphorylation is developmentally regulated and correlates with the 
expression pattern of CDKL5. The known roles of end-binding proteins in microtubule dynamics 
align with the cellular and synaptic phenotypes we report upon loss of CDKL5 in mice (e.g., 
disrupted NMDA receptor subunit trafficking and spine morphology). Importantly, we also 
demonstrate that restoration of Cdkl5 expression in adulthood is capable of restoring EB2 
phosphorylation to wild-type levels (Chapter 4), highlighting the dynamic regulation by CDKL5 of 
this microtubule-associated substrate. Thus, CDKL5 may play a role in regulating microtubule 
dynamics, particularly those related to spine morphology and receptor trafficking at the post-
synaptic density, via its continual regulation of microtubule-associated proteins such as EB2. An 
EB2-related family member, EB3, has previously been implicated in regulating dendritic spine 
morphology within hippocampal neurons(Leterrier et al., 2011). However, the extent to which 
CDKL5-mediated phosphorylation of EB2 may play similar roles remains undetermined. 
Interestingly, it has been reported that EB2 suppresses neurite outgrowth and attenuates the 
microtubule growth mediated by EB1 activity, but how phosphorylation of EB2 at Ser222 
specifically modulates this action is untested(Laketa, Simpson, Bechtel, Wiemann, & Pepperkok, 
2006).  
We also demonstrate that CDKL5 plays a critical role in maintaining the post-synaptic 
composition of NMDA receptor subunits, namely GluN2B. During development, the canonical 
switch from predominantly GluN2B-containing to predominantly GluN2A-containing NMDA 
receptors across the CNS is thought to be a regulatory mechanism involved in shaping circuits 
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and constraining synaptic plasticity during the critical period of synaptogenesis for several brain 
regions(Paoletti et al., 2013). Interestingly, the peak expression of CDKL5 in mouse forebrain 
appears to coincide with this subunit composition switch during a time window also associated 
with circuit refinement and acquisition of learning abilities. Loss of CDKL5 may therefore result in 
an elongated or unconstrained critical period that ultimately leads to maladaptive plasticity across 
multiple neural circuits and the subsequent heterogeneous collection of symptomology 
associated with CDD(H. E. Olson et al., 2019). Surprisingly, post-developmental restoration of 
CDKL5 expression reverses this elevation of GluN2B expression and NMDA hyperexcitability 
phenotype observed in germline knockout mice, arguing that CDKL5 may persistently regulate 
NMDA receptor composition beyond the early stages of development. Interestingly, CDKL5 has 
been reported to target EB2 pS222 via an NMDAR-dependent mechanism, providing a potential 
link between disrupted NMDAR signaling, microtubule dynamics, and CDKL5 loss-of-function 
phenotypes(Lucas L. Baltussen et al., 2018). Nonetheless, the causal relationship among the 
molecular, cellular, and behavioral domains examined in this study requires further examination. 
Temporal Dissection of CDKL5 Deficiency Disorder Pathophysiology 
Several mouse models of CDD have been characterized to date, and although they 
recapitulate many of the hallmark phenotypes of the human disorder, it remained unclear whether 
these phenotypes were a consequence of detrimental changes exclusively accumulating in the 
developing nervous system or are similarly inducible upon loss of CDKL5 in mature neurons. 
Furthermore, from a therapeutic perspective, it remained imperative to determine the reversibility 
of CDD-related deficits particularly after the early stage of brain development, and to delineate 
the temporal requirement of CDKL5 action needed to establish as well as maintain proper 
neurological function. Prior to this dissertation, it remained unknown if CDD symptomology was 
treatable and whether a critical developmental time window was required for treatment. Our 
temporal knockout and temporal rescue experiments highlighted in Chapters 3-4 address these 
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questions, and constitute a seminal foundation for future endeavors to dissect the pathogenic 
origins and design effective therapeutic strategies for CDD. 
Our findings demonstrate that multiple behavioral and circuit phenotypes in knockout 
mouse models of CDD are recapitulated following adult deletion of Cdkl5. In parallel, post-
developmental restoration of Cdkl5 expression ameliorates most of these loss-of-function deficits 
in mice, suggesting that the underlying circuitry critical for many of the behavioral domains 
disrupted upon loss of CDKL5 are amenable to later kinase restoration. Thus, CDKL5 appears to 
be required not only during development, but also in adulthood, suggesting that chronic, lifelong 
treatment of CDD will likely be required.  
Notably, working memory, as measured via spontaneous alternations in a Y-Maze assay, 
was not significantly affected by adult loss or restoration of CDKL5 expression, demonstrating 
that CDKL5 does function critically in early development. It remains relevant to dissect the 
emergence of this working memory phenotype in developing animals, and to examine the circuit 
and cellular mechanisms that drive its perturbation early in life. In parallel, adult knockout of Cdkl5 
resulted in significantly enhanced motor learning in contrast to the impaired motor learning and 
coordination reported in germline knockout animals. How loss of CDKL5 in adulthood leads to 
improved motor coordination and learning remains uncertain, but also represents an interesting 
future avenue to investigate temporally-distinct influences of CDKL5 loss on the same behavioral 
output.   
Through genetic manipulation of endogenous Cdkl5 expression in a temporal manner, we 
uncover for the first time that CDKL5 is required to maintain proper spine morphology, sensory-
information processing, and behavioral output in the adult brain. Consistent with this, post-
developmental restoration of Cdkl5 expression is sufficient to ameliorate NMDAR-related synaptic 
deficits, and leads to significant reversal of multiple behavioral domains related to CDD. Together, 
our findings highlight the promise of disease reversal in CDD across a broader than expected 




Therapeutic Insights for CDKL5 Deficiency Disorder 
Previous studies have applied the concept of late gene reversal in rodents to attempt 
phenotypic rescue in various models of neurodevelopmental disorders(Creson et al., 2019; Guy 
et al., 2007; Y. Mei et al., 2016). Late restoration of Mecp2 expression in knockout mice has been 
reported to alleviate impairments associated with Rett syndrome, and adult restoration of Shank3 
is capable of rescuing selective autistic-like phenotypes(Guy et al., 2007; Y. Mei et al., 2016). 
Meanwhile, a recent finding reported that adult restoration of the SynGAP protein selectively 
improved electrophysiological measures of memory and seizures(Creson et al., 2019).  CDD, 
however, is distinct from these and other autism spectrum and neurodevelopmental disorders in 
that it is characterized by early-onset features within the first few weeks after birth as opposed to 
a developmental regression after the first few years of life(Ozonoff, Heung, Byrd, Hansen, & 
Hertz-Picciotto, 2008; Zoghbi & Bear, 2012). Thus, our temporal reversal findings provide a novel 
development over these previous studies, and demonstrate the potential for treatment of 
neurological symptoms despite the lack of a relatively stable early-postnatal period. We also 
found that post-developmental restoration of Cdkl5 expression significantly ameliorated multiple 
behavioral deficits related to CDD, rather than a few behavioral domains as was reported in 
previous reversal studies, arguing a uniquely critical role for CDKL5 in the maintenance of various 
neurological functions throughout life. 
Surprisingly, we observed that a relatively rapid reversal of Cdkl5 expression led to 
significant lethality in rescue mice, in line with previous findings from a Mecp2 re-expression 
study(Guy et al., 2007). As with MeCP2, a gradual restoration of CDKL5 expression alleviated 
this lethality issue, and resulted in significant phenotypic reversal. Thus, the time course and 
dosage of CDKL5 re-introduction need to be carefully considered in future gene replacement 
trials to avoid contravening outcomes, particularly in a system that may have partially 
compensated for its loss(Benke & Kind, 2020). Additionally, post-hoc examination of CDKL5 
restoration revealed that several rescue mice showed only 20-50% of wild-type protein 
expression. The rescue of numerous behavioral domains in these mice underscores the potential 
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that even partial restoration of CDKL5 expression may show notable therapeutic benefit, at least 
in mice. 
We acknowledge that many of our findings are limited to studies in male mice in order to 
avoid potential confounding effects of mosaic Cdkl5 expression in females from random X-
chromosome inactivation. However, our preliminary behavioral rescue data in heterozygous 
Cdkl5 knockout female mice (Chapter 4) presents a promising outlook for the reversal of 
additional CDD-related cellular and circuit deficits in female models. In the future, it will be 
necessary to extend these experiments to heterozygous female mouse models of CDD, 
determine the minimum and maximum levels of CDKL5 expression required for safe phenotypic 
reversal, and define the latest time window allowable for rescue, at least in mouse models(Benke 
& Kind, 2020). Finally, the potential for seizure mitigation with Cdkl5 re-expression also highlights 
promising outcomes for seizure management and phenotypic reversal for the pervasive epilepsy 
in CDD. 
 
Materials and Methods 
Regulatory approval. Experiments were conducted in accordance with the ethical guidelines of 
the National Institutes of Health and with the approval of the Institutional Animal Care and Use 
Committee of the University of Pennsylvania. Mice were group-housed in cages of two to five in a 
twelve-hour light/dark cycle with food and water provided ad libitum. 
 
Mouse strains and genotyping. Cdkl5TAVI mice were generated using CRISPR-mediated 
genomic editing techniques. A specific gRNA was chosen upon screening for targeting specificity 
and efficacy just upstream of the Cdkl5 stop codon. The DNA repairing template constituted a 
TAVI sequence containing a TEV protease cleavage site and a 15 amino acid biotinylation 
consensus sequence (ENLYFQGLNDIFEAQKIEWHE), flanked by 100bp of DNA as the 5’ 
homologous arm and 100bp of DNA as the 3’ homologous arm. Synthesized gRNA, single strand 
DNA repairing template, as well as Cas9 mRNA were co-injected into a one-cell zygote of 
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C57BL/6 background to allow for homology-directed repair, followed by implantation. PCR 
primers specific to the 5’ and 3’ integration sites flanking the gRNA sequence at the 3’ end of the 
Cdkl5 locus were used to screen for positively targeted pups. Southern blotting was finally 
conducted to confirm the correct targeting of the F1 generation, followed by establishment 
a CDKL5-TAVI colony in a C57BL/6J genetic background.  
R26cBirA (BirA) mice were generated as previously described, and Nex-Cre mice (RRID: 
MGI: 4429523), generously shared by Klaus-Armin Nave (Max Planck Institute of Experimental 
Medicine, Göttingen, Germany) and Lazzerini Denchi (The Scripps Research Institute)(Goebbels 
et al., 2006; Johnson et al., 2017). All lines have been maintained in the C57BL/6J background. 
Experimental cohorts were all weaned at 3 weeks of age and littermates housed 
together. Mice were genotyped using a qPCR based strategy optimized by Transnetyx. 
  
Brain microdissection. To assess protein expression in various brain regions, adult male mice 
were sacrificed by cervical dislocation. After decapitation, brains were removed and sectioned 
into 1mm coronal slices using a mouse brain matrix. Tissue was dissected from the 
somatosensory cortex, striatum, hippocampus, and cerebellum and homogenized in RIPA lysis 
buffer (150mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate [DOC], 0.1% sodium dodecyl 
sulfate [SDS], 25mM Tris [pH7.4] with protease inhibitors [Roche, cOmplete, EDTA-free protease 
inhibitor cocktail tablets; 5056489001]). To prepare protein extracts, homogenized lysates were 
incubated on ice for 15 min, and then centrifuged at 21,000 x g for 15min at 4°C. The supernatant 
fraction was removed and sonicated using a Biorupter for 3 alternating session at max frequency 
for 15 sec, each followed by a 60 sec cooldown period. The lysate was then centrifuged at 21,000 
x g for 15min at 4°C, and the top aqueous layer carefully removed and collected as the total 
protein fraction. 
 
Streptavidin-Mediated Pull-Down. Brain tissue lysates were prepared as described above. 
500μg of protein lysate was utilized for each pull-down reaction, with 10% of the lysate collected 
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prior to streptavidin treatment as an “input” loading control. Protein lysates were incubated with 
70μL streptavidin-conjugated magnetic beads (Dynabeads M-280 Streptavidin; Invitrogen 
11205D) for 1hr at 4°C while rotating. Magnetic beads were separated away from the remaining 
lysate using a DynaMag-2™ rack (Invitrogen; 12321D), and 20μL of remaining lysate collected as 
“flow-through.” The lysate was then discarded and the beads subsequently washed 4X with 1% 
NP-40 in 150mM NaCl wash buffer. Beads were resuspended in the appropriate amount of LDS 
Sample buffer and β-mercaptoethanol, and then heat denatured at 90°C for 15min. 
 
Western blot. Protein concentration was measured using a Bradford assay. Purified synaptic 
density membrane proteins or protein lysates were prepared for gel electrophoresis by adding 4X 
LDS Sample Buffer (NuPAGE, NP0008) to a final concentration of 1X and β-mercaptoethanol to 
a final concentration of 5%. Samples were heat-denatured at 75°C for 20 min, and 7.5µg or 25 µg 
of protein was loaded into each well of a 4–12% Bis-Tris gradient gel (Invitrogen, 10-well, 1.5mm; 
NP0335) for PSD protein or brain lysate quantification, respectively. Protein gels were run for 2hr 
at 125V at room temperature on a XCell SureLock mini-cell electrophoresis box (ThermoFisher; 
EI001) using a PowerPac HC High-Current Power Supply (BioRad; 1645052), then transferred 
onto a polyvinylidene fluoride (PVDF) membrane (0.45µm pore-size; Biorad 162–0115) at 27V for 
1hr and 10min at room temperature. The resulting membrane was blocked with a 1:1 solution of 
Odyssey blocking buffer (LICOR; 927-40100) and 1X PBS for 1hr at room temperature.  
Primary antibodies used were rabbit anti-N-terminal CDKL5 (in house; diluted 1:500), 
rabbit anti-BirA consensus sequence (Abcam; ab1400; diluted 1:1,000), and mouse anti-β-Actin 
(Abcam; ab8226; diluted 1:10,000). A streptavidin-conjugated fluorophore, IRDye 680RD 
Streptavidin (LI-COR; 926-68079; diluted 1:1,000), was utilized for visualization of biotinylated 
proteins. Secondary antibodies (LI-COR) used were goat anti-rabbit IgG IRDye800CW and rabbit 
anti-mouse IgG IRDye680LT, all incubated for 50min at room temperature at dilutions of 
1:10,000. Standard protocols were used for the Odyssey Infrared Imaging System (LI-COR) for 












































Figure 1. Generation and characterization of CDKL5-TAVI mice.  
 
(a) Diagram of Tavi-tagged CDKL5 showing the kinase domain and amino acid sequence of the 
TAVI tag (TEV protease cleavage site plus biotinylation consensus sequence). (b) Breeding 
strategy to biotinylated the TAVI tag in a Cre-dependent manner. (c) Representative western 
blots showing the conditions in which the TAVI tag is biotinylated using whole-brain tissue lysates 
from male mice. Top left: Blot was probed with antibody to the CDKL5 N-terminus, highlighting 
the presence of CDKL5 in both wild-type and CDKL5-TAVI tissues; Top right: Blot was probed 
with streptavidin for detection of biotinylated proteins, demonstrating a biotinylated CDKL5 
product only in CDKL5-TAVI; BirA/+; Cre mice (asterisk denotes endogenous biotinylated 
products detectable from brain lysate at 75kDa and 150kDa). Bottom: overlay of CDKL5 antibody 
(green) and streptavidin (red) staining demonstrating the overlap of biotinylated CDKL5 product. 
(d) Representative western blot demonstrating the enrichment of CDKL5 protein from mouse 
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